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Drug dependence is the process by which the brain learns to depend on a drug 
and crave for it in its absence. This learning takes place through modifications of synaptic 
connections between neurons, changing synaptic structure and function, and causing 
long-lasting neuroadaptations. Over the past decade, several microRNAs have been 
proposed as playing a key role in regulating local mRNA translation into protein, 
specifically in the synaptic compartments of the cell (pre-synaptic terminals and post-
synaptic densities). There is limited evidence, however, regarding how synaptic 
microRNAs control local mRNA translation during chronic drug exposure and how this 
contributes to the development of dependence. Can alcohol-responsive synaptic mRNAs 
and microRNA be identified? Do synaptic microRNAs regulate the synaptic mRNA 
expression changes in response to alcohol? Can changes in synaptic microRNA 
composition affect alcohol consumption? 
In this thesis, I present research supporting microRNA regulation of local mRNA 
translation and how drugs of abuse target this process. In the first section, I focus on the 
identification of alcohol-responsive synaptic mRNAs. In the second section, I focus on 
identifying alcohol-responsive synaptic microRNAs and predict key mRNA-microRNA 
 ix 
interactions. Identifying the primary regulatory elements in the synapse is imperative for 
an accurate model of the synaptic interactions that lead to mRNA translation underlying 
plasticity. Since the neuroadaptations associated with response to alcohol rely on many 
mRNAs, therapy with microRNAs provides a potential treatment for alcohol dependence. 
In the third section, I focus on manipulating key microRNAs in-vivo to reverse and prevent 
alcohol consumption and alcohol-induced-neuroadaptations. The ability of synaptic 
microRNAs to rapidly regulate mRNAs provides a discrete, localized system that could 
potentially be used as diagnostic and treatment tools for alcohol and other addiction 
disorders. 
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CHAPTER 1: INTRODUCTION 
Overview  
The first chapter of this thesis consists of two main sections. In the first, I review 
the effects of alcohol consumption on the central nervous system as a whole. In the 
second, I focus specifically on the synaptic compartment of the cell, and detail the 
interplay between alcohol consumption, synaptic mRNAs and microRNAs. 
The work presented in the first section of this chapter has been published as a review in 2014 in the 
Handbook for Clinical Neurology. Most D, Ferguson L, Harris RA. Molecular basis of alcoholism. 125:89-
111. PubMed PMID: 25307570. The published text has been modified in order to fit the thesis. 
The work presented in the second section of this chapter has been published as a review in 2014 in 
Frontiers Molecular Neuroscience. Most D, Workman E, Harris RA. Synaptic adaptations by alcohol and 
drugs of abuse: changes in microRNA expression and mRNA regulation. 7:85. PubMed PMID: 25565954. 
The published text has been modified in order to include some more recent information which is pertinent 
to this thesis. 
The Effects of Alcohol on the Nervous System 
Alcohols are organic compounds containing a hydroxyl (-OH) group attached to a 
carbon atom and the aliphatic alcohols are described by the general formula CnH2n+1OH. 
Ethanol, the psychoactive constituent of alcohol, has been used recreationally for tens of 
thousands of years (Hanson 1995) and is one of the largest health burdens on society 
(Cargiulo 2007). For the remainder of this thesis, alcohol will refer to ethanol, and 
alcoholism as the functional equivalent of alcohol use disorder, as outlined by the 
Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V) (American 
Psychiatric Association, 2013). 
The maladaptive behaviors of alcoholism rely on changes in the brain that lead to 
compulsive and excessive drinking, afflicting all organs, with damage as a secondary 
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consequence of alcoholism. While acute use of alcohol, such as binge drinking and 
intoxication, causes cellular changes in the brain that last for hours, chronic alcohol use 
induces widespread neuroadaptations in the nervous system that can last a lifetime. This 
involves the remodeling of synapses that are dependent upon changes in gene expression 
in the presence of chronic alcohol use (Wilke, Sganga et al. 1994), and is illustrated in 
Figure 1.1. 
In order to fully understand the effects of alcohol on behavior and thus enable the 
development of efficacious treatments, it is necessary to understand the actions of 
alcohol at the molecular level. It is remarkable how little is known about alcohol’s 
molecular targets in view of alcohol’s burden on public health and its long-term and 
widespread use. One reason for this might be alcohol’s low binding affinity to proteins, 
reflected by the fact that clinically relevant intoxication levels of alcohol are measured in 
millimolar concentrations whereas most other drugs of abuse are measured in nanomolar 
concentrations. A consequence of the high concentrations in the body is that there are a 




FIGURE 1.1: A SCHEMATIC ILLUSTRATING THE DYNAMIC INTERACTIONS BETWEEN ALCOHOL AND THE 
NERVOUS SYSTEM 
Figure has been adapted from Spanagel, 2009. 
In the early days of alcohol research, it was thought that because of the small size 
and non-specific nature of the alcohol molecule, it would likely not have a specific binding 
domain on proteins, but would instead interfere with the lipid membranes of the central 
nervous system (CNS). However, alcohol has only been shown to interact with the lipid 
bilayer at concentrations much higher than clinically relevant (Pang, Braswell et al. 1980, 
Goldstein 1984, Peoples, Chaoying et al. 1996). For this reason, researchers have focused 
their search on other molecular targets of alcohol. Most of the examples below come 
from postmortem tissue analysis of alcoholics, animal models, and cell cultures. Many of 
the molecular pathways that are sensitive to alcohol are highly conserved across species 
such as humans, mice, rats, worms, and fruit flies (Dick and Foroud 2002, Mayfield, 
Lewohl et al. 2002). In addition, considerable progress has been made in defining binding 
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cavities for alcohol in several proteins, including ion channels (Harris, Trudell et al. 2008, 
Howard, Slesinger et al. 2011, Sauguet, Howard et al. 2013). 
This section of the chapter will discuss the known and proposed molecular targets 
of alcohol in the brain that may be important for behaviors meeting the DSM-V criteria 
for alcohol use disorder. Additionally, the molecular mechanisms of approved and 
prospective treatments for alcoholism will be discussed. 
Primary Targets 
Alcohol’s effects on the brain are diverse and include changes in levels and 
function of neurotransmitters, synaptic changes in brain circuitry regulating compulsivity 
and inhibition. Changes in these molecular systems lead to tolerance and withdrawal 
when alcohol is removed from the system. 
Alcohol metabolism and distribution can be summarized as follows: After 
consumption, alcohol is absorbed into the blood stream through the stomach and 
intestines where it readily crosses the blood–brain barrier. Alcohol is then distributed 
with body water and is found at approximately the same concentration in all tissues, 
including the nervous system. Most of the metabolism of alcohol occurs in the liver, 
whereas the brain has limited metabolism by the mitochondrial cytochrome P450 
(CYP2E1), catalase, and other pathways (Zakhari 2006). See Table 1.1 for a list of the 
















Involved in alcohol metabolism. Binds alcohol through a zinc atom 





Allows for transcriptional activation through histone acetylase 
activity. Acute alcohol exposure increases levels of CBP. 
Withdrawal produces the opposite effect. 
(Pandey, Ugale 
et al. 2008) 
NPY Neuropeptide Y 
Acute alcohol exposure increases levels of NPY. Withdrawal 
produces the opposite effect. 
(Pandey, Ugale 




Mice lacking HDAC5 become hypersensitive when chronically 
exposed to cocaine. Chronic cocaine administration inactivates 
HDAC5 by exporting it out of the nucleus, resulting in histone 
hyperacetylation and increased mRNA expression of HDAC5 target 
genes. 
(Renthal, Maze 





NK1R is increased during both chronic cocaine and alcohol 
exposure. Silencing the translation of the NK1R using RNA 
interference was found to reduce alcohol consumption in mice. 
NK1R antagonist (L822429) decreases voluntary alcohol 
consumption, suppresses stress-induced reinstatement of alcohol 
seeking, and increases sensitivity to the sedative effects of alcohol 
in rats. 
An NK1R antagonist suppresses spontaneous alcohol cravings, 
improves overall well-being, blunts cravings induced by a challenge 
procedure, and attenuates concomitant cortisol responses in 
detoxified alcoholic inpatients. An analysis of brain function of 
human alcoholics performing behavioral emotional tasks, 
corroborates the above results, suggesting NK1R antagonism as a 
potential therapeutic target for the treatment of alcoholism. 
(George, Gilman 
et al. 2008, 
Baek, Jung et al. 
2010, Schank, 
Pickens et al. 
2011) 
TABLE 1.1: SUMMARY OF GENES DISCUSSED IN THE FIRST SECTION OF THIS CHAPTER 
CYP2E1 metabolism of alcohol produces acetaldehyde and is a source of 
acetaldehyde in the brain. Additional acetaldehyde may enter the brain from peripheral 
conversion of alcohol to acetaldehyde by an enzyme found in the liver called alcohol 
dehydrogenase (ADH). In fact, ADH can be considered a “target” of alcohol since it binds 
alcohol through a zinc atom on ADH and the hydroxyl group of alcohol. 
In the periphery, acetaldehyde is the primary metabolite of alcohol and is 
responsible for the flushing effect that encompasses face flushing, nausea, vomiting, 
headache, tachycardia, and sweating. Disulfiram (Antabuse), the first of three approved 
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treatments for alcoholism, employs the aversive nature of acetaldehyde by inhibiting 
aldehyde dehydrogenase enzyme, thereby allowing for an accumulation of acetaldehyde. 
See Table 1.2 for a list of the pharmaceutical treatments discussed in this chapter. 
 
Drug  Description  Advantages  Disadvantages 
Disulfiram (Antabuse)* 





Aversive therapy and does not 
reduce alcohol cravings, leading 
to poor patient compliance. 
Acamprosate (Campral)* 
Mechanism of action 
is unclear. Proposed 
to be altering 
glutamatergic system. 
Few side-effects and 
high patient 
compliance. 
Treatment is available only for 
patients who had already been 
withdrawn from alcohol. 
Abstinence rates are lower than 
naltrexone and the 






Highest abstinent rates 
among FDA-approved 
drugs for alcoholism. 
Anxiety, trouble sleeping and 
nausea. A better response to 
naltrexone has been associated 
with possession of the G allele of 
the A118G polymorphism of the 







Has abuse potential. Causes 












May reduce alcohol 
consumption in some 
patients (late-onset 
individuals). 
Human studies show inconsistent 







No clinical trials have been 










Mechanism of action 
is unclear. Associated 
with glutamatergic 
system inhibition. 
Successful in treating 
heavy drinkers. 
May effect memory/thinking and 
cause sedation. 










Drugs have been found 
to be hepatoprotective 
and neuroprotective in 
rodents 






No human data. Alters 
metabolism of oral contraceptives 
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GABA analog, calcium 
channel and GABA 
modulator 
Increases sleep quality 
in alcoholics. Analgesic 
and anxiolytic 
Causes sedation. Does not affect 
mood or craving 
TABLE 1.2: SUMMARY OF PHARMACEUTICAL TREATMENTS DISCUSSED IN THE FIRST SECTION OF THIS 
CHAPTER 
*Food and Drug Administration (FDA)-approved for treatments of alcoholism. #FDA-approved for the treatment of 
other diseases. Baclofen refers to Kemstro, Lioresal, Liofen, Gablofen, Beklo and Baclosan. Doxycycline refers to 
Vibramycin, Monodox, Oracea, Doryx, Vibrox, Adoxa, Doxyhexal, Doxylin, Doxoral, Doxy-1 and Atridox. GABA (γ-
aminobutyric acid). 
Disulfiram is a rather non-specific enzyme inhibitor and may be useful in the 
treatment of cocaine dependence and even cancer chemotherapy due to actions on sites 
other than aldehyde dehydrogenase (Shorter and Kosten 2011, Schmitt, Frezza et al. 
2012). Although disulfiram decreases drinking when taken regularly, it has low patient 
compliance because of its aversive effects (Moriarty 1950, Barth and Malcolm 2010). In 
addition to the peripheral flushing effect, acetaldehyde may have actions in the brain 
relevant to the acute effects of alcohol (Quertemont, Tambour et al. 2005) and even on 
the development of alcoholism (Deng and Deitrich 2008). Acetaldehyde is self-
administered by rodents through intravenous and intracerebral ventricular routes (Amit, 
Brown et al. 1977, Myers, Ng et al. 1984). Rats show preference for the physical place 
where they received central or peripheral administration of acetaldehyde over places 
where they received saline (conditioned place preference, abbreviated as CPP) 
(Quintanilla and Tampier 2003, Spina, Longoni et al. 2010). Although more research is 
necessary to fully understand these mechanisms, the neurobiological – and consequently 
the behavioral – actions of alcohol most likely depend on central contributions from both 
alcohol and its metabolites, acetaldehyde and acetate (Jiang, Gulanski et al. 2013). The 
development of alcohol tolerance and dependence comes from alterations in brain 
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structure and function over time, and is long-lasting. This involves the remodeling of 
synapses that are dependent upon changes in gene expression in the presence of chronic 
alcohol (Rhodes and Crabbe 2005). Here we focus on the molecular adaptations at the 
acute and chronic stages of alcohol use that underlie the hallmarks of alcoholism: 
withdrawal, tolerance, relapse, and craving. 
It is important to note that these long-lasting drug responsive alterations are 
unlikely to be encoded in RNAs or proteins due to the fast turnover rate of those 
molecules. This suggests that DNA is in charge of cellular memory, and that epigenetic 
mechanisms may be critical components of long-term learning and memory processes 
(Levenson and Sweatt 2005, Ponomarev, Wang et al. 2012), as well as chronic 
dependence on drugs (Renthal and Nestler 2008). 
THE EFFECTS ON DNA 
Both the sequence and structure of DNA molecules control all downstream 
processes such as RNA transcription and protein translation, and both can contribute to 
the development, progression, and persistence of alcoholism. Recent research has 
emphasized the notion that epigenetic mechanisms (which exert lasting control over gene 
expression through structural modifications of the DNA without altering the sequence) 
could mediate stable changes in brain function associated with alcoholism (Wallner, 
Hanchar et al. 2003). DNA methylation, histone acetylation, and phosphorylation are 
three common epigenetic-enzymatic modifications to chromatin structure that make the 
DNA more or less accessible to transcription factors and enzymes, thus changing the 
transcriptional activity of the target genes. Chronic exposure to alcohol was found to 
induce changes in the chromatin structure, specifically on gene promoters causing 
changes in gene expression in alcoholics (Guerri and Pascual 2010, Ponomarev, Wang et 
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al. 2012). This suggests that epigenetic mechanisms are involved in both biochemical and 
behavioral responses to alcohol. 
Histone deacetylase (HDAC) is an enzyme that removes the acetyl group from 
histone proteins on DNA, making the DNA less accessible to transcription factors. Acute 
alcohol was found to decrease HDAC activity and increase acetylation of histones (H3 and 
H4) in the rat amygdala. Conversely, withdrawal from chronic alcohol in rats was found 
to increase HDAC activity and decrease H3 and H4 acetylation in the rat amygdala 
(Pandey, Ugale et al. 2008). An HDAC inhibitor (trichostatin A) blocks the increase in HDAC 
activity and rescues the deficits in H3 and H4 acetylation in the amygdala. This change 
prevents the development of withdrawal-related anxiety in rats, suggesting a potential 
role for HDAC inhibitors as therapeutic agents in treating alcohol withdrawal symptoms 
(Pandey, Ugale et al. 2008). CREB-binding protein (CBP) is a histone acetylase (HAT) that 
acetylates nearby histones, and allows for subsequent transcriptional activation. Acute 
alcohol exposure increases levels of CBP and neuropeptide Y (NPY), while withdrawal 
produces the opposite effect. Moreover, the withdrawal-induced anxiety behavior was 
found to correlate with the levels of CBP and NPY in the amygdala (Pandey, Ugale et al. 
2008). Mutations in CBP cause a form of mental retardation in humans (Tsankova, Renthal 
et al. 2007), suggesting it is important for normal learning and memory mechanisms in 
the brain. This finding goes hand in hand with the well-known hypothesis that alcoholism 
is an aberrant process of learning and memory (Hyman, Malenka et al. 2006). 
An example of a target gene of HDAC5 that is found to be increased during both 
chronic cocaine and alcohol exposure is neurokinin 1 receptor (NK1R). This receptor is 
also known as the substance P receptor due to its importance in pain transmission. 
Silencing the translation of the NK1R using RNA interference reduces alcohol drinking in 
mice, emphasizing the role that NK1R plays in alcoholism (Baek, Jung et al. 2010). In fact, 
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an NK1R antagonist (L822429) decreased voluntary alcohol consumption, suppressed 
stress-induced reinstatement of alcohol seeking, and increased sensitivity to the sedative 
effects of alcohol in rats (Schank, Pickens et al. 2011). Similar effects were also seen in 
detoxified alcoholic inpatients, as an NK1R antagonist suppressed spontaneous alcohol 
cravings, improved overall well-being, blunted cravings induced by a challenge procedure, 
and attenuated concomitant cortisol responses. Furthermore, functional magnetic 
resonance imaging (fMRI) of brains of human alcoholics, during a behavioral emotional 
task was performed and corroborated the above results, suggesting NK1R antagonism as 
a potential therapeutic target for the treatment of alcoholism (George, Gilman et al. 
2008). Figure 1.2 summarizes the epigenetic changes associated with alcohol. 
 
 
FIGURE 1.2: EPIGENETIC MODIFICATIONS ASSOCIATED WITH ALCOHOLISM 
CREB-binding protein (CBP) and histone deacetylase (HDAC) activity are altered by acute alcohol exposure. Chronic 
alcohol exposure results in neuroadaptations opposing the acute effects of alcohol in order to maintain a homeostatic 
state. Withdrawal after chronic alcohol exposure is associated with increased HDAC activity and decreased levels of 
CBP and the associated histone acetylation. DNMT, DNA methyltransferase; Ac, acetyl; Me, methyl; HAT, histone 
acetylase. Figure has been adapted from Starkman et al., 2012. 
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DNA is the master regulator in the cell and is possibly a molecular implementation 
of the persistence of drug effects (and even memories) in the brain. DNA exerts its control 
through gene expression which includes: RNA transcription, protein translation, and 
regulatory processes like microRNA and RNA splicing. In addition to alcohol’s indirect 
effect on gene expression via epigenetic actions on chromatin, alcohol can directly target 






FIGURE 1.3: THE ‘NORMAL’ SYNAPSE AND THE CELLULAR ADAPTATIONS IN RESPONSE TO CHRONIC ALCOHOL 
CONSUMPTION 
A. Synaptic transmission is the process by which the brain communicates information. Depending on the inputs to the 
presynaptic neuron’s dendrites, an action potential will be generated at the axon hillock and propagate down the 
axon through the movement of charged particles (i.e., the ions – Na+ and K+). The synapse is the gap between the 
axon of the presynaptic neuron and the dendrite of the postsynaptic neuron. In order for the information to cross the 
synapse, the electrical signal of the action potential must be converted into a chemical signal. This is achieved by 
releasing neurotransmitters from the presynaptic nerve terminal in a voltage-dependent (and therefore calcium-
dependent) manner. The presynaptic nerve terminal contains the neurotransmitter release machinery needed for this 
to occur. Once released, the neurotransmitter will diffuse across the synapse and bind to receptors on the 
postsynaptic nerve’s dendrites. The two major types of receptors of concern here are ligand-gated ion channels and 
G-protein-coupled receptors. Ligand-gated ion channels undergo a conformational change when a ligand (i.e., 
neurotransmitter) is bound and allow a particular ion (e.g. Cl–, Na+, Ca2+ , etc.) to flow into or out of the cell. When 
G-protein-coupled receptors are activated, they affect secondary messengers and molecular cascades, resulting in 
changes in the postsynaptic neuron. It is necessary to understand the basics of synaptic transmission because acute 
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and chronic alcohol exposure cause changes in many molecules important for transmission as well as changes 
transmission properties. Figure has been adapted from Clapp et al., 2008. B. An example of a synapse stimulated by 
alcohol use and the molecular effects on cellular cascades. VGCC, voltage-gated calcium channel; CaMK, calmoldulin 
kinase; MAPK, mitogen-activated protein kinase. Figure has been adapted from Koob et al., 2005. 
THE EFFECTS ON NEUROTRANSMITTER SYSTEMS 
Glutamate 
Glutamate is the primary excitatory neurotransmitter in the brain. Glutamatergic 
(glutamate-using) systems contain both ionotropic ligand-gated receptors coupled to the 
flow of charged particles (NMDA, AMPA and Kainate) and metabotropic (mGluR) 
receptors. The glutamatergic system plays an important role in long-term potentiation 
and long-term depression and therefore has physiological implications that are important 
for learning and memory. Generally, all glutamate receptors are inhibited by acute alcohol 
treatment, although some subtypes are only affected by very high concentrations. 
Alcohol’s acute actions on the glutamatergic system have been implicated in tolerance, 
withdrawal, craving, relapse, and dependence. Alcohol acts as a non-competitive inhibitor 
of the AMPA/kainate receptors at high concentrations (Dildy‐Mayfield and Harris 1992, 
Dildy-Mayfield and Harris 1995, Akinshola, Yasuda et al. 2003). Out of all the 
glutamatergic receptors, the NMDA receptor (NMDAR) is highly sensitive to the effects of 
alcohol. Alcohol’s binding site on the NMDAR is not known, and there has been some 
evidence to suggest that alcohol exerts its effect on the NMDAR through protein kinase C 
(Li, Mochly‐Rosen et al. 2005). Acute application of alcohol to hippocampal neuronal 
slices reduces NMDA activity at a concentration that produces intoxication in humans and 
is linearly related to alcohol’s intoxicating potency (Lovinger, White et al. 1989). In a drug 
discrimination test, MK-801, an NMDA antagonist, elicited the same response that 
animals were trained to give in the presence of alcohol, indicating that alcohol’s NMDA-
antagonizing effects are important for mediating the subjective effects of alcohol 
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(Butelman, Baron et al. 1993). In recently detoxified alcoholics, ketamine, an NMDA 
antagonist, was able to mimic the behavioral effects of alcohol (Krystal, Petrakis et al. 
1998). Ketamine reduces alcohol consumption in alcohol-preferring rats (dose-
dependently), and this mechanism is mediated through the mammalian target of 
rapamycin (mTOR) pathway (Sabino, Narayan et al. 2013). Ketamine has also been found 
effective in treating major depression disorder (Rasmussen, Lineberry et al. 2013) as well 
as depressive symptoms, such as the depressive-like behavior produced by abstinence 
from alcohol (Holleran, Wilson et al. 2016). When tested on individuals with a family 
history of alcohol dependence, ketamine caused an attenuated response in dysphoric 
mood, relative to those without such a family history (Petrakis, Limoncelli et al. 2014). 
The production of alcohol-like effects by ketamine and the reduction in alcohol 
consumption and alcohol-related symptoms supports the clinical role of NMDAR function 
facilitating alcohol’s effects on humans. 
The response to alcohol depends on the subunit composition of the glutamatergic 
receptor. A study using rat NMDAR subunits expressed in Xenopus oocytes suggests that 
NMDARs containing certain subunits are more sensitive to alcohol than others (Raeder, 
Holter et al. 2008). Alterations in subunit composition of glutamate receptors were seen 
after chronic use of alcohol in mice (Ortiz, Fitzgerald et al. 1995). Chronic alcohol was also 
found to increase the expression of AMPA receptor (AMPAR) subunit (GluA) 1 in the 
brains of alcoholics (Lewohl, Wang et al. 2000). 
Once alcohol is removed from the system, the hyperglutamatergic state can 
produce a severe withdrawal syndrome characterized by agitation, anxiety, and 
disorientation and is associated with a susceptibility to seizures and excitotoxic cell death. 
NMDAR antagonists can be applied to protect cells from this type of death (Hoffman, 
Lorio et al. 1995, Al Qatari, Khan et al. 2001). The acute withdrawal syndrome is clinically 
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relevant and well characterized. The question remains as to whether the 
neuroadaptations leading to acute withdrawal syndrome contribute to the propensity of 
relapse or lead to alcoholism. 
Acute alcohol inhibits the function of the NMDAR, while chronic use of alcohol 
seems to upregulate NMDAR expression in the brain (Qiang and Ticku 2005). This 
upregulation is thought to counteract the acute inhibition of the glutamatergic system 
and also the sedative effects of increased g-aminobutyric acid receptor A (GABA-A) 
activity, as discussed below. 
Acamprosate, one of the three approved treatments for alcoholism, is proposed 
to exert at least part of its effect by altering glutamatergic function (De Witte, Littleton et 
al. 2005), though the exact mechanism by which it interacts is unclear. Acamprosate was 
found to reduce relapse rate, increase abstinence rate, and decrease excessive drinking 
in alcohol-dependent rats, and had no effect in non-dependent rats (Spanagel, Hölter et 
al. 1996, Spanagel, Putzke et al. 1996, Spanagel, Zieglgänsberger et al. 1996). In dozens of 
clinical trials conducted in Europe, about half of the alcoholics treated with acamprosate 
maintained sobriety compared to the placebo group (Mason and Ownby 2000, Mann, 
Lehert et al. 2004), but results of US clinical trials have shown less beneficial effects of 
acamprosate (Anton, O’Malley et al. 2006, Mason, Goodman et al. 2006). Several studies 
seeking to identify acamprosate’s mechanism of action have failed to show direct 
modulation of NMDARs at clinically relevant concentrations (Reilly, Lobo et al. 2008) and 
a recent study suggests that calcium is the active moiety of acamprosate (Spanagel, 
Vengeliene et al. 2014). Application of acamprosate on GABA-A receptors and voltage-
gated Na+ channels did not exert any effect (Reilly, Lobo et al. 2008). On the other hand, 
knocking out some of the subunits of the mGluRs in mice or by using an mGluR antagonist 
reduces the ability of acamprosate to affect behavior (Blednov and Harris 2008). Taken 
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together, the evidence indicates that alcohol’s modulation of the glutamatergic system is 
an important molecular mechanism by which alcohol exerts its behavioral effects and a 
potential target for the treatment of alcoholism. Figure 1.4 presents an illustration of the 
main neurotransmitter systems and brain regions involved in the neuroadaptations 







FIGURE 1.4 : THE MOLECULAR ADAPTATIONS IN THE MESOCORTICOLIMBIC PATHWAY OCCURRING WITH 
ALCOHOLISM 
A. The mesocorticolimbic system includes several brain areas: prefrontal cortex (PFC), nucleus accumbens (NAc), 
ventral tegmental area (VTA), and amygdala (Amg). Alcohol consumption induces major effects on the dopaminergic, 
glutamatergic, and GABAergic systems in this pathway. Acute effects of alcohol include: increased dopamine release 
(associated with reward), increased GABA receptor activity (associated with anxiolysis, sedation, and motor 
incoordination), and decreased glutamate receptor activity. DA, dopamine; EtOH, ethanol; NMDA-R, N-methyl-D-
aspartate receptor; GABA-R, g-aminobutyric acid receptor.  B. Chronic alcohol consumption causes neuroadaptations 
to oppose the effects of acute alcohol and include: decreased dopamine release and increased dopamine receptor 




Dopamine is a neurotransmitter involved in reward related mechanisms in the 
brain. Dopamine is thought to contribute to alcoholism by signaling in the midbrain 
dopaminergic system, a brain circuit involved in associative learning, incentive salience, 
and reward prediction (Gonzales, Job et al. 2004). The midbrain dopaminergic system 
originates in the ventral tegmental area (VTA) and projects to regions of the brain such as 
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the striatum, nucleus accumbens (NAc), and prefrontal cortex (PFC). Alcohol and other 
drugs of abuse increase dopaminergic activity in the midbrain region of rodents and 
humans (Boileau, Assaad et al. 2003). Dopamine release in the midbrain partially 
mediates the positive-reinforcing properties of acute alcohol exposure necessary for the 
development of alcoholism (Raeder, Holter et al. 2008). Moreover, preference for alcohol 
has been directly correlated with alcohol-induced dopamine release in the midbrain. This 
is illustrated by the fact that rats which are bred to prefer alcohol release more dopamine 
than wild-type rats in an alcohol self-administration study (Weiss, Lorang et al. 1993). 
Also, mice lacking different dopamine receptors and transporters show modified alcohol 
preference compared with controls, further illustrating dopamine’s involvement in 
alcohol-related behaviors (Crabbe, Phillips et al. 2006). 
Acute alcohol exposure activates dopamine reward pathways, whereas chronic 
treatment produces a hypodopaminergic state associated with dysphoria, which can lead 
to craving and relapse (Koob and Volkow 2010). A 1-year-long chronic alcohol treatment 
in rats decreased dopamine and its metabolite in the striatum, decreasing tyrosine 
hydroxylase protein levels and increasing dopamine transporter protein levels compared 
to controls (Rothblat, Rubin et al. 2001). Positron emission tomography scans show that 
chronic alcoholics have fewer dopamine receptors of type D2 compared with non-
alcoholics. D2 receptors in the striatum are mainly localized on GABA-synthesizing cells. 
These results provide evidence of GABAergic involvement in the dopaminergic 
abnormalities seen in alcoholics (Volkow, Wang et al. 2002). These results also reflect the 
brain’s homeostatic mechanism to adapt to initial increases in dopamine levels after 
chronic exposure to alcohol. 
The dopamine receptor antagonist fluphenazine will block alcohol self-
administration when injected into the NAc (Rassnick, Pulvirenti et al. 1992). Additionally, 
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several clinical trials have shown that aripiprazole, an atypical antipsychotic, reduces 
craving and increases positive subjective feelings in alcoholics (Martinotti, Nicola et al. 
2007, Brunetti, Di Tizio et al. 2012). Although these clinical trials are promising, the 
mechanism by which dopamine malfunction caused by alcohol contributes to clinical 
alcoholism is currently unknown. 
GABA-A 
GABA is the primary inhibitory neurotransmitter, and the GABA-A receptor, a 
ligand-gated chloride channel, is the most abundant inhibitory receptor in the 
mammalian brain. Acute alcohol exposure enhances GABA-A function. The molecular 
actions by which alcohol may exert its effects on GABAergic activity are by directly binding 
to the receptor, increasing presynaptic release of GABA or releasing GABAergic steroids 
(Lobo and Harris 2008). This acute action of alcohol on the GABAergic system, along with 








FIGURE 1.5: THE GABAERGIC SYSTEM AND THE EFFECTS OF ACUTE AND CHRONIC ALCOHOL EXPOSURE. 
A. GABA acts in part through the activation of GABA-A receptors, which are ligand-gated ion channels that allow 
chloride ions (Cl-) to flow into the neuron after GABA binds to it. Greater influx of Cl- into the neuron makes it more 
difficult for the cell to generate a new action potential (which is why GABA is considered to be an inhibitory 
neurotransmitter). The molecular actions by which alcohol may exert its effects on GABAergic activity is by directly 
binding to the receptor, increasing presynaptic release of GABA, or releasing GABAergic steroids that activate 
extrasynaptic receptors . B. After chronic alcohol exposure and during withdrawal, GABA activity at the synapse is 
reduced, leading to reduced inhibition of the postsynaptic neuron. This results in development of anxiety and 
hyperexcitability. Figure has been adapted from Clapp et al., 2008. 
Alcohol intoxication is characterized by anxiolysis, sedation, impaired cognitive 
function, hypnosis, and impaired motor function. Many of these behaviors are mimicked 
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by the administration of pharmacological GABA-A agonists like muscimol and 
benzodiazepines (Grobin, Matthews et al. 1998). Moreover, the effects of alcohol can be 
diminished by using pharmacological GABA antagonists like bucucilline and picrotoxin 
(Hyytiä and Koob 1995), suggesting that GABA-A signaling is directly involved in the acute 
actions of alcohol. Electrophysiological data support alcohol’s actions on GABA-A 
receptors, showing potentiation of GABA-mediated chloride influx following alcohol 
administration in a variety of preparations. Mihic et al. 1997 identified a 45-amino-acid 
residue necessary and sufficient for the enhancement of GABA-A receptor function by 
alcohol, suggesting that alcohol’s binding site is between the transmembrane 2 and the 
transmembrane 3 regions of the receptor (Mihic, Ye et al. 1997). This is supported by 
crystallographic analysis of alcohol binding to a related ligand-gated ion channel, GLIC 
(Sauguet, Howard et al. 2013). Chronic alcohol use causes changes in GABA receptor 
subunit composition in human alcoholics (Lewohl, Crane et al. 1997), and it should be 
noted that alcohol’s pharmacological action on GABA-A receptors (and consequently 
behavioral responses) strongly depends on the subunit composition of the receptor. 
Alcohol increases GABAergic neurotransmission over a wide range of concentrations, with 
some studies showing that δ-containing receptors are more sensitive than other GABA-A 
receptors (Wallner, Hanchar et al. 2003). Use of mutant mice either lacking a subunit or 
containing an ethanol-resistant subunit demonstrated that the α2 and α3 subunits take 
part in mediating the motor-impairing effects of alcohol, and that the α2 subunit also 
takes part in the aversive properties of alcohol (Blednov, Borghese et al. 2011, Blednov, 
Benavidez et al. 2013). 
Chronic alcohol use causes the downregulation of GABA-A receptors due to the 
initial overstimulation by the alcohol. In turn, glutamate receptors are upregulated to 
counteract the sedative effects of increased GABA-A. During withdrawal from alcohol, the 
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excess of glutamate receptors combined with the lack of GABA-A, causes anxiety, 
dysphoria, and in severe cases, seizures. Topiramate, an anticonvulsant seizure 
medication, was found to reduce voluntary alcohol intake in humans with alcohol 
dependence in recent clinical trials (Johnson, Rosenthal et al. 2008). Alcoholic patients 
achieved a rate of continuous abstinence much higher than those in a placebo group. 
They also reported fewer cravings compared to a placebo group but complained of other 
side-effects. Topiramate is associated with glutamate system inhibition, although the 
exact mechanism by which topiramate promotes abstinence is not yet understood. 
GABA-B 
GABA-B receptors are metabotropic receptors responsible for mediating slow 
inhibitory responses in the brain and have been implicated in alcoholism. Acute alcohol 
was seen to increase inhibitory GABA-B signaling in a concentration-dependent manner 
in rat midbrain dopaminergic neurons (Federici, Nistico et al. 2009). Silencing the GABA-
B receptor in fruit flies using RNA interference decreases acute motor impairment after 
alcohol exposure (Dzitoyeva, Dimitrijevic et al. 2003). Similarly, in mice, cerebellar 
injections of GABA-B agonists accentuated and antagonists attenuated motor impairment 
following acute alcohol (Dar 1996). Conversely, recordings in CA1 pyramidal neurons have 
indicated that GABA-B signaling was immune to the acute effects of alcohol but became 
modulated after chronic exposure, perhaps because of neuroadaptations from 
dependence (Frye, Taylor et al. 1991). Baclofen, a GABA-B agonist prescribed to treat 
muscle spasticity, reduces relapse in dependent humans and decreases alcohol 
consumption in rats (Addolorato, Caputo et al. 2002, Maccioni and Colombo 2009, 
Agabio, Maccioni et al. 2012). Dr. Olivier Ameisen describes attending over 5000 AA 
meetings over the course of several years in an attempt to reduce his alcohol craving and 
abstain from drinking. Despite all efforts, he continued drinking and eventually treated 
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himself with high doses of baclofen; he was able to “cure” his disease (Ameisen 2005, 
Ameisen 2012). Preclinical studies show that baclofen is able to suppress withdrawal 
symptoms in alcoholics, promote alcohol abstinence, and reduce withdrawal-related 
anxiety and alcohol craving (Addolorato, Caputo et al. 2002). There is also evidence for 
baclofen having no significant effect on alcoholics (Garbutt, Kampov‐Polevoy et al. 2010), 
suggesting that baclofen may be effective in treating only certain subtypes of alcoholics. 
There is still research to be done on baclofen and its side-effects, and therefore it has not 
yet been approved by the Food and Drug Administration (FDA) for the treatment of 
alcoholism (Leggio, Garbutt et al. 2010). 
RNA splicing is a process that removes the intervening, non-coding sequences of 
genes (introns) from premRNA and joins the protein-coding sequences (exons) together 
in order to enable translation of mRNA into a protein. Sometimes, exons are extended or 
skipped, or introns are retained during the splicing process, leading to “alternative 
splicing.” Alternative splicing of the premRNA creates different splice variants for the 
same gene, which results in a functional diversity of proteins (Matlin, Clark et al. 2005). 
Eventually, the mRNA transcripts are exported to the cytoplasm and translated into 
different isoforms of the same protein that vary in their functional properties (Coetzee, 
Amarillo et al. 1999, Dredge, Polydorides et al. 2001). Drugs of abuse, such as alcohol, can 
affect alternative splicing. For example, chronic alcohol consumption enhances the 
complexity of GABA-B receptor splicing (Lee, Mayfield et al. 2010, Lee, Mayfield et al. 
2014). Human alcoholics show differences in GABA-B receptor splice variants when 
compared to non-alcoholics, which may contribute to the pharmacological effects of 




In summary, pharmacologic, behavioral, and electrophysiological evidence 
supports a role for GABA-B in mediating the effects of alcohol. Moreover, many of the 
behaviors associated with alcoholism result from the direct alcohol-induced modulation 
of GABAergic neurotransmission. It should be noted that the specific behaviors elicited by 
alcohol depend highly on receptor subtype expression and cellular location. 
Serotonin (5-HT) 
Serotonin is a neurotransmitter that serves many functions, including regulating 
mood, sleep, appetite, learning, memory, and other phenomena. The supply of neuronal 
serotonin originates mostly from neurons in the raphe nuclei whose axons innervate 
almost the entire brain, reflecting serotonin’s vast physiological roles. There are many 
types of receptors for serotonin in the CNS and all are metabotropic, except for 5-HT3, 
which is a ligand gated ion channel. Evidence indicates that serotonin is involved in 
mediating both acute and chronic alcohol action and perhaps the development and 
maintenance of alcoholism. 
Alcohol facilitates serotonergic transmission in part by increasing the potency for 
the agonist activation of the 5-HT3 receptor (Sung, Engel et al. 2000) and the open state 
duration of the channel (Zhou, Verdoorn et al. 1998). In general, an inverse relationship 
between serotonin transmission and alcohol drinking has been established. In animal 
models of drinking and in human alcoholics, increased serotonergic transmission is 
associated with less alcohol consumption while less serotonergic transmission is linked to 
more alcohol consumption (Lovinger 1997). 
Electrophysiological recordings in neuroblastoma cells show that acute alcohol 
potentiates 5-HT3 receptor mediated ion currents (Lovinger and White 1991). Acute 
alcohol was also found to activate the 5-HT3 receptor in oocytes (Harris, Mihic et al. 
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1995), ganglion neurons (Lovinger and White 1991), frontal cortex neurons (Sung, Engel 
et al. 2000), and human embryonic kidney 293 cells (Lovinger and Zhou 1994). 
Serotonin levels in animal brains are elevated after acute alcohol exposure 
(Murphy, McBride et al. 1982, LeMarquand, Pihl et al. 1994). Mice lacking the 5-HT1B 
serotonin receptor consume larger amounts of alcohol compared to wild-type. Mice 
lacking the receptor show much higher incoordination compared to wild-type mice (after 
just one injection of alcohol), suggesting this receptor is involved in the intoxication 
process (Crabbe, Phillips et al. 1996). The 5-HT2 receptor seems to be important for the 
reinforcing properties of alcohol because antagonists selectively decrease acute alcohol 
reinforcement (Roberts, McArthur et al. 1998). Blockade of the serotonin transporter (5-
HTT) with fluoxetine, a selective serotonin reuptake inhibitor (SSRI) (a widely used 
antidepressant, also known as Prozac), or by genetic knockout, decreases alcohol 
consumption in rodents (Kelaï, Aïssi et al. 2003). Decreased consumption of alcohol 
following SSRI treatment has been observed in almost every rat model of alcoholism 
(Amit, Brown et al. 1977, Sellers, Higgins et al. 1992, Ciccocioppo, Economidou et al. 
2006). Human studies have given less consistent results, but it appears that SSRIs may be 
effective in some subpopulations of alcoholics, such as late-onset individuals (Kranzler, 
Feinn et al. 2012). 
In addition to enhancing 5-HT activity in the brain using SSRIs, another approach 
widely used to understand serotonin’s effect on alcohol consumption has been to 
selectively block the 5-HT3 receptor. 5-HT3 antagonists decrease alcohol self-
administration (Fadda, Garau et al. 1991, Hodge, Samson et al. 1993) and consumption in 
rodents (Sellers, Toneatto et al. 1994). 
In humans, the drug ondansetron, a 5-HT3 antagonist that is FDA-approved for the 
treatment of chemotherapy-induced nausea, is a promising treatment for alcoholics. In a 
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clinical trial, alcoholics were randomly selected to receive either ondansetron or a 
placebo for 11 weeks. The ondansetron patients with early-onset alcoholism had fewer 
drinks per day and reported more days of total abstinence than the placebo group 
(Johnson, Roache et al. 2000). In another clinical trial with 71 alcoholic men receiving a 6-
week treatment with a low dose of ondansetron (0.25 mg) showed significant levels of 
decreased drinking when compared to placebo (Sellers, Toneatto et al. 1994). In another 
study analyzing the reinforcing properties of alcohol and 5-HT3 receptor function, 
treatment with ondansetron decreased the subjective pleasurable effects of alcohol and 
the desire to drink (Johnson, Campling et al. 1993). Since the serotonin transporter is 
important for regulating the serotonergic system, alleles at the gene encoding 5-HTT 
might predict the severity of the alcoholism and the therapeutic response to treatment 
with ondansetron. A clinical trial with 283 alcoholics found that ondansetron recipients 
had fewer drinks per day and more days spent totally abstinent than those who received 
placebo. The effect was greater in alcoholics with the LL genotype than the SS or LS 
genotype of the 5’-regulatory region of the serotonin transporter gene (Johnson, Ait-
Daoud et al. 2011). Moreover, animal studies have demonstrated that ondansetron might 
also be useful for treating opioid withdrawal symptoms (Pinelli, Trivulzio et al. 1997). 
Big potassium (BK) channels 
The BK channel is a high-conductance calcium- and voltage-dependent potassium 
channel (Atkinson, Robertson et al. 1991) that plays a dominant role in shaping neuronal 
activity and, unlike other voltage-gated ion channels, is strongly affected by alcohol 
(Treistman and Martin 2009). Tolerance, which is the loss of drug effectiveness over time, 
is an important component of addiction. Acute tolerance can have a rapid onset within 
minutes of alcohol exposure, whereas tolerance after prolonged alcohol exposure 
develops over the course of days or weeks. The degree of acute behavioral tolerance to 
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alcohol exhibited by a naïve subject can predict the likelihood of alcoholism (Treistman 
and Martin 2009). Thus, the determinants of acute tolerance are important to 
understand. The BK channel is a key target in the development of tolerance in 
invertebrates and mammals (Davies, Pierce-Shimomura et al. 2003, Martin, Hendrickson 
et al. 2008). There are several variables that influence the response of the BK channel to 
alcohol, including subunit composition, splice variant, and posttranslational mechanisms 
(covered in “The effects of alcohol on synaptic elements” below). BK channels from 
neurons of wild-type mice (in which the β4 subunit is well represented) exhibit little 
tolerance. By contrast, neuronal BK channels from β4 knockout mice do display acute 
tolerance. In addition to displaying tolerance, the β4 knockout mice drink more than their 
wild-type counterparts in an alcohol self-administration paradigm (Martin, Hendrickson 
et al. 2008). 
Tolerance was found to involve the alternative splicing of the α subunit of the BK 
channel. The BK channel was found to have a sensitive and non-sensitive splice variant to 
alcohol. Within minutes of exposure to alcohol, the expression of the more alcohol-
sensitive variant was selectively decreased, therefore producing tolerance (Treistman and 
Martin 2009). The development of acute tolerance to alcohol provides another example 
that demonstrates the effects of alternative splicing of mRNAs on alcohol-related 
behavior (seen previously with the GABA-B receptors). 
Transcription factors 
Transcription factors serve as a key mechanism by which distinct gene programs 
are controlled because they bind to highly specific DNA-regulatory sequences (control 
elements) (Renthal and Nestler 2008, Rahman 2012). Activation of alcohol-responsive 
transcription factors is also likely to result in changes in the expression of those genes 
with the corresponding control elements. 
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Heat shock factor protein 1 (HSF1) is a transcription factor which was found to be 
involved in the effects of acute alcohol application. Acute alcohol was found to increase 
GABA-A receptor α4 subunit mRNA by increasing the binding of HSF1 to the promoter 
regions of GABA, increasing its transcription. Blocking the expression of HSF1 reduced the 
alcohol-induced increases in the α4 subunit and conversely, an active form of HSF1 
induced α4 subunit transcription in the absence of alcohol (Pignataro, Miller et al. 2007). 
Acute alcohol also facilitates activation of HSF1 to the promoter region of synaptotagmin-
1, a protein involved in synaptic transmission and release, suggesting that alcohol has a 
direct control of neurotransmitter release in an acute fashion (Pignataro, Miller et al. 
2007, Pignataro, Varodayan et al. 2009). HSF family of mRNA was found to be different 
between alcoholic and control postmortem frontal cortices (Lewohl, Wang et al. 2000), 
as well as in cultured cortical neurons exposed to chronic alcohol treatment (Wang, 
Krishnan et al. 2007). These results indicate that these transcription factors are also 
involved in alcohol dependence. 
The activation of several signaling pathways involving cAMP, Ca2+ and extracellular 
signal regulated kinase lead to the phosphorylation of the transcription factor cyclic AMP 
response element-binding protein (CREB) (Winstanley, LaPlant et al. 2007). Some 
chromatin-remodeling enzymes target chromatin by interacting with specific 
transcription factors by guiding them to a specific locus on the DNA. When 
phosphorylated, the transcription factor CREB interacts with CBP, a HAT that helps 
facilitate target gene activation by acetylating neighboring histones. This process was 
found to play a major role in behavioral responses to cocaine (Levine, Guan et al. 2005, 
Malvaez, Mhillaj et al. 2011). Long-term treatment with alcohol was found to increase 
CREB transcription factor activation, which subsequently increases the binding of CREB to 
the promoter of the glutamate receptor, increasing the transcription of a specific 
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glutamate receptor subunit - NR2B. Site-directed mutation in the sequence where CREB 
binds, abolished the stimulatory effect by alcohol, suggesting that CREB is involved in 
mediating alcohol induced upregulation of the NR2B gene (Rani, Qiang et al. 2005). This 
is a great example of an alcohol-responsive transcription factor affecting downstream 
expression of receptors which are also involved in mediating the response to alcohol. 
Another example suggesting that the downstream transcription of genes is 
selective to either the acute or chronic stages of addiction is that of the immediate-early 
genes, such as c-Fos and FosB. These immediate-early genes are induced rapidly in the 
brain by acute use of drugs such as cocaine and alcohol, whereas the transcription of 
genes such as Cyclin-dependent kinase 5 (Cdk5) and brain-derived neurotrophic factor 
(BDNF) is induced by chronic use of cocaine (Taylor, Lynch et al. 2007). Chronic use of 
drugs also causes the accumulation of ΔfosB, a member of the Fos family of transcription 
factors. ΔfosB accumulates in specific regions of the brain in response to drugs and 
persists for several weeks after the end of the stimulus (Watanabe, Henriksson et al. 2009, 
Damez-Werno, LaPlant et al. 2012). ΔfosB represents a molecular mechanism that can 
initiate and then sustain changes in gene expression that persist long after drug exposure 
ceases (Nestler, Barrot et al. 2001). 
THE EFFECTS ON THE NEUROIMMUNE SYSTEM 
Substantial evidence has accumulated that implicates an unlikely target, the 
neuroimmune system, in the development, progression, and persistence of alcoholism. 
The term neuroimmune refers to signaling molecules that were first associated with 
innate immunity but are also commonly found in the brain. The brain uses immune 
signaling systems as neuromodulators that have functions distinct from their role in the 
peripheral immune system and are critical for normal brain functions like neuronal 
 
30 
plasticity (Boulanger, Huh et al. 2001). One example of this is the major histocompatibility 
complex (MHC) class I molecule, which serves as a primary mediator of immune response 
in the periphery. However, it also modulates activity-dependent refinement and plasticity 
in cortical synapses and the developing visual system in the CNS (Glynn, Elmer et al. 2011, 
Elmer and McAllister 2012). Alcohol-related behavior can be affected by immune 
signaling that originates in the brain or immune signaling derived from the periphery that 
crosses the blood–brain barrier to act on the brain. 
Ingesting alcohol activates the neuroimmune system (Crews, Zou et al. 2011), 
which is proposed to lead to further increases in alcohol consumption, producing an 
escalating feedforward loop not conducive to a homeostatic state. Alcohol consumption 
compromises the tight junctions in gut epithelium, allowing lipopolysaccharide (LPS), a 
Gram-negative bacterial endotoxin that is normally confined to the gut, to leak into the 
blood stream, where it binds to and activates Toll-like receptors (TLRs) expressed on liver 
Kupffer cells and other tissues. This initiates a signaling cascade that culminates in the 
release of proinflammatory cytokines in the blood stream that can then cross the blood–
brain barrier and interact with the brain, thus affecting behavior. Researchers have found 
that alcohol increases TLR expression in the brain and increases its sensitivity to LPS 
(Crews, Qin et al. 2012, Vetreno and Crews 2012). To test how peripheral release of LPS 
would affect drinking behavior, Blednov et al. 2011 injected mice with LPS and found that 
a single injection produces long-lasting increases in alcohol consumption consistent with 
neuroimmune signaling, mediating the reinforcing properties of alcohol. The single 
injection of LPS also increased the firing rate of dopamine neurons in the ventral 
tegmental area, providing an example of how neuroimmune activation following 
peripheral LPS administration modulates brain reward circuitry (Blednov, Benavidez et al. 
2011). Indeed, peripheral immune function has been found to be important for other 
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mental illnesses such as schizophrenia, depression, and autism (Dantzer, O'Connor et al. 
2008, Kelley and Dantzer 2011, Derecki, Cronk et al. 2012, Jones and Thomsen 2013, 
Takao, Kobayashi et al. 2013); however, the mechanism by which peripheral immune 
activation exerts its effects on the brain is unknown and presents a field to be explored. 
Immune signaling molecules are also found within the brain where they can be 
used for normal, non-immune signaling, but can also reflect pathology and lead to 
neurodegeneration if proinflammation is left unchecked (El Khoury 2010). 
Neurodegenerative effects of immune signaling have been demonstrated in Alzheimer’s 
and Parkinson’s disease (Carta and Pisanu 2013, Hickman and El Khoury 2013). 
Neurodegeneration has been observed in alcoholics and is especially prominent in the 
PFC (Fadda and Rossetti 1998). Neurodegeneration in the PFC can affect judgment and 
reasoning capabilities and further exacerbate chronic alcohol consumption. It is possible 
that neuroimmune activation from alcohol consumption could contribute to the 
neurodegeneration seen in alcoholics (Blanco, Valles et al. 2005, Hua, Ma et al. 2007, 
Alfonso-Loeches, Pascual-Lucas et al. 2010, Qin and Crews 2012). 
Other evidence linking neuroimmune function with alcoholism is that immune 
gene expression in the brain was found to be altered in human alcoholics (Liu, Lewohl et 
al. 2006, Crews, Qin et al. 2012, Ponomarev, Wang et al. 2012), mice, and fruit flies after 
alcohol exposure (Qin, He et al. 2008, Kong, Allouche et al. 2010), and rodent genetic 
models of high alcohol consumption (Mulligan, Ponomarev et al. 2006, Saba, Bhave et al. 
2006). Furthermore, mice lacking genes related to immune function show decreased 
alcohol consumption compared to littermate controls (Blednov, Ponomarev et al. 2012). 
Acute and chronic alcohol use activates microglia, the resident macrophages of the brain, 
and increases proinflammatory cytokines via nuclear factor ĸ B (NFĸB) in the brain (Crews, 
Zou et al. 2011). Behavioral responses to acute alcohol were altered in mice that lack TLR 
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receptors, TLR2 or TLR4 (Wu, Lousberg et al. 2011). In a key publication, the knockdown 
of TLR4 in the rat amygdala decreased alcohol self-administration, demonstrating that 
neuroimmune signaling, independent of input from peripheral cytokines, was sufficient 
in regulating alcohol behavior (Liu, Yang et al. 2011). 
Pioglitazone and rosiglitazone, agonists of the peroxisome proliferator activator 
receptor (PPAR) type γ, have anti-inflammatory properties largely mediated through their 
ability to inhibit the transcription factor NFĸB and thus decrease proinflammatory 
cytokine production (Daynes and Jones 2002). Pioglitazone was found to reduce alcohol 
drinking, abolish reinstatement of alcohol seeking, reduce alcohol self-administration, 
and decrease the severity of physical withdrawal symptoms in rats (Stopponi, Somaini et 
al. 2011). Another PPAR agonist, clofibrate, prevents the acquisition of nicotine self-
administration in naïve rats and monkeys and decreases nicotine self-administration in 
nicotine-dependent rats and monkeys, suggesting that the PPAR agonist might be viable 
options for treating the neuroimmune pathologies in alcoholism and other forms of 
addiction. The pharmacological blockade of neuroimmune activation reduces alcohol 
reward and decreases consumption using many types of anti-inflammatory drugs like 
minocycline, doxycycline, topiramate, anakinra, indomethacin, and CAPE (Agarwal 2001, 
Pascual, Blanco et al. 2007, Breslin, Johnson et al. 2010, Wu, Lousberg et al. 2011, McIver, 
Muccigrosso et al. 2012, Zalewska-Kaszubska, Bajer et al. 2013). Taken together, these 
findings have built substantial evidence for neuroimmune modulation of acute and 
chronic alcohol consumption and offer unique unexplored targets for therapeutic 
intervention. 





Neurotransmitter system Associated reference 
Glutamate 
Acute alcohol inhibits NMDA receptor function, while chronic use of alcohol upregulates 
NMDA receptor expression in the brain. 
Lovinger et al., 1989 and  
Qiang and Ticku, 2005 
Alcohol acts as a non-competitive inhibitor of the AMPA/Kainate receptors at high 
concentrations. 
Dildy-Mayfield and Harris, 
1992,  
Dildy-Mayfield and Harris, 
1995 and Akinshola et al., 2003 
MK-801, an NMDA antagonist, mimics the subjective effects of alcohol in animals. Butelman et al., 1993 
Ketamine, an NMDA antagonist, mimics the behavioral effects of alcohol in detoxified 
alcoholics. 
Krystal et al., 1998 
Chronic alcohol increases the expression of AMPA1 subunit (GluA1) in the brains of 
alcoholics. 
Lewohl et al., 2000 
NMDA receptors containing specific subunits are more sensitive to alcohol than others. Raeder et al., 2008 
Alterations in subunit composition of glutamate receptors were seen after chronic use of 
alcohol in mice. 
Ortiz et al., 1995 
Dopamine 
Acute alcohol exposure activates dopamine reward pathways, whereas chronic 
treatment produces a hypodopaminergic state associated with dysphoria, which could 
lead to craving and relapse. 
Koob and Volkow, 2010 
Alcohol increases dopaminergic activity in the midbrain region of rodents and humans. Boileau et al., 2003 
Dopamine release in the midbrain partially mediates the positive reinforcing properties 
of acute alcohol exposure. 
Raeder et al., 2008 
Alcohol-preferring rats release more dopamine than wild-type rats in response to 
alcohol self-administration. 
Weiss et al., 1993 
Mice lacking different dopamine receptors and transporters show modified alcohol 
preference compared with controls. 
Crabbe et al., 2006 
Chronic alcohol treatment decreases dopamine and its metabolite in the striatum, 
decreases tyrosine hydroxylase protein levels, and increases dopamine transporter 
protein levels in rats compared to controls. 
Rothblat et al., 2001 
PET scans show that chronic alcoholics have fewer D2 receptors when compared with 
non-alcoholics. 
Volkow et al., 2002 
The dopamine receptor antagonist fluphenazine will block alcohol self-administration 
when injected into the nucleus accumbens. 
Rassnick et al., 1992 
Aripiprazole, an atypical antipsychotic, reduces craving and increases positive subjective 
feelings in alcoholics. 
Martinotti et al., 2007 and 
Brunetti et al., 2012 
GABA-A 
Behavioral intoxication is mimicked by the administration of pharmacologic GABA-A 
agonists like muscimol and benzodiazepines. 
Grobin et al., 1998 
The effects of alcohol can be diminished by using pharmacologic GABA antagonists like 
bicuculline and picrotoxin. 
Hyytia and Koob, 1995 
Chronic alcohol use causes changes in GABA receptor subunit composition in human 
alcoholics. 
Lewohl et al., 1997 
Alcohol increases GABAergic neurotransmission over a wide range of concentrations, 
with some studies showing that delta-containing receptors are more sensitive than other 
GABA-A receptors. 
Wallner et al., 2003 
α2 and α3 subunits take part in mediating the motor-impairing effects of alcohol. Blednov et al., 2011b 




Acute alcohol increases inhibitory GABA-B signaling in a concentration-dependent 
manner in rat midbrain dopaminergic neurons. 
Federici et al., 2009 
Silencing the GABA-B receptor in fruit flies decreases acute motor impairment after 
alcohol exposure. 
Dzitoyeva et al., 2003 
Cerebellar injections in mice of GABA-B agonists accentuated and antagonists 
attenuated motor impairment following acute alcohol. 
Dar, 1996 
CA1 pyramidal neuron recordings indicated that GABA-B signaling was immune to the 
acute effects of alcohol but became modulated after chronic exposure. 
Frye et al., 1991 
Baclofen, a GABA-B agonist, reduces relapse in dependent humans and decreases 
alcohol consumption in rats. 
Addolorato et al., 2002a, 
Addolorato et al., 2002b, 
Maccioni and Colombo, 2009 
and Agabio et al., 2012 
GABA-B has complex alternative splicing leading to several splice variants in the alcoholic 
brain. 
Lee et al., 2013 
Serotonin (5-HT) 
Acute alcohol potentiates 5-HT3 receptor. 
Lovinger, 1991, Lovinger and 
White, 1991 and Lovinger and 
Zhou, 1994; Harris et al., 1995 
and Sung et al., 2000 
Serotonin levels in animal brains are elevated after acute alcohol exposure. 
Murphy et al., 1982 and 
LeMarquand et al., 1994 
Mice lacking the 5-HT1B serotonin receptor consume larger amounts of alcohol 
compared to wild type. 
Crabbe et al., 1996 
5-HT2 antagonists selectively decrease acute alcohol reinforcement. Roberts et al., 1998 
Blockade of the serotonin transporter (5-HTT) with selective serotonin reuptake 
inhibitors (SSRIs), or by genetic knockout, decreases alcohol consumption in rats and 
partially in humans. 
Brown et al., 1979, Sellers et 
al., 1992, Kelai et al., 2003, 
Ciccocioppo et al., 2006 and 
Kranzler et al., 2012 
Selective antagonists of the 5-HT3 receptor decrease alcohol self-administration and 
consumption in rodents. 
Fadda et al., 1991, Hodge et 
al., 1993 and Sellers et al., 
1994 
Selective antagonists of the 5-HT3 receptor decrease the amount of drinks per day and 
increase the amount of abstinence time in alcoholics. Also, decreases the subjective 
pleasurable effects of alcohol and the desire to drink. 
Johnson et al., 1993, Johnson 
et al., 2000 and Sellers et al., 
1994 
TABLE 1.3: SUMMARY OF NEUROTRANSMITTER SYSTEMS DISCUSSED IN THE FIRST SECTION OF THIS CHAPTER 
DA (dopamine); PET (positron emission tomography). 
The Effects of Alcohol on Synaptic Elements 
Chronic alcohol use causes changes in synaptic structure and function which is 
believed to be caused by persistent changes of many genes. Local translation of mRNAs 
in the synapse may be responsible for the neuroadaptations resulting from chronic 
alcohol use and abuse. Over the past decade, several microRNAs have been proposed as 
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playing a key role in regulating local mRNA translation. As ‘master regulators’ of many 
mRNAs, changes in microRNAs could account for the systemic alterations in mRNA and 
protein expression observed in drug abuse and dependence. There is limited evidence, 
however, regarding how synaptic microRNAs control local mRNA translation during 
chronic drug exposure and how this contributes to the development of dependence. 
Because alcohol dependence is tightly linked to changes in the expression of many 
genes in the brain, an effective therapy must therefore rely on the ability to target 
multiple alcohol-related genes. Recent studies indicate that manipulation of microRNAs 
affects addiction-related behaviors such as the rewarding properties of cocaine, cocaine-
seeking behavior, alcohol consumption and preference over water. However, little is 
known about the synaptic microRNAs involved in the regulation of mRNA translation in 
alcohol dependence. Here, I present the current knowledge regarding the microRNA 
composition in the synapse, the regulatory actions over synaptic mRNA, and the resulting 
effect on chronic alcohol consumption in mice. 
Local Translation and mRNAs 
Chronic drug abuse induces long-term changes in brain gene and protein 
expression, which likely contribute to the neuropathologies associated with abuse and 
dependence (Nestler 2001, Kauer and Malenka 2007). Drug-induced transcriptional 
reprogramming in the brain may account for some of the effects of repeated drug 
exposure (Mayfield, Harris et al. 2008, Robison and Nestler 2011, Ron and Messing 2013). 
Ultimately, neuroadaptations due to chronic drug use are controlled by the regulation of 
many genes expressed within individual neurons or glial cells (Farris and Miles 2012). At 
the cellular level, changes in molecular pathways originate from changes in gene 
expression and translation of proteins. Re-organization of synaptic structure and function 
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is one manifestation of these changes. Many of the functional pathways that are altered 
in addiction paradigms include growth factors (Ron and Messing 2013), serine-threonine 
kinases (Sanna, Simpson et al. 2002, Lesscher, Wallace et al. 2009), glutathione pathway 
enzymes, protein translation (Neasta, Ben Hamida et al. 2010, Barak, Liu et al. 2013), and 
inflammatory pathways (Blednov, Benavidez et al. 2011, Gorini, Harris et al. 2014). 
Proteins can be directly translated in synaptic regions, allowing cells to rapidly 
respond to stimuli and bypassing the need to transport proteins to the synapse, an 
energetically costly and slow process. Translation is an important mechanism underlying 
synaptic plasticity and is controlled locally in response to environmental signals (Ule and 
Darnell 2006, Schratt 2009). Synaptic translation is one way by which drugs of abuse 
induce targeted neuroadaptations (Nunez and Mayfield 2012). Drug-induced 
neuroadaptations and transcriptional changes influence a complex regulatory network 
that controls how and when the synaptic mRNAs are translated (Smalheiser and Lugli 
2009). MicroRNAs, in part, regulate local protein synthesis and the molecules that control 
it. Many of the characteristic alterations in synaptic composition due to chronic drug 
exposure may arise from alterations in microRNAs (Eipper-Mains, Kiraly et al. 2011). This 
section of the thesis examines how microRNAs regulate synaptic translation and how this 
relates to the molecular pathways in drug use disorders. 
Synaptic translation occurs in response to neural activity following chemical 
changes in the extracellular milieu. The first evidence came from electron micrographs 
showing clusters of polyribosomes at the synapse (Steward and Levy 1982). Twenty years 
later, the first dynamic visualization of localized protein synthesis was demonstrated 
when Aakalu et al. 2001 definitively showed translation within isolated dendrites in 
response to BDNF (Aakalu, Smith et al. 2001). In addition, application of dopamine to cells 
induced local protein translation (Smith, Starck et al. 2005). Discrete increases in protein 
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levels can occur in as little as 5 minutes, as shown for activity-regulated cytoskeleton-
associated protein (Arc) (Niere, Wilkerson et al. 2012), or in 20 minutes for 
Ca2+/calmodulin-dependent protein kinase II (CaMKII)(Gong, Park et al. 2006). 
Location- and time-specific translation at an activated synapse allows for spatially 
restricted expression of new proteins (Wang, Martin et al. 2010). This specialized control 
works to fine-tune translational mechanisms (Jung, Gkogkas et al. 2014). Newly translated 
proteins have fewer post-translational modifications, and thus will have different 
signaling properties than older proteins (Jung, Gkogkas et al. 2014). All of these factors 
help ensure the rapid and targeted responses required for neuronal signaling, and 
perturbations to this balanced system can profoundly alter cellular pathways. 
Some of the first evidence of synaptic translation came from synaptoneurosome 
(SN) preparations that enrich for pre-and post-synaptic compartments of neurons, 
astrocytes, oligodendrocytes, and microglia (Hollingsworth, McNeal et al. 1985). This 
preparation can be used to study the synaptic transcriptome (Hollingsworth, McNeal et 
al. 1985, Quinlan, Philpot et al. 1999) and synaptic translation of mRNAs (Raab-Graham, 
Haddick et al. 2006, Sosanya, Huang et al. 2013). The development of this preparation, 
together with advances in microscopy and molecular cloning, have facilitated the 
discovery of the regulatory processes that govern mRNA translation at the synapse. 
SNs and post-synaptic enriched preparations helped identify the method by which 
mRNA is distributed into synaptic compartments. The targeting of mRNA to dendrites 
occurs through the 3′UTR (Kislauskis and Singer 1992, Mayford, Baranes et al. 1996, 
Aakalu, Smith et al. 2001, Miller, Yasuda et al. 2002, Martin and Ephrussi 2009). The 3′UTR 
contains targeting elements that direct where and how mRNA is translated. Evidence 
suggests that the targeting of mRNA to the dendrite relies on cis-acting elements, often 
called zip codes (Meer, Wang et al. 2012). Cis-acting elements are recognized by trans-
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acting factors for proper dendritic targeting and regulation. For example, localization of 
the β-actin protein requires a 54-nucleotide cis-acting zip code in the 3′UTR to target it to 
dendrites and growth cones (Kislauskis and Singer 1992, Zhang, Singer et al. 1999, Eom, 
Antar et al. 2003). 
The zip codes can be single- or double-stranded stem loop structures comprised 
of multiple independent cis-acting elements that aggregate and confer distinct 
localization properties for each mRNA (Jambhekar and Derisi 2007, Holt and Bullock 
2009). Cis-acting elements are normally within the 3′UTR but have also been found in the 
coding region and the 5′UTR. Regulation of local translation occurs through extensive 
interactions between the 3′UTR zip codes of mRNAs and microRNAs in concert with RNA-
binding proteins. Drug-induced alterations in microRNAs may affect mRNA translation 
and distribution in the synapse via these mechanisms. 
Local Translation and microRNA Regulation 
MicroRNAs comprise a specific class of small non-coding RNAs that bind to 
complementary sequences on target mRNAs to repress translation and silence gene 
expression (Ambros 2001, Lee and Ambros 2001). MicroRNAs can regulate translation of 
many genes at once, making them ‘master regulators’ of cellular gene expression. They 
are highly abundant in the brain and play important roles in multiple biological processes, 
including brain development (Krichevsky, King et al. 2003), synapse formation (Schratt, 
Tuebing et al. 2006), synaptic plasticity (Smalheiser and Lugli 2009, Cohen, Lee et al. 
2011), neuroimmune signaling (Soreq and Wolf 2011), learning and memory (Gao, Wang 
et al. 2010, Konopka, Kiryk et al. 2010) and mental disorders (Beveridge, Tooney et al. 
2008, Parsi, Smith et al. 2015). 
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MicroRNAs control both translational repression and degradation, and they also 
act in concert with RNA-binding proteins to pinpoint their target mRNAs which often 
occurs through interaction with cis-acting elements. MicroRNAs are transcribed in the 
nucleus as pri-microRNA. They are then cleaved by Drosha into pre-microRNA and then 
transported into the cytoplasm. Alternatively, they may be spliced from introns in other 
genes, and then folded into pre-microRNA. Dicer then completes processing in the 
cytoplasm and assembly into the RNA-induced silencing complex (RISC) as dsRNA 
(Iwasaki, Kobayashi et al. 2010). The RISC complex retains the strand of microRNA with 
the lowest free energy at the 5′UTR which can bind to its target mRNAs. MicroRNAs 
associate with Argonaute (Ago) in the RISC complex to target their mRNAs (Bartel 2009). 
MicroRNAs need only contiguous pairing of the ‘seed’ region (nucleotides 2–7) to 
successfully pair with an mRNA (Stark, Brennecke et al. 2005, Nielsen, Shomron et al. 
2007). However, different binding patterns have been observed that may alter the target 
affinity of the microRNA. Because of this, microRNAs can target and bind multiple mRNAs, 
and mRNAs can have multiple microRNA regulatory sites (Goldie and Cairns 2012). 
MicroRNAs repress translation by blocking ribosomal interaction with target 
mRNA, by preventing interaction of Eukaryotic initiation factor (eIF4E) with mRNA, or by 
targeting mRNAs to P-bodies (processing bodies) for degradation (Pillai, Bhattacharyya et 
al. 2005, Mathonnet, Fabian et al. 2007, Filipowicz, Bhattacharyya et al. 2008). 
Degradation occurs when mRNAs de-circularize and ribosomes dissociate. MRNA-
microRNA interactions are reversible, allowing activity-dependent conditions to dictate 
which mRNAs are targeted by the RISC (Filipowicz, Bhattacharyya et al. 2008). 
MicroRNAs target the cis-acting elements in the 3′UTRs of mRNAs, similar to how 
RNA-binding proteins operate. Several systems portray a ‘push–pull’ mechanism of 
inhibiting and/or promoting translation in which both microRNAs and RNA-binding 
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proteins participate. Kv1.1, a voltage gated potassium channel, is regulated by both HuD, 
an RNA-binding protein, and by miR-129, and this occurs in response to mTOR activation 
(Sosanya, Huang et al. 2013). Kv1.1 is translated in dendrites only when mTOR activity is 
low (Raab-Graham, Haddick et al. 2006). Blocking mTOR activity releases Kv1.1 from miR-
129 repression and frees HuD from higher affinity targets, enabling HuD to initiate 
translation of Kv1.1. Moreover, NMDAR activity alters the expression levels of multiple 
microRNAs, including those that inhibit mTOR inhibitors (Kye, Neveu et al. 2011). In 
addition, miR-125 is bi-directionally regulated by mGluR activity (Muddashetty, Nalavadi 
et al. 2011). MiR-125a regulates the expression of post synaptic density protein (PSD-95) 
in response to mGluR, and the process involves the formation of an inhibitory complex 
between miR-125a and Ago2 (Muddashetty, Nalavadi et al. 2011). These examples 
demonstrate that local translational control by microRNAs is dependent on the activity 
conditions and the coordinated work of other proteins. 
MicroRNA translational regulation may play a prominent role in diseases such as 
temporal lobe epilepsy where neuronal activity is high. Silencing of miR-134 in a rat model 
of epilepsy decreased the number of spontaneous seizures. The seizure-suppressive 
effects implicate a neuroprotective role for some microRNAs in the brain (Jimenez-
Mateos, Engel et al. 2012). In Parkinson’s disease, disruptions of microRNA processing 
involving dicer produce an upregulation of mRNAs in dendrites of dopaminergic neurons, 
and symptoms can be alleviated by reintroducing functional microRNAs (Gibbings, 
Leblanc et al. 2012, Gibbings, Mostowy et al. 2013, Heman-Ackah, Hallegger et al. 2013). 
Conversely, increasing levels of miR-125b induces cognitive defects in mouse models of 
Alzheimer’s disease (Banzhaf-Strathmann, Benito et al. 2014). These studies suggest that 
microRNAs provide a crucial link between cellular activity and rapid, reversible control of 
mRNAs in disease states (Bhattacharyya, Habermacher et al. 2006). The remainder of this 
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thesis section will discuss the role of microRNAs and local mRNA targets in response to 
different drugs of abuse. 
MicroRNAs Regulation Following Exposure to Stimulants 
Stimulants are psychoactive substances that increase the activity of the nervous 
system. Cocaine and amphetamines interact directly with the dopamine transporter, 
blocking dopamine reuptake into presynaptic terminals, thus increasing the dopamine 
levels in the synapse. Dopamine exerts positive effects on the local synthesis of glutamate 
receptors, possibly enhancing drug-induced reward by stimulating the VTA. Dopamine 
D1/D5 receptor activation stimulates protein synthesis in dendrites of cultured 
hippocampal neurons and increases GluA1 synaptic expression (Smith, Starck et al. 2005). 
Miniature excitatory post-synaptic currents (mEPSCs) increased in frequency within 15 
minutes after application of a dopamine agonist which correlated with the increased 
GluA1. In a second study, this lab examined the effects of blocking the glutamatergic 
transmission of action potentials locally by blocking NMDAR in dendrites while action 
potentials were blocked globally with the sodium channel blocker tetrodotoxin (Sutton, 
Wall et al. 2004). The loss of NMDAR signaling in dendrites increased the expression of 
calcium permeable AMPAR at synapses, resulting in a rapid increase in mEPSC amplitude, 
complementary to the increase in synaptic AMPARs. The results suggest a homeostatic 
role for tonic NMDAR activity that actively controls some types of protein synthesis and 
suggest that the sensitivity of the dendritic glutamatergic system is due in large part to 
rapid, local changes in protein synthesis. 
Within the VTA, cocaine induces immediate changes in synapse composition and 
increases excitability through an increased number of AMPARs (Bellone and Luscher 
2006). Activation of mGluRs leads to long-term depression (LTD) at many brain synapses 
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(Malenka and Bear 2004), and mGluR-LTD in the VTA efficiently reverses cocaine-induced 
strengthening of excitatory inputs onto dopamine neurons (Bellone and Luscher 2006). It 
was later demonstrated that the mGluR-LTD mediated reversals in cocaine-induced 
excitability occur through an exchange of GluA2-lacking AMPARs for GluA2-containing 
receptors (Mameli, Balland et al. 2007). Synaptic insertion of GluA2 depends on rapid 
protein synthesis of GluA2 mRNA through the mTOR pathway (Mameli, Balland et al. 
2007), the pathway discussed above in alcohol-related memories. Overall, the dynamic 
expression of glutamate receptors at post-synaptic synapses is important for 
neuroadaptations following drugs of abuse (Saba, Storchel et al. 2012), and the glutamate 
system also plays a key role in protein synthesis-dependent forms of synaptic plasticity. 
Cocaine regulates protein synthesis in multiple brain regions. For example, 
cocaine elevates levels of BDNF in the NAc, a key region in the reward circuit. Grimm et 
al. 2003 showed a time-dependent increase in BDNF expression as well as increases in 
cocaine craving in response to a protracted abstinence period (Grimm, Lu et al. 2003). 
BDNF inhibition in the NAc decreases cocaine-seeking (Graham, Edwards et al. 2007). In 
contrast, BDNF injections into the medial PFC (mPFC) decreases cocaine self-
administration (Berglind, Whitfield et al. 2009), drug seeking (Sadri-Vakili, Kumaresan et 
al. 2010), and cue- and priming-induced reinstatement (Berglind, Whitfield et al. 2009). 
BDNF injection into the NAc core, but not the shell, causes protein synthesis- and kinase-
dependent increases in cell surface GluA1 30 minutes post-injection. GluA2 and GluA3 
were unaffected, suggesting an effect of BDNF on homomeric GluA1 calcium permeable 
AMPARs (Li and Wolf 2011). BDNF injections into the VTA and NAc also produce persistent 
enhancement of cocaine-seeking (Lu, Dempsey et al. 2004). These results demonstrate 
that exogenous BDNF rapidly increases AMPAR surface expression in the rat NAc core, 
supporting an interaction between increases in endogenous BDNF levels and alterations 
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in AMPAR transmission in cocaine-experienced rats (Li and Wolf 2011). As discussed 
earlier, alcohol also affects BDNF expression levels and BDNF may regulate alcohol 
consumption and reward. 
CREB is a candidate for mediating some of the neuroadaptations following drugs 
of abuse. The role of CREB in the rewarding properties of cocaine and methamphetamines 
was investigated using CPP to measure reward memories (Kuo, Liang et al. 2007). The 
drugs were injected in one of three compartments of the animal cage, and the time spent 
in the drug-injected compartment was compared to the saline-injected and drug-free 
compartments. If the drug is rewarding, the animal will choose to spend longer periods 
of time in the drug-injected compartment. Cocaine-induced CPP (2.5–5.0 mg/kg/dose) 
was abolished by pretreatment with a protein synthesis inhibitor, whereas 
methamphetamine-induced (0.5 or 1.0 mg/kg/dose) CPP was not affected by the 
pretreatment. Moreover, post-treatment with a protein synthesis inhibitor (2 h after each 
drug-place pairing) disrupted cocaine- but not methamphetamine-induced CPP. 
Increased CREB levels in NAc were associated with cocaine, but not methamphetamine, 
rewarding memories. Intra-NAc CREB antisense infusion diminished cocaine- but not 
methamphetamine-induced CPP. Taken together, the data show cocaine- but not 
methamphetamine-associated memory formation requires de novo protein synthesis. 
The studies above highlight the various pathways through which drugs of abuse 
modulate local protein synthesis. Alteration in the glutamatergic system is an example of 
the dynamic changes in synaptic receptor composition and function following drugs of 
abuse. The intricate ways in which BDNF alters the effects of alcohol and cocaine suggest 
that it has region-specific roles which rely upon its ability to alter synaptic composition by 
interacting with local protein synthesis. Furthermore, BDNF is a downstream target of 
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various drugs in different brain regions and may represent a common target for treating 
drug dependence. 
Stimulants such as cocaine and amphetamines increase the levels of dopamine in 
the synapse in both humans and animals (Di Chiara and Imperato 1988). MiR-181a 
expression is induced by exposure to dopamine, cocaine, and amphetamines in NAc 
(Saba, Storchel et al. 2012). MiR-181a was enriched in synapses following cocaine 
administration (Chandrasekar and Dreyer 2009). Using bioinformatics tools, 
Chandrasekar and Dreyer (2009) detected conserved binding sites for miR-181a within 
the mRNA encoding for the GluA2 subunit of AMPARs and subsequently showed that both 
overexpression and knockdown of miR-181a regulates GluA2 translation (Figure 1.6). 
Decreased GluA2 expression coincided with decreased spine formation and mEPSCs. MiR-
181a overexpression increased cocaine-induced CPP, while knockdown of miR-181a 
produced the opposite effect (Chandrasekar and Dreyer 2011). Taken together, these 
results identify miR-181a as a key synaptic regulator of mammalian AMPARs with the 
potential to regulate drug-induced synaptic plasticity (Jonkman and Kenny 2013). 
Over-expression of let-7, a microRNA that is decreased in response to cocaine, 
attenuated cocaine-induced CPP (Chandrasekar and Dreyer 2011). Let-7 targets CREB and 
BDNF, and cocaine-induced decreases in let-7 increases the expression of its targets 






FIGURE 1.6: MODEL FOR COCAINE-INDUCED MICRORNA-MRNA INTERACTIONS 
Cocaine causes the downregulation of let-7d, resulting in induction of its target genes, BDNF and CREB. In contrast, 
miR-181a is upregulated by cocaine. Figure and legend were modified from the original in Jonkman and Kenny (2013). 
The X-linked transcriptional repressor, methyl CpG binding protein 2 (MeCP2), 
plays an important role in Rett syndrome, a form of mental retardation. MeCP2 
translation has been found to be regulated by miR-132. Blocking miR-132 activity 
increased MeCP2 and BDNF levels in cultured rat neurons, and the loss of MeCP2 reduced 
BDNF and miR-132 levels in vivo (Klein, Lioy et al. 2007). Further studies showed that 
MeCP2 facilitates cocaine intake in rats with extended access to the drug, and this 
depends on interactions with miR-212, a family member of miR-132. The relationship 
between MeCP2 and miR-212 mediates the cocaine-induced effects on BDNF levels 
(Figure 1.7) (Im, Hollander et al. 2010). Moreover, miR-212 decreases responsiveness to 
the motivational properties of cocaine (Hollander, Im et al. 2010). These findings suggest 
a mechanism by which microRNA homeostatic control of MeCP2 and BDNF expression 
affects cocaine intake and related behaviors. The role of microRNAs (and mRNAs) in 
regulating the BDNF system is important in both cocaine and alcohol action. 
MiR-124 and let-7d are significantly downregulated in the striatum after chronic 
cocaine administration. Decreased BDNF and dopamine D3 receptor mRNA and protein 
levels were regulated by miR-124 and let-7d, respectively (Chandrasekar and Dreyer 
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2009). Overall, brain-specific microRNA-mRNA interactions are altered by drugs of abuse, 




FIGURE 1.7: THE INTERACTIONS BETWEEN MIR-212, CREB, METHYL CPG-BINDING PROTEIN 2 (MECP2), 
AND BDNF 
Cocaine activates CREB-miR-212 and MeCP2-BDNF signaling and the balance between these pathways likely regulates 
escalation of cocaine intake (‘loss of control’). Figure has been adapted from Jonkman and Kenny (2013). 
MicroRNA Regulation Following Alcohol Exposure 
Overall, many microRNAs are upregulated in the human alcoholic brain (Lewohl, 
Nunez et al. 2011). Some of these alcohol-responsive microRNAs overlap with known local 
translational pathways. 
As discussed earlier, the BK channel is a well-established alcohol target (Dopico, 
Anantharam et al. 1998) and an important contributor to behavioral and molecular 
alcohol tolerance (Davies, Pierce-Shimomura et al. 2003). Alcohol was found to 
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upregulate miR-9, which in turn regulates the expression of the BK channel subunits. This 
leads to post-transcriptional reorganization of BK splice variants and results in 
downregulation of the specific splice variant that is sensitive to alcohol. This mechanism 
is proposed to mediate development of cellular tolerance to alcohol (Pietrzykowski, 
Friesen et al. 2008). 
A persistent upregulation of miR-206 expression was observed in mPFC, but not 
VTA, amygdala or NAc after 3 weeks of withdrawal from a 7-week exposure to alcohol 
vapor (Tapocik, Solomon et al. 2013). Overexpression of miR-206 in the mPFC of non-
dependent rats reproduced the escalation of alcohol self-administration seen following a 
history of dependence and significantly inhibited BDNF expression (Tapocik, Barbier et al. 
2014). BDNF expression was repressed by miR-206, but not miR-9, in a 3′UTR reporter 
assay, confirming BDNF as a functional target of miR-206. Furthermore, the decreased 
expression was dependent on the presence of all three miR-206 target sites in the 3′UTR 
of BDNF (Tapocik, Barbier et al. 2014). These results implicate miR-206 and BDNF in 
escalation of alcohol consumption which is a hallmark of alcoholism. Thus, both 
microRNAs and mRNAs (discussed earlier) regulate alcohol consumption via BDNF 
signaling. 
Some microRNAs are downregulated by alcohol exposure, such as miR-382 in NAc 
(Li, Li et al. 2013). MiR-382 directly targets the dopamine receptor D1 (DRD1) and can 
modulate the expression of ΔfosB. Overexpression of miR-382 attenuated the alcohol 
induced upregulation of DRD1 and ΔfosB, decreased voluntary alcohol intake and 
preference and inhibited the DRD1-induced action potentials. 
Bahi et al. 2013 showed that miR-124a was downregulated in the dorso-lateral 
striatum (DLS) following alcohol drinking. Silencing miR-124a attenuated ethanol-induced 
CPP as well as voluntary alcohol consumption. Moreover, overexpression of miR-124a 
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enhanced ethanol-induced CPP as well as voluntary alcohol consumption in a two-bottle 
choice drinking paradigm. Importantly, none of these treatments had an effect on 
saccharin and quinine intake (Bahi and Dreyer 2013). 
Some microRNAs are upregulated in response to alcohol (Lewohl, Nunez et al. 
2011). Darcq et al. 2015 showed that a mouse paradigm for binge alcohol drinking caused 
an upregulation of miR-30a-5p in the mPFC of mice. Overexpression of miR-30a-5p 
produced an escalation of alcohol intake and a preference over water. Conversely, 
inhibition of miR-30a-5p decreased excessive alcohol intake (Darcq, Warnault et al. 2014). 
A single microRNA has the potential to target many genes (Nunez and Mayfield 
2012, Tapocik, Solomon et al. 2013), and multiple microRNAs can cooperate to target the 
same genes (Grimson, Farh et al. 2007, Lewohl, Nunez et al. 2011). This mechanism may 
be of particular importance in the synaptic proteome where slight adaptations can greatly 
impact synaptic plasticity. For example, miR-7 and miR-153 were found to be differentially 
expressed between human alcoholics and controls. Interestingly, miR-7 and miR-153 
were found to both regulate the expression of a-synuclein (Doxakis 2010). a-synuclein is 
a protein that plays a major role in neurotransmitter release in presynaptic terminals (Liu, 
Ninan et al. 2004, Greten-Harrison, Polydoro et al. 2010) and is involved in dopaminergic 
neurotransmission and neurodegenerative disorders (Doxakis 2010). Studies show that 
alcohol dependence in humans, as well as in rodents, is related to levels of a-synuclein 
(Bonsch, Greifenberg et al. 2005, Bonsch, Lenz et al. 2005). Interestingly, overexpression 
of miR-7 and miR-153 significantly reduces endogenous α-synuclein levels, whereas 
inhibition of miR-7 and miR-153 enhances translation of α-synuclein. These findings 
illustrate a mechanism by which alcohol changes the expression of two microRNAs and 
how they can cooperate to target an mRNA that is known to be involved in alcoholism as 
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well. This cooperation between the microRNAs allows regulation of gene expression with 
a reduced number of active microRNAs. 
Summary 
Excessive alcohol consumption causes widespread persistent changes throughout 
the brain. These molecular and cellular adaptations are thought to be the mechanisms by 
which neurons adapt to chronic alcohol use. These changes can eventually lead to 
alcoholism, depending on several factors, such as genetic predisposition, sex and 




FIGURE 1.8: THE DIFFERENT FACTORS INFLUENCING ALCOHOLISM 
Alcoholism is a complex disease caused by genetic and environmental factors. The neural changes characterized by 
alcoholism result from a complex dynamic system with a plethora of contributing factors. These factors are both 
environmental and internal. These internal factors depend on complex genetic states and molecular interactions. 
Since the normal brain is one of recursive feedback loops and regulatory controls, a drug like alcohol (whose effects 
are global) demonstrates radical alterations with a variety of entry points. Articulating the causes of alcoholism thus 
relies on research at a variety of scales and modalities. (Adapted from Starkman et al., 2012.) 
Once a person becomes an alcoholic, drinking becomes increasingly compulsive 
and seems to escapes voluntary control. The heterogeneous nature of alcoholism reflects 
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the complex and multifaceted nature of alcohol’s molecular effects on the CNS. The fact 
that multiple neurotransmitter systems are affected by alcohol makes it difficult to 
pinpoint the molecular mechanisms that are primarily responsible for the disease. Indeed, 
alcohol’s molecular targets are many and varied, and include modifications of the 
genome, transcriptome, and proteome. Alcoholism is most likely the result of the 
cumulative interactions within and between all three systems. Nevertheless, identifying 
the molecular targets is a crucial step in understanding alcoholism and developing new 
treatments.  
MicroRNAs are one type of molecule that is clearly involved in the neuroadaptive 
responses induced by exposure to substances of abuse, and their large number of targets 
encompasses a dynamic regulatory network. However, the processes by which 
microRNAs and mRNAs target cellular and synaptic function are not well-understood. 
Because a single microRNA targets many mRNAs, drugs of abuse can effectively hijack a 
complex network. Indeed, the biological pathways that have been mentioned here are 
diverse and indicative of the complex disease states associated with drugs of abuse. 
Identification of the important RNA signaling systems involved in drug dependence 
provides new areas of focus for therapeutic interventions. 
The diverse mRNAs and neuroadaptations associated with drug dependence may 
be controlled by some common microRNAs. Also, a subset of the mRNA changes within a 
single disease state may be driven by even a smaller number of microRNAs, underscoring 
the potential impact of finding those key molecules. While microRNAs may be crucial for 
regulating synaptic plasticity, a pivotal neuroadaptation in addictive behaviors, we must 
also understand their role in mediating a variety of context-dependent behaviors. 
In the rest of this thesis, I identify the alcohol-responsive synaptic mRNAs as a 
result of chronic alcohol use and determine whether they are different in the synapse 
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compared to the cell body (chapter 2). I then focus on identifying the alcohol-responsive 
synaptic microRNAs and predicting their regulatory interactions with synaptic mRNAs 
(chapter 3). Lastly, I manipulate these key microRNAs in-vivo to reverse and prevent 
alcohol consumption and alcohol-induced-neuroadaptations (chapter 4). 
In the first experimental section (chapter 2), I show that chronic alcohol use causes 
persistent changes in networks of synaptic mRNAs, and that this effect may be mediated 
by microRNAs localized in the synapse. In the second experimental section (chapter 3), I 
describe a subset of alcohol-responsive microRNAs and predict which alcohol-responsive 
mRNAs they may be targeting, providing a list of key microRNA-mRNA interactions. In the 
final experimental section of this thesis (chapter 4), I focus on manipulation of synaptic 
microRNAs and demonstrate that a change in expression of one specific synaptic 
microRNA, miR-411, can cause a decrease in alcohol consumption and preference in 
chronically consuming mice, without affecting total fluid intake or saccharin consumption, 
and without changing acquisition of alcohol consumption in naïve mice. Furthermore, 
manipulation of miR-411 in alcohol consuming mice did not induce anxiolysis nor 
locomotion, as measured with elevated plus maze and open field test. We show that 
these effects were caused through changes in expression of a predicted protein, providing 
a mechanism by which interaction between synaptic microRNAs and alcohol can affect 
proteins, synaptic structure and ultimately, behavior. 
The role of individual microRNAs in discrete cellular compartments underscores 
their essential role in cellular function and the widespread impact that drugs of abuse can 
exert by targeting microRNAs. This thesis describes the first study to target synaptic 
mRNA, such that the microRNA regulation over mRNA will take place in the synapse, 
having a larger impact on synaptic plasticity. Results use as proof of concept that synaptic 
gene networks may yield viable candidates for manipulation of behavior. Findings impact 
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the basic and translational science of drug dependence and prevention, spurring the 
development of new treatments. 
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CHAPTER 2: THE SYNAPTONEUROSOME TRANSCRIPTOME:  
A MODEL FOR PROFILING THE MOLECULAR EFFECTS OF ALCOHOL 
The work presented in this chapter has been published in 2015 in the Pharmacogenomics Journal. Most 
D, Ferguson L, Blednov Y, Mayfield RD, Harris RA. The synaptoneurosome transcriptome: a model for 
profiling the molecular effects of alcohol. 2:177-88. PubMed PMID: 25135349. Supplementary material 
to this work can be found in the online version of the Manuscript at 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334750/#SD2. 
Abstract 
Chronic alcohol consumption changes gene expression, likely causing persistent 
remodeling of synaptic structures via altered translation of mRNAs within synaptic 
compartments of the cell. We profiled the transcriptome from synaptoneurosomes (SNs) 
and paired total homogenates (THs) from mouse amygdala following chronic voluntary 
alcohol consumption. In SN, both the number of alcohol-responsive mRNAs and the 
magnitude of fold-change were greater than in the THs, including many GABA-related 
mRNAs upregulated in SNs. Furthermore, SN gene co-expression analysis revealed a 
highly connected network, demonstrating coordinated patterns of gene expression and 
highlighting alcohol-responsive biological pathways, such as long-term potentiation, long-
term depression, glutamate signaling, RNA processing and upregulation of alcohol-
responsive genes within neuroimmune modules. Alterations in these pathways have also 
been observed in the amygdala of human alcoholics. SNs offer an ideal model for 
detecting intricate networks of coordinated synaptic gene expression and may provide a 
unique system for investigating therapeutic targets for the treatment of alcoholism. 
Introduction 
Alcohol dependence is a severe and widespread disease. Over 17 million 
Americans suffer from alcohol-related problems; total cost estimates of substance abuse 
in the United States exceed $600 billion annually, with 39% of that cost related to alcohol 
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(Rehm, Mathers et al. 2009). The pharmacotherapies available today are significantly 
limited due to side effects and failure to relieve drug craving, leading to high relapse rates. 
Chronic alcohol use produces long-term neuroadaptations in synaptic structure 
and function, which are likely caused by persistent changes in gene expression 
(Rimondini, Arlinde et al. 2002, Arlinde, Sommer et al. 2004, Liu, Lewohl et al. 2006, 
Melendez, McGinty et al. 2012). This leads to a remodeling of neural circuitry (Mayfield, 
Lewohl et al. 2002, Kerns, Ravindranathan et al. 2005, Hansson, Rimondini et al. 2008) 
and is one of the main features of addiction (Nestler 2001, Kauer and Malenka 2007). 
Synaptic translation of mRNA is a cardinal process underlying normal synaptic functions 
(Raab-Graham, Haddick et al. 2006, Zhu, Cao et al. 2011), and perturbation by alcohol 
represents a mechanism contributing to synaptic neuroadaptations (Barak, Liu et al. 
2013). The composition of specific mRNAs in the synaptic compartment may give insight 
into the neurobiology of different states of addiction and is an unexplored avenue of 
research. 
Given the role of synaptic plasticity in alcohol dependence, selecting a biologically 
relevant system for analyzing the synaptic transcriptome is of critical importance. 
Although total homogenate (TH) preparations have been used for mRNA and alcohol 
studies in the past, this method limits identification of regional mRNAs and likely 
underestimates the number and magnitude of alcohol-responsive transcripts in the 
synapse. Synaptoneurosomes (SNs) contain membrane vesicles of presynaptic and 
postsynaptic compartments composed of primarily neurons as well as astrocytes and 
microglia. SNs have been used to study local translation of mRNAs in the synapse (Raab-
Graham, Haddick et al. 2006) and may prove to be a superior model system for alcohol 
effects confined to synaptic regions of the cell.  
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In order to measure discrete changes within the synaptic transcriptome following 
chronic alcohol consumption, we profiled mRNAs from SN (Hollingsworth, McNeal et al. 
1985, Sung, Weiler et al. 2004, Raab-Graham, Haddick et al. 2006) and TH samples from 
mouse amygdala, a brain region known to be involved with the negative reinforcement 
of alcohol and other drugs of abuse. The present findings reveal greater expression of 
alcohol-responsive mRNAs in SN compared with TH. Using gene expression patterns to 
generate biological networks, the SN preparation appears ideally suited for detecting 
alcohol-responsive groups of genes that have been shown to be important in human 
alcoholism. The gene clusters isolated in SN could prove useful in developing targets for 
the future treatment of alcoholism.  
Materials and Methods 
Animal Housing and Alcohol Self-Administration 
Adult (2-month old) C57BL/6 J female mice were purchased from The Jackson 
Laboratory (Bar Harbor, ME, USA) and were maintained at the University of Texas at 
Austin Animal Research Center. Mice were given a one-week acclimation period in 
combined housing and another week to acclimate to the bottle position in individual 
housing. Food and water were provided ad libitum and monitored daily, as were the 
temperature and light/dark cycles. Mice underwent a 30-day two-bottle choice paradigm 
with continuous (24 h) access to one bottle of 20% ethanol and one bottle of water, 
similar to that described previously (N=8 alcohol group, N=13 control group). Bottle 
weights were recorded daily, and the amount of alcohol consumed throughout the 30 
days was calculated as g/kg (Supplementary Figure S1). Bottle positions were changed 
daily to control for position preferences, and mice were weighed every 4 days. All 
procedures were approved by the Institutional Animal Care and Use Committee at the 
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University of Texas at Austin and adhere to NIH Guidelines for the ethical care and use of 
animals in research. 
SN Preparation and RNA Extraction 
Mice were euthanized by cervical dislocation and then decapitated. Brains were 
removed and washed for 1 minute with 1 ml of ice-cold Homogenizing Buffer (HB) 
containing 20 mM Hepes, 1 mM EDTA (pH 7.4), 40 U/ml RNAseOut (Invitrogen, Carlsbad, 
CA, USA), phosphatase inhibitor cocktail 3 (Sigma, St Louis, MO, USA) and protease 
inhibitors ‘Complete’ (Roche, Indianapolis, IN, USA). Brains were then placed in a coronal 
Zivic mouse brain slicer with a 0.5 mm resolution (Zivic Instruments, Pittsburgh, PA, USA) 
and sliced in the following coordinates in order to isolate extended amygdala (two coronal 
slices were made for greater ease of dissection): coronal level 56–66 (Bregma (−0.18)–
(−1.155)) and 66–80 (Bregma (−1.155)–(−2.55)). The extended amygdala was dissected, 
placed in ice- cold HB (250 ml) and homogenized for 1 minute using a VWR homogenizer 
and pestle (VWR, Radnor, PA, USA). To minimize homogenate loss, pestles were washed 
with 50 ml HB after use, and the wash was collected and added to the sample. Ten percent 
of the homogenate (30 ml) was snap-frozen in liquid nitrogen and stored at − 80 °C for 
subsequent RNA TH analysis. 
Paired SNs (Hollingsworth, McNeal et al. 1985) were isolated from the rest of the 
homogenate (270 ml) in a manner similar to that described previously (Raab-Graham, 
Haddick et al. 2006, Smalheiser 2008, Sosanya, Huang et al. 2013). Briefly, homogenates 
were filtered through a 100-μm pore filter and subsequently through a 5-μm pore filter 
(Millipore, Billerica, MA, USA); filters were washed with HB before use for protection from 
RNAse. To maximize yield, the filters were washed with 50 ml HB after use, and the wash 
was collected and added to the homogenate. The homogenate was then centrifuged at 
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14,000g for 20 minutes at 4 °C in order to pellet the cell fraction containing SNs (Raab-
Graham, Haddick et al. 2006, Sosanya, Huang et al. 2013). The supernatant was removed 
and the pellet snap-frozen and stored at −80 °C for SN RNA analysis. Microscopy was used 
to further characterize the SN preparation (see Supplementary Methods). 
Total RNA was extracted from 21 SN and 21 paired TH samples with the Direct-Zol 
RNA extraction kit (Zymo Research Corporation, Irvine, CA, USA), using IC columns 
according to the manufacturer’s instructions. The RNA was quantified using NanoDrop 
1000 (Thermo Fisher Scientific Inc., Rockford, IL, USA) and assayed for quality using 
Agilent 2100 Tape- Station (Agilent Technologies, Santa Clara, CA, USA). The cutoff criteria 
were set on 280/260>1.7, RIN>6.5 and amount of total RNA>500 ng. 
Microarray Hybridization, Data Quality Assessments and Analysis 
RNA samples were processed at the University of Texas Southwestern Medical 
Center microarray facility in Dallas. MRNA was amplified and biotin-labeled using the 
Illumina TotalPrep RNA Amplification kit (Ambion, Austin, TX, USA) and hybridized to 
Mouse WG-6 v2.0 Expression BeadChips (Illumina, San Diego, CA, USA). Each array 
contained SN and paired TH samples from control and alcohol-treated mice. These were 
assigned randomly to each array. The array data were analyzed using R environment and 
Bioconductor packages, similar to our published studies (Ponomarev, Wang et al. 2012, 
Osterndorff-Kahanek, Ponomarev et al. 2013). The ‘Lumi’ package (Du, Kibbe et al. 2007, 
Du, Kibbe et al. 2008, Lin, Du et al. 2008) was used to preprocess the data using variance 
stabilization transformation (variance within array) quantile normalization (variance 
between arrays) and background subtraction (Dunning, Ritchie et al. 2008, Lin, Du et al. 
2008). Quality measures were taken before and after preprocessing using the 
arrayQualityMetrics package (Kauffmann, Gentleman et al. 2009, Kauffmann and Huber 
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2010) to remove outliers determined by at least two out of the three tests in the package, 
and care was taken that the normalization did not skew the data. This package was also 
used to generate the principal component analysis. Transcripts significantly detected on 
80% of the arrays were used in the analysis (detection probability >0.05). The data 
presented in this publication have been deposited in NCBI's Gene Expression Omnibus 
(Edgar, Domrachev et al. 2002) and are accessible through GEO Series accession number 
GSE51730. 
The ‘Limma’ package (Smyth 2005) was used for differential expression analysis 
between SN and paired TH samples (paired/dependent t-test) and between the alcohol 
and control samples in SN and TH (two independent t-tests). A list of alcohol-responsive 
mRNAs was compiled from the list of genes differentially expressed between alcohol and 
control samples. A weighted gene correlation (co-expression) network analysis  was 
generated for the combined control and alcohol data, using the weighted gene 
correlation (co-expression) network analysis (WGCNA) package (Langfelder and Horvath 
2008). Alcohol-responsive mRNA enrichment analysis was performed for each module 
using an over-representation (hypergeometric) test with a cut off P<0.05. To determine 
alcohol-responsive SN and TH modules, we used the ‘alcohol-responsive mRNAs’ lists 
from our data. For details on the WGCNA parameters, see Supplementary Methods. We 
evaluated whether the correlation between alcohol consumption and TH modules would 
increase depending on WGCNA parameters. We generated another TH WGCNA network 
and optimized for the highest correlation of modules with consumption (top 10% of the 
modules). Enrichment and clustering analyses were performed using KEGG pathways, 
Wikipathways, gene ontologies and protein interactions, part of the Database for 
Annotation Visualization and Integrated Discovery (DAVID) (Huang, Sherman et al. 2009, 
Huang, Sherman et al. 2009), WEB-based GEne SeT AnaLysis Toolkit (Webgestalt) (Zhang, 
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Kirov et al. 2005, Wang, Duncan et al. 2013) and Ingenuity Pathway Analysis (IPA; Qiagen, 
Valencia, CA, USA). All P-values from these analyses were adjusted using the Benjamini–
Hochberg method (BH). Synaptic mRNA enrichment was assessed using a list of mRNAs 
enriched in the synaptic neuropil and in process-localized mRNAs (Cajigas, Tushev et al. 
2012). For alcohol-responsive mRNA enrichment, we used a human alcoholic mRNA data 
set (Ponomarev, Wang et al. 2012) from the amygdala, quantitative trait loci mRNA list 
(Mulligan, Ponomarev et al. 2006) and a list of mRNAs from prefrontal cortex of C57BL6 
after a two-bottle choice paradigm (Osterndorff-Kahanek, Ponomarev et al. 2013). For 
cell types and immune response enrichment, we used the following lists of genes: 
neuronal, astrocytic and oligodendrocyte (Cahoy, Emery et al. 2008), microglial (Oldham, 
Konopka et al. 2008), glutamate/GABA (Sugino, Hempel et al. 2006) and 




The SN Transcriptome is Composed of Synaptic mRNAs and is Distinct from the TH 
We compared SN and TH transcriptomes from mouse amygdala and detected 
17,514 and 18,318 transcripts in the SN and TH microarrays respectively, with a high 
overlap of detected transcripts (17,265). We studied the expression levels using principal 
component analysis and found a distinct clustering of the two types of preparations, while 
showing a homogenous sample population within each preparation (Figure 2.1A). The 
clustering was evident along the first principal component, indicating that the largest 
variation stems from distinct expression levels in the two preparations. We identified 
4,539 differentially expressed unique mRNAs (BH, P<0.05), with 2,119 mRNAs enriched in 
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the SN (Supplementary Table S1) and 2,420 mRNAs enriched in the TH (Supplementary 
Table S2). We used DAVID to compare the SN- and TH-enriched cellular components and 
found that the SN contained fewer somatic and intracellular components, while 
preserving and enriching the synaptic mRNAs (Table 2.1). 
 
DAVID Enrichment Clustering SN Score TH Score 
Intracellular 20 (1370) 32.4 (1528) 
Organelle 6.2 (438) 29.7 (621) 
Organelle Membrane 3.5 (137) 13.2 (179) 
Synapse 2.9 (64) 1.3 n.s. (21) 
TABLE 2.1: COMPARISON OF THE DAVID ENRICHMENT SCORES OF SN- AND TH-ENRICHED CELLULAR 
COMPONENTS 
Abbreviations: The table illustrates reduction of somatic and intracellular components and preservation/enrichment 
of synaptic mRNAs in SN (the number of genes detected in a cluster are shown in parenthesis). All scores for 
enrichment clustering are significant with a BH P<0.05. A n.s. score was defined as a cluster containing only one 
significant group out of five. DAVID, Database for Annotation Visualization and Integrated Discovery; n.s., non-
significant. 
Among the SN-enriched transcripts, many known synaptic mRNAs were over-



















4.1 18 8.60E-06 1.60E-02 
KCNMA1, MYO6, GNAI2, GRIK5, CTNND2, 
MECP2, GJA1, ATP1A2, CSPG5, ADORA1, 
RIMS1, PTPN11, HDAC4, SLC1A3, NTRK2, 
HOPX, DLG4, CAMK2A. 
Synapse 4.0 26 4.00E-07 1.20E-04 
GRIK5, TIMP4, RIMS1, ADORA1, SLC1A2, 
GP1BB, SNPH, DLG4, CAMK2A, DLG2, 
MT3, KCNMA1, PHACTR1, ARC, MYO6, 
DLGAP3, SPARCL1, PSD3, SSPN, SHANK3, 
PPP1R9B, HDAC4, NTRK2, VAMP3, 
UNC13C, SNTA1. 
PDZ/DHR/GLGF 3.8 14 4.10E-05 3.40E-02 
SNX27, PREX1, PDLIM4, PDLIM2, MPP6, 
SLC9A3R1, RIMS1, SHANK3, PPP1R9B, 
MAST2, SIPA1L1, DLG4, DLG2, SNTA1. 
Cytoskeleton 3.8 51 3.30E-05 2.00E-03 
KIF23, KIFC2, GFAP, TUBB2B, AIF1, 
FERMT2, PDLIM2, ADORA1, CTNNB1, 
NDE1, EVI5, DLG4, DLG2, ARC, MYO6, 
INPPL1, KIF5A, KIF5C, PSD3, SPIRE1, 
MID1IP1, TBCEL, RB1, DNAIC1, CTNNA1, 
FMN2, KIF1A, MAST2, KIF1B, PDE4DIP, 
ADD3, CAPZB, LLGL1, KLC1, GP1BB, 
STRBP, CDC42EP4, ACTB, DLGAP3, 
CKAP5, CSRP1, COTL1, SIRT2, SHANK3, 
PTPN11, EPB4.1L2, PPP1R9B, HDAC4, 
EPB4.1L1, NTRK2, SNTA1. 
Transmission of 
nerve impulse 
3.0 18 3.90E-05 2.40E-02 
KCNMA1, SCD2, MYO6, ALDH5A1, GRIK5, 
MECP2, TIMP4, ATP1A2, ADORA1, 
CTNNB1, MBP, ATXN1, KIF1B, ABAT, 
LGI4, UNC13C, NCAN, DLG2. 
TABLE 2.2: FUNCTIONAL CLUSTERING OF SN-ENRICHED MRNAS 
446 mRNAs were enriched in the SN and there were 163 functional clusters. In order to find the most synaptically-
enriched pathways, we used a higher threshold fold-change of 25%. The top 5 clusters are shown (BH, P<0.05). Gene 
symbols are shown for each cluster. 
Most of these synaptic functional groups were not detected in the TH, indicating 
that enriched synaptic mRNAs are more readily detected in the SN. Webgestalt was used 
to investigate known pathways (KEGG and Wikipathways; Supplementary Table S3) and 






FIGURE 2.1: THE SN TRANSCRIPTOME IS COMPOSED OF SYNAPTIC MRNAS AND IS DISTINCT FROM THE TH 
A. Principal component analysis of expression profiles from paired SN (green) and TH (blue) samples. Preparation 
difference is the first principal component and explains 17% of the variance. B. SN-enriched mRNA network 
illustrating known protein interactions between the SN-enriched mRNAs. The bottom right portion of the figure is an 
overview of the entire network, and the highlighted portion of this network has been enlarged. The green nodes 
represent the mRNAs enriched in the SN compared with the TH preparation (fold-change threshold of >10%, 
Benjamini–Hochberg method P<0.05). Many known synaptic mRNAs are found in the center of this network, 
emphasizing enrichment of the synaptic components in the SN preparation. 
 
The network was associated with axon guidance and cell leading edge and 
highlighted the Dlg family (also known as postsynaptic density proteins or PSDs). SN (but 
not TH) transcripts were also over-represented with synaptic mRNAs in a high-resolution 
study exploring the synaptic neuropil (Cajigas, Tushev et al. 2012). 
The Greater Resolution of SN Preparation Captures the Molecular Effects of Alcohol 
We next identified mRNAs from the amygdala of 8 alcohol-treated and 13 control 
mice, for a total of 21 SN and paired TH samples. In SNs, 1,531 alcohol-responsive mRNAs 
were identified, compared with 462 in THs (Figure 2.2A). Examples of alcohol-responsive 
mRNAs, fold-changes and P-values are shown in Table 2.3, and the full list is shown in 




























-0.47 0.81 2.37E-02 1.04 5.74E-01 
ILMN_2483253 Dicer1 
dicer 1, 
ribonuclease type III 
-0.54 0.86 5.71E-03 1.01 8.13E-01 
ILMN_1240346 Socs5 
suppressor of 
cytokine signaling 5 























receptor, type 2 
-0.42 0.88 4.04E-02 0.98 5.22E-01 







-0.47 0.90 2.25E-02 0.97 5.43E-01 
ILMN_2713841 Hspd1 
heat shock protein 
1 (chaperonin) 









(class III), chi 
polypeptide 





0.46 1.15 2.76E-02 0.96 5.25E-01 
ILMN_1214715 Gfap 
glial fibrillary acidic 
protein 
0.49 1.16 1.31E-02 1.03 4.81E-01 
ILMN_1231625 Cyp4f14 
cytochrome P450, 
family 4, subfamily 
f, polypeptide 14 
0.62 1.17 2.82E-03 1.01 6.59E-01 































0.44 1.18 2.09E-02 1.07 9.35E-02 
ILMN_2719908 Cyp2j9 
cytochrome P450, 
family 2, subfamily 
j, polypeptide 9 
0.49 1.18 2.03E-02 1.06 6.38E-02 
ILMN_2705777 Gstm5 
glutathione S-
transferase, mu 5 






0.71 1.20 2.65E-04 1.00 9.80E-01 
ILMN_2760800 Cxcl14 
chemokine (C-X-C 
motif) ligand 14 
0.53 1.20 9.84E-03 1.03 6.64E-01 
ILMN_2680745 Gabbr1 
γ-aminobutyric acid 
(GABA) B receptor, 
1 
0.40 1.20 3.23E-02 1.00 9.82E-01 
ILMN_2776008 Gstk1 
glutathione S-
transferase kappa 1 
0.52 1.21 1.36E-02 0.99 7.63E-01 
ILMN_2619620 C1qb 
complement 
component 1, q 
subcomponent, β 
polypeptide 








elongation factor 2 
0.47 1.42 1.48E-02 1.08 2.69E-01 
TABLE 2.3: THIRTY ALCOHOL-RESPONSIVE MRNAS IN SN THAT WERE NOT SIGNIFICANTLY CHANGED IN TH 
SN mRNA correlation with alcohol consumption, SN and TH treatment fold-change, and p-values are shown. Fold-
change >1 indicates an increase in expression and fold-change <1 indicates a reduction. 
 
We examined the number and magnitude of fold-changes (Figure 2.2B) as a 
potential means for identifying the most important mRNAs involved in alcohol-induced 
changes. SNs had three times more alcohol-responsive mRNAs and larger fold-changes 
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than THs. 23% percent of the TH alcohol-responsive mRNAs were also detected in SN, 




FIGURE 2.2: THE GREATER RESOLUTION OF SN PREPARATION CAPTURES THE MOLECULAR EFFECTS OF 
ALCOHOL 
A. The number of alcohol-responsive annotated mRNAs identified in paired SN and TH samples for P<0.05 are shown 
(N=8 for alcohol and N=13 for control). B. Fold-change produced by alcohol consumption is shown as a function of the 
cumulative number of transcripts. Alcohol-induced changes in the number of transcripts and magnitude of fold-
changes. C. Venn diagram showing the overlap in alcohol-responsive unique mRNAs between the SN and TH 
preparations (P<0.05). 
 
A functional annotation of the top alcohol-responsive mRNAs revealed a higher 
enrichment score for synaptic mRNAs in SNs than in THs. IPA was used to study the 
molecular and cellular functions of SN alcohol responsive mRNAs, highlighting the 
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following top five pathways: molecular transport, protein trafficking, RNA 
posttranscriptional modification, cell morphology, and DNA replication, recombination, 
and repair. Importantly, the alcohol-responsive mRNA list from SNs was strikingly similar 
to the mRNA list obtained from human alcoholics (Table 2.4), suggesting that the alcohol-
drinking paradigm used in this study induced similar mRNA changes in mouse amygdala 
to that observed in human amygdala (Ponomarev, Wang et al. 2012) and also 
demonstrating that SNs are ideal for characterizing transcriptome changes in chronic 
ethanol-treated mice that are relevant in human alcoholics. The SN alcohol-responsive 
mRNAs were highly enriched for neuron process-localized mRNAs (Cajigas, Tushev et al. 
2012) and contained many alcohol-consumption quantitative trait locus genes found in 
mice (Mulligan, Ponomarev et al. 2006), further highlighting this preparation as a tool to 


























83 7.59E-01 358 7.54E-02 114 2.77E-01 
TABLE 2.4: OVER-REPRESENTATION OF HUMAN ALCOHOLIC MRNA, PROCESS MRNAS AND QTL GENES 
Abbreviation: QTL, quantitative trait loci. The significant over-representations are highlighted in pink. 
 
Alcohol Affects the Transcriptome in a Coordinated Manner 
 We used WGCNA (Langfelder and Horvath 2008) to group genes into modules 
that have strong co-varying (similar) patterns of expression across the sample set. 
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Hierarchical clustering showed that the SN preparation contains groups of mRNAs that 
have highly coordinated patterns of expression (Figure 2.3A). When using the same 
parameters for THs, the majority of mRNAs showed dissimilar levels of expression 
(marked by the gray color) (Figure 2.3B). 
 
 
FIGURE 2.3: ALCOHOL AFFECTS THE TRANSCRIPTOME IN A COORDINATED MANNER AS SEEN IN SN 
A. Results of a dendrogram-hierarchical cluster of mRNAs from SN (N=21). In the cluster, each end point represents a 
gene, and the genes are arranged by similarity in covariance. Genes under the same branch of the dendrogram are 
more similar than those outside of the branch, and their dissimilarity is represented by the y axis. Gray represents 
genes unrelated to others. SN preparation contains groups of mRNAs that have highly coordinated patterns of 
expression as seen by the low dissimilarity values. B. Results of a dendrogram-hierarchial cluster of mRNAs from TH 
(N=21). High dissimilarity values (marked by the gray color) indicate that the TH contains fewer mRNAs with similar 
patterns of expression. 
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We adjusted the TH network parameters to optimizing module correlation with 
alcohol consumption. Allowing for less similarity between the mRNAs would enable 
greater detection of group-clustered modules in THs (Supplementary Figure S3A). 
However, the change in parameters did not significantly affect the correlation between 
the TH modules and alcohol consumption (Supplementary Figure S3B). In SNs, 40% of the 
modules were significantly correlated with alcohol consumption (average r=0.6, P<.05) 
(Supplementary Figure S3C). We then determined the modules that were 
overrepresented with alcohol-responsive mRNAs (referred to as ‘alcohol-responsive 
modules’). In SNs, 10 out of the 54 alcohol responsive modules were detected (8 were 
upregulated and 2 were downregulated; Supplementary Table S5). 
These modules were significantly associated with biological pathways such as 
pathways for long-term potentiation and depression and RNA processing, and contained 
many mRNAs associated with potassium channels, glutamate and GABA systems. 
Upregulated mRNAs include Camkk2, Camta1, Capn2, Ntrk2, Ntsr2, Stx18, Stx8, Stxbp4, 
Syap1, Synj2bp, Prkcdbp and Grk6. Downregulated mRNAs include brain-derived 
neurotrophic factor (BDNF), Camsap3, Capn6, Negr1, Nptn, Ntrk2, Unc5c, Stx3, Stxbp1, 
Stxbp2, Syncrip, Sst, Sstr2, Sncb and Timp4. The potassium channel family was also highly 
responsive to alcohol and includes the voltage-gated potassium channels (Kcna6 and 
Kcnq2, downregulated), calcium-activated Kcnu1 (SLO-3-slowpoke3, downregulated) and 
inwardly rectifying potassium channels (Kcnj1 and Kctd20, upregulated). The following 
glutamate- and GABA-related transcripts were upregulated: Grk6, Glud1, Slc1a2, Slc1a3, 
Gabbr1, and Gabrb2, whereas the following were downregulated: Grina, Gria2, Grip1, 
VGlut2 (Slc17a6), Grm7, and Narg2. 
As mentioned, RNA processing machinery was a highly overrepresented biological 
pathway associated with alcohol-responsive mRNAs (Figure 2.4). These mRNAs include 
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RNA transcriptional, translational, spliceosomal and editing machineries, as well as many 
mRNAs for ribosomal proteins, suggesting that chronic alcohol affects translational 
mechanisms in the synapse. 
 
FIGURE 2.4: ALCOHOL REGULATES RNA PROCESSING AND TRANSLATIONAL MACHINERY IN THE SYNAPSE 
Examples of alcohol-responsive mRNAs related to known RNA processing pathways, illustrated on a postsynaptic 
compartment of a neuron, which was enriched in the synaptoneurosome preparation. 
SN Alcohol-Responsive Effects are Cell-Type Specific 
A cell-type-specific enrichment analysis was performed for the alcohol-responsive 
mRNAs using neuronal, astrocytic, oligodendrocyte, microglial, GABA and glutamate gene 
lists (see Methods for details). The upregulated alcohol-responsive mRNAs in SNs were 
enriched with microglial, astrocytic and GABAergic cell types, while the downregulated 
mRNAs were enriched in neuronal cell types (Table 2.5). This trend of upregulation of 




FIGURE 2.5: SN ALCOHOL-RESPONSIVE EFFECTS ARE CELL-TYPE SPECIFIC 
A. Alcohol-responsive synaptic modules, correlation with alcohol consumption and cell specificity. The dendrogram 
shows the hierarchical relationship between the gene modules for the SN mRNA network. Below the dendrogram, a 
heat map shows the module correlation to amount of alcohol consumed; red and green indicate strong positive and 
negative correlations, respectively. The boxed correlations represent the significant alcohol-responsive modules 
(over-representation-hypergeometric test), and the letters inside the boxes represent the cell type over-represented 
in the modules: N=neuron, M=microglia, and A=astrocyte. The different colors under the dendrogram correspond to 
the different modules. B. Alcohol-responsive modules, cell specificity and biological pathways. The KEGG and 
Wikipathways and biological functions identified as alcohol-responsive are shown for each of the modules in SN, 
illustrating the most critical biological functions in groups of co-expressed mRNAs (DAVID (Database for Annotation 
Visualization and Integrated Discovery) and Webgestalt, BH (Benjamini–Hochberg method) corrected P<0.05). 
Pathways from modules with similar expression were grouped together for each of the over-represented cell types. 
The arrow in each box represents the direction of alcohol response (that is, upregulation or downregulation by 
alcohol treatment). The text-box border colors correspond to the module colors. Boxes A and B are enriched for 
neurons; Box C is enriched for microglia and astrocytes; Box D is enriched for astrocytes. Cell type illustrations were 




Of the eight alcohol-responsive upregulated modules in SN, six were also 
positively correlated with alcohol consumption and enriched with microglia and astrocyte 
mRNAs (Table 2.6). The two downregulated modules were negatively correlated with 
alcohol consumption and enriched in neuronal mRNAs. DAVID and Webgestalt were used 
to find the KEGG and Wikipathways over-represented in each of the modules (Figure 
2.5B). In the THs, only three modules were found to be cell specific (two 
astrocytic/microglial and one neuronal). 
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Data set Microglia P-value Astrocytes P-value Neuron P-value 
Oligodend
rocytes P-value Glutamate P-value GABA P-value 
SN enriched 28 5.02E-04 250 1.03E-27 39 8.68E-01 45 6.10E-05 102 1.13E-03 152 4.71E-22 
TH enriched 15 5.97E-01 43 1.00E+00 101 2.55E-13 24 7.34E-01 166 1.71E-20 74 4.88E-01 
             
Alcohol's effect on 
SN 
25 5.40E-02 115 5.33E-05 55 5.87E-01 19 9.94E-01 99 4.10E-01 99 1.30E-01 
Alcohol's effect on 
TH 
7 3.94E-01 26 4.95E-01 18 4.92E-01 7 8.60E-01 32 4.53E-01 27 6.46E-01 








5 8.52E-01 24 9.52E-01 47 5.12E-07 5 9.95E-01 39 4.88E-01 29 8.94E-01 
TABLE 2.5: OVER-REPRESENTATION OF THE SPECIFIC CELL TYPES ASSOCIATED WITH THE ALCOHOL-RESPONSIVE MRNAS IN SN AND TH 
The number of overlapping mRNAs and over-representation P-values are shown for microglia, astrocyte, neuron, oligodendrocyte, glutamate and GABA mRNA lists. 
































































































































KEGG pathways Wikipathways 
Tan 237 4.27E-64 1.08 11 6.52E-04 27 1.71E-05 3 1.00E+00 7 4.47E-01 0.05 8.30E-01 
Oxidative phosphorylation, Metabolic 
pathways, Parkinson's disease, Systemic 
lupus erythematosus, Peroxisome, 
Huntington's disease, Alzheimer's disease, 
Valine, leucine and isoleucine 
degradation, Pyrimidine metabolism, 
Ribosome, Staphylococcus aureus 








Ivory 39 1.88E-08 1.07 4 8.82E-03 15 3.95E-08 1 9.83E-01 3 1.90E-01 0.50 2.23E-02 
Keap1-Nrf2, Glutathione metabolism, 
Glutathione and one carbon metabolism 
Glutathione 
metabolism, B cell 
receptor signaling 
pathway 




Metabolic pathways, Proteasome, 
Oxidative phosphorylation, Protein 
processing in endoplasmic reticulum, 
Phagosome, Aminoacyl-tRNA 
biosynthesis, Protein export, Lysosome, 
Ubiquitin mediated proteolysis, 
Parkinson's disease, Collecting duct acid 
secretion, Glycolysis / Gluconeogenesis, 
RNA transport, Nucleotide excision repair, 
SNARE interactions in vesicular transport, 








Chain, TCA Cycle 
Sienna3 42 6.84E-06 1.06 2 2.60E-01 11 3.40E-04 0 1.00E+00 0 1.00E+00 0.50 1.98E-02 Systemic lupus erythematosus NA 
Lightgree
n 
82 9.00E-06 1.06 10 5.29E-05 24 8.66E-08 2 1.00E+00 2 9.06E-01 0.52 1.55E-02 
Ribosome, Oxidative phosphorylation, 
Huntington's disease, Parkinson's disease, 
Alzheimer's disease, SNARE interactions in 







Steelblue 40 3.51E-03 1.05 5 5.75E-03 14 1.78E-05 1 9.97E-01 1 8.83E-01 0.38 9.06E-02 NA NA 
Green 141 1.41E-04 1.03 4 6.96E-01 26 5.56E-03 33 2.54E-02 5 9.40E-01 
-
0.57 































































































































KEGG pathways Wikipathways 
Floralwhit
e 
24 2.08E-02 1.03 0 1.00E+00 6 2.21E-02 0 1.00E+00 0 1.00E+00 0.52 1.51E-02 
Amino Acid metabolism, mRNA 




Yellow 149 1.07E-04 0.96 0 1.00E+00 4 1.00E+00 49 3.63E-07 6 8.64E-01 0.32 1.57E-01 NA 
Hypothetical Network 
for Drug Addiction, 
TNF-α NF-kB Signaling 
Pathway, PluriNetWork, 
mRNA processing, 
Splicing factor NOVA 
regulated synpatic 
proteins 








for Drug Addiction 
TABLE 2.6: OVER-REPRESENTATION OF THE SPECIFIC CELL TYPES AND BIOLOGICAL PATHWAYS ASSOCIATED WITH THE SN MODULES 
The significant values (P<0.05) are marked in distinct colors per cell type. Average fold-change >1 indicates an increase in gene expression in a module and fold-change 
<1 indicates reduction in gene expression. 
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The immune system, specifically the neuroimmune system, has been recently implicated in 
alcohol dependence (Mayfield, Ferguson et al. 2013), and LPS treatment, which activates an immune 
response and enhances alcohol consumption in mice (Blednov, Benavidez et al. 2011). An over-
representation analysis of the SN alcohol-responsive mRNAs with a list of LPS-regulated mRNAs 
showed a significant representation of LPS mRNAs (P<0.05) and highlighted 55 common mRNAs found 
in chronic alcohol and chronic LPS treatment. Many astrocyte and microglial transcripts related to 
neuroimmune signaling were upregulated by chronic alcohol consumption. Key 
immune/inflammatory genes, including Tnfaip8l2, Tnfrsf10b, Traf4 and Tollip, were all upregulated 
by alcohol. In addition, chemokine and complement-related transcripts were upregulated, including 
the following: Ccr5, C1qa, C1qb, Ccrn4l, CCR4, Cxcl14, Gfap and Gbas. The gluthathione and 
peroxisome pathways were altered by alcohol, almost all of which were upregulated (Gstk1, Gstm5, 
Gstm6, Gpt2, Gpx4, Gpx7, Pex5,Pex6, Prdx3). 
Discussion 
We profiled mRNAs from SNs and paired TH preparations from the amygdala of ethanol-
treated mice, using a within-subject comparison, and found a robust difference between the SN and 
TH alcohol-responsive mRNAs. A greater number of alcohol-responsive mRNAs with larger fold-
changes were detected in the SNs as well as a greater enrichment of synaptic mRNAs. Our results 
suggest that the SN is a useful preparation for studying synaptic (both neuronal and glial) molecular 
changes associated with chronic alcohol consumption. 
Although there are other reports of RNA composition in synaptic preparations (Tian, 
Nakayama et al. 1999, Sung, Weiler et al. 2004, Poon, Choi et al. 2006, Cajigas, Tushev et al. 2012), 
there have been no direct comparisons of synaptic vs paired TH. The SN preparation has been used 
to identify synaptic networks related to neurodegenerative disorders (Williams, Shai et al. 2009), 
mental retardation (Zalfa, Eleuteri et al. 2007), schizophrenia (Smalheiser, Lugli et al. 2014) and 
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cocaine addiction (Eipper-Mains, Kiraly et al. 2011). However, this is the first alcohol study utilizing 
SN preparations. We used a model of alcohol consumption that produces intoxicating blood ethanol 
concentrations (Middaugh, Szumlinski et al. 2003) and induces mRNA expression changes in the 
prefrontal cortex of mice (Osterndorff-Kahanek, Ponomarev et al. 2013), as well as functional changes 
in the nucleus accumbens (Middaugh, Szumlinski et al. 2003). Our results, showing that the THs from 
amygdala contained 500 differentially expressed mRNAs, are consistent with previous findings 
(Osterndorff-Kahanek, Ponomarev et al. 2013). A key finding is that the chronic alcohol paradigm used 
here in mice induces changes in the transcriptome of the amygdala that are similar to those observed 
in the amygdala of human alcoholics (see Table 2.4) (Ponomarev, Wang et al. 2012). Our current 
results also highlight the utility of SNs compared with THs in studying alcohol’s molecular effects, 
given that the overlapping expression changes between mouse and human were observed using SNs 
but not in our previous studies using THs (Osterndorff-Kahanek, Ponomarev et al. 2013). 
There are two possible explanations for the difference between the SN and TH preparations. 
First, restricting gene expression profiling to the synaptic compartments (preventing dilution with the 
somatic transcriptome) should facilitate detection of specific mRNAs that are localized to the synapse. 
Our results from the weighted gene co-expression networks showed many mRNAs with similar or 
overlapping patterns of expression in SNs, while the TH network contained few overlapping networks. 
The similarity in functional gene networks in SNs facilitates the detection of alcohol actions that are 
specific to the synaptic region. Second, alcohol could selectively target synaptic mRNAs, ultimately 
changing gene expression in the synapse. This is supported by the finding that RNA processing 
machinery was responsive to alcohol. For example, RNA transcriptional, translational, spliceosomal 
and editing machineries, as well as many ribosomal proteins, were over-represented in the alcohol-
responsive mRNAs and the different modules, suggesting that chronic alcohol use affects translation 
in the synapse. Studies of synaptic compartments show involvement of microRNAs in regulating 
synaptic translation of mRNAs (Raab-Graham, Haddick et al. 2006, Rajasethupathy, Fiumara et al. 
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2009). Furthermore, microRNAs, their precursors and processing enzymes show synaptic localization, 
suggesting a well-orchestrated microRNAs regulation in the synapse (Lugli, Larson et al. 2005, Lugli, 
Torvik et al. 2008, Huang, Ruiz et al. 2012). In fact, our data show that synaptic microRNAs enzymes 
such as Dicer1 and Eif2c3 are alcohol sensitive. Previous studies from our group anticipated that Dicer 
would be a predicted target of microRNAs in human alcoholic brain samples (Lewohl, Nunez et al. 
2011). It is appealing to propose that alcohol affects synaptic microRNAs machinery, allowing for 
targeted regulation of gene expression in the synapse. 
We found that BDNF and its receptor TrkB as well as potassium channels were all altered by 
alcohol, corroborating well-documented alcohol-induced changes in these receptors. BDNF was 
downregulated, whereas one TrkB transcript was downregulated and one was upregulated. These 
results might be due to probe hybridization differences stemming from different splice variants. BDNF 
is involved in synaptic plasticity (Im, Hollander et al. 2010, Lobo, Covington et al. 2010), obesity (Cao, 
Lin et al. 2009) and addiction (Im, Hollander et al. 2010, Lobo, Covington et al. 2010), and potassium 
channels have been associated with increased sensitivity and tolerance to the sedative effects of 
ethanol (Ghezzi, Al-Hasan et al. 2004, Cowmeadow, Krishnan et al. 2005), seizure susceptibility 
(Yamada, Ji et al. 2001), neonatal familial convulsions and epilepsy (Singh, Charlier et al. 1998) and 







FIGURE 2.6: THEORETICAL MODEL FOR METABOLISM OF ALCOHOL IN THE BRAIN 
 Upregulated mRNAs are shown in red, and downregulated mRNAs are in green. 
 
Chronic alcohol use might result in increased metabolism of alcohol or acetate in the brain 
(Volkow, Hitzemann et al. 1992, Wang, Volkow et al. 2000). A study in human alcoholics showed an 
increase in glutamate–glutamine and GABA labeling in heavy compared with light drinkers (Jiang, 
Gulanski et al. 2013). In our study, we found many alcohol-metabolizing enzymes that were 
upregulated by alcohol consumption, in agreement with a previous study (Liu, Lewohl et al. 2004). 
Furthermore, alcohol-responsive glutamate and GABA mRNAs were detected in SNs (GABA-related 
mRNAs were associated with the upregulated alcohol-responsive mRNAs, see Table 2.5). Figure 2.6 
illustrates how the alcohol-responsive mRNAs can participate in alcohol degradation to produce 
metabolites that can enter the TCA cycle and be converted into glutamate, which may contribute to 
the dysregulation in the glutamate system seen in alcoholics. 
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The sensitivity of the SN preparation compared with the TH also allowed for improved cell-
type enrichment analysis, enabling the detection of a high positive correlation of astrocyte and 
microglial mRNAs with alcohol consumption in the SNs. All of the alcohol responsive genes in these 
astrocyte/microglia modules were upregulated. Given that these cell types are generally associated 
with neuroinflammation, a potential consequence of chronic alcohol use is activation of 
neuroimmune signaling. The adaptation of the neuroimmune system is consistent with data from the 
amygdala of human alcoholics (Ponomarev, Wang et al. 2012) and supports the emerging concept 
that there is a neuroimmune response to chronic alcohol use (Mayfield, Ferguson et al. 2013). In 
addition, astrocytes might have role in regulating synaptic plasticity by altering the levels of 
glutamate, GABA and tumor necrosis factor-α available in the synapse (Pickering, Cumiskey et al. 
2005, Perea, Navarrete et al. 2009). We found that all three of these systems were sensitive to 
alcohol, including glutamate and GABA metabolizing enzymes, receptors and transporters and tumor 
necrosis factor-α receptors and their interacting proteins. This suggests that the upregulated 
astrocyte specific genes could induce a wide range of effects following chronic alcohol consumption, 
ranging from neuroimmune to plasticity responses. The SN preparation also enriches for Peri-synaptic 
microglial and astroglial processes (Halassa, Fellin et al. 2007, Gerstner, Vanderheyden et al. 2012). 
As microglia and astrocytes can actively engage in synaptic function (Halassa, Fellin et al. 2007) and 
have been associated with alcoholism (Ponomarev, Wang et al. 2012), the SN preparation may be 
useful in investigating alcohol’s effects on the neuroimmune system. Because the cell-type specificity 
in our SN preparation is not known, we used a comprehensive bioinformatics approach similar to 
Ponomarev et al. (Ponomarev, Wang et al. 2012) (Ponomarev, Wang et al. 2012) (Ponomarev, Wang 
et al. 2012) (Ponomarev, Wang et al. 2012) (Ponomarev, Wang et al. 2012) (Ponomarev, Wang et al. 
2012) (Ponomarev, Wang et al. 2012) (Ponomarev, Wang et al. 2012) (Ponomarev, Wang et al. 2012) 
(Ponomarev, Wang et al. 2012), including identifying mRNAs which are co-expressed with known 
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astro-glial markers and examining the astro-glia mRNAs altered by alcohol consumption (Ponomarev, 
Wang et al. 2012). 
Extra-nuclear splicing has been discovered as a process involved in synaptic structure and 
function (Glanzer, Miyashiro et al. 2005), and this process may explain why nuclear mRNAs were 
found in the SN preparation. Alternatively, there could be some nuclear contamination. The estimate 
of nuclear contamination in our SN preparation is based on two main measurements: (1) DAPI (4',6-
diamidino-2- phenylindole) staining of nuclear DNA, showing no detected staining in the SNs 
(Supplementary Figure S2)(Sosanya, Huang et al. 2013). (2) Neun (a nuclear protein) western blots, 
showing the SN preparation decreases 75% of the Neun found in the TH (Sosanya, Huang et al. 2013). 
Although there is evidence for synaptic translation in postsynaptic neuronal compartments (Zalfa, 
Eleuteri et al. 2007), translation might also take place in the presynaptic compartment (axonal 
terminal) (Akins, Berk-Rauch et al. 2009). The SN preparation enriches for both the presynaptic and 
the postsynaptic fractions, and further research is warranted to determine whether alcohol 
differentially affects these two compartments. 
In summary, we identified coordinated changes in mRNA expression in SNs and THs following 
chronic alcohol consumption. The expression changes in SNs from mouse amygdala corroborate that 
seen in the amygdala of human alcoholics and include overlapping changes in GABA, glutamate and 
neuroimmune pathways. Our results demonstrate that (1) the mouse chronic-drinking paradigm used 
in this study is sufficient to produce the same expression changes previously seen in human alcoholics 
and (2) the parallel changes are evident for the SN but not TH mouse transcriptome. Our results 
highlight the advantage of the mouse SN preparation for identifying therapeutic gene targets for 
alcohol dependence that are relevant in humans and for studying synaptic plasticity under normal 
and disease conditions. 
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CHAPTER 3: SYNAPTIC MICRORNAS COORDINATELY REGULATE SYNAPTIC MRNAS:  
PERTURBATION BY CHRONIC ALCOHOL CONSUMPTION 
The work presented in this chapter has been published in 2016 in Neuropsychopharmacology. Most D, Leiter C, Blednov 
YA, Harris RA, Mayfield RD. Synaptic microRNAs Coordinately Regulate Synaptic mRNAs: Perturbation by Chronic 
Alcohol Consumption. 41(2):538-48. PubMed PMID: 26105134. Supplementary material to this work can be found in 
the online version of the manuscript at http://www.nature.com/npp/journal/v41/n2/suppinfo/npp2015179s1.html. 
Local translation of mRNAs in the synapse plays a major role in synaptic structure and function. 
Chronic alcohol use causes persistent changes in synaptic mRNA expression, possibly mediated by 
microRNAs localized in the synapse. We profiled the transcriptome of synaptoneurosomes (SN) 
obtained from the amygdala of mice that consumed 20% ethanol (alcohol) in a 30-day continuous 
two-bottle choice test to identify the microRNAs that target alcohol-induced mRNAs. SN are 
membrane vesicles containing pre- and post-synaptic compartments of neurons and astroglia and are 
a unique model for studying the synaptic transcriptome. We previously showed that chronic alcohol 
regulates mRNA expression in a coordinated manner. Here, we examine microRNAs and mRNAs from 
the same samples to define alcohol-responsive synaptic microRNAs and their predicted interactions 
with targeted mRNAs. The aim of the study was to identify the microRNA–mRNA synaptic interactions 
that are altered by alcohol. This was accomplished by comparing the effect of alcohol in SN and total 
homogenate preparations from the same samples. We used a combination of unbiased bioinformatic 
methods (differential expression, correlation, co-expression, microRNA-mRNA target prediction, co-
targeting, and cell type-specific analyses) to identify key alcohol-sensitive microRNAs. Prediction 
analysis showed that a subset of alcohol-responsive microRNAs was predicted to target many alcohol-
responsive mRNAs, providing a bidirectional analysis for identifying microRNA–mRNA interactions. 
We found microRNAs and mRNAs with overlapping patterns of expression that correlated with 
alcohol consumption. Cell type-specific analysis revealed that a significant number of alcohol-
responsive mRNAs and microRNAs were unique to glutamate neurons and were predicted to target 
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each other. Chronic alcohol consumption appears to perturb the coordinated microRNA regulation of 
mRNAs in SN, a mechanism that may explain the aberrations in synaptic plasticity affecting the 
alcoholic brain. 
Introduction 
Local translation of synaptic mRNAs is essential for the functional properties of brain cells 
(Raab-Graham, Haddick et al. 2006, Wang, Kim et al. 2009). The extensive neuroadaptations 
associated with alcohol dependence are likely caused by persistent changes in the expression of 
hundreds of mRNAs (Mayfield, Lewohl et al. 2002, Ponomarev, Wang et al. 2012, Nunez, Truitt et al. 
2013). Many of the alcohol-responsive adaptations are related to synaptic structure and function and 
may be caused by coordinated changes in local mRNA translation (Wang, Martin et al. 2010, Nunez 
and Mayfield 2012). MicroRNAs are short, noncoding RNAs that can regulate the translation of many 
target mRNAs, and this process is known to occur in the synaptic compartments of the cell (Lugli, 
Larson et al. 2005, Lugli, Torvik et al. 2008, Smalheiser and Lugli 2009, Sosanya, Huang et al. 2013). 
The ability of microRNAs to regulate mRNAs provides a localized regulatory system that may be 
important in the treatment of alcoholism.  
Exposure to alcohol and other drugs of abuse modulates microRNA expression in the brain 
(Pietrzykowski, Friesen et al. 2008, Eipper-Mains, Kiraly et al. 2011, Lewohl, Nunez et al. 2011, 
Tapocik, Solomon et al. 2013). MicroRNAs have important roles in learning and memory (Konopka, 
Kiryk et al. 2010), and are also altered in addiction-related behaviors, such as cocaine conditioned 
place preference (Chandrasekar and Dreyer 2011), cocaine-seeking behavior (Novak, Halbout et al. 
2010), and self-administration of alcohol (Tapocik, Solomon et al. 2013). Little is known about the 
microRNAs involved in the regulation of synaptic mRNA translation during alcohol dependence. 
Studies investigating the effects of chronic alcohol consumption in standard tissue (total homogenate, 
TH) preparations found a persistent change in the expression of microRNAs and their target mRNAs 
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in humans, mice, and rats (Lewohl, Nunez et al. 2011, Gorini, Nunez et al. 2013, Nunez, Truitt et al. 
2013, Tapocik, Solomon et al. 2013). However, the standard TH preparation likely underestimates the 
number and magnitude of alcohol responsive transcripts localized in the synapse (Lewohl, Nunez et 
al. 2011, Most, Ferguson et al. 2015). 
Synaptoneurosomes (SN) (Hollingsworth, McNeal et al. 1985, Quinlan, Philpot et al. 1999, 
Raab-Graham, Haddick et al. 2006, Sosanya, Huang et al. 2013) contain membrane vesicles of pre- 
and postsynaptic compartments of neurons as well as Peri-synaptic compartments of astrocytes and 
microglia and offer an improved model for studying the synaptic transcriptome. We recently showed 
that alcohol-induced mRNA changes are greater in SN compared with TH (Most, Ferguson et al. 2015). 
Here, we profiled the microRNA transcriptomes from paired SN and TH samples of mouse amygdala 
after a voluntary alcohol consumption paradigm. We identified alcohol-induced microRNAs that were 
correlated with alcohol consumption and also identified their predicted mRNA synaptic targets. 
Materials and Methods 
Animal Housing and Alcohol Consumption 
Adult (two-month-old) C57BL/6J female mice were maintained at the University of Texas at 
Austin Animal Resources Center. Mice were group-housed and given a one-week acclimation period 
in combined housing and another week to acclimate to the bottle positions in individual housing. 
Food and water were provided ad libitum and monitored daily, as were the temperature and reverse 
light/dark cycle. Mice underwent a 30-day two-bottle choice paradigm with continuous (24-h) access 
to one bottle of 20% ethanol (referred to as alcohol) and one bottle of water (Blednov, Mayfield et al. 
2012). A control group of mice received two bottles of water. Bottle weights were recorded daily, 
mice were weighed every four days, and the amount of alcohol consumed was calculated as g/kg/24h 
(see Supplementary Figure S1 for amounts of alcohol consumed). Alcohol bottle positions were 
alternated daily to control for position preferences. The stage of the menstrual cycle was not 
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determined. All procedures were approved by the Institutional Animal Care and Use Committee at 
the University of Texas at Austin and adhere to NIH Guidelines for the ethical care and use of animals 
in research. 
RNA Extraction 
As described previously (Most, Ferguson et al. 2015), after 30 days of the two-bottle choice 
drinking, 8 alcohol-consuming and 12 control mice were killed by cervical dislocation and decapitated 
at the beginning of the light phase of the light/ dark cycle. Brains were removed and washed for 1 
minute with 1ml of ice-cold homogenizing buffer (HB) containing 20mM HEPES, 1 mM EDTA (pH 7.4), 
40 U/ml RNAseOut (Invitrogen, CA), phosphatase inhibitor cocktail 3 (Sigma, MO) and protease 
inhibitors ‘Complete’ (Roche, IN). Brains were then placed in a coronal Zivic mouse brain slicer with a 
0.5mm resolution (Zivic Instruments, PA) and sliced in the following coordinates in order to isolate 
extended amygdala: coronal level 56-66 (Bregma (−0.18)-(−1.155)) and 66–80 (Bregma (−1.155)-
(−2.55)). The extended amygdala was dissected, placed in ice-cold HB (250μl), and homogenized for 
1 minute using a VWR homogenizer and pestle (VWR, PA). To minimize homogenate loss, pestles 
were washed with 50μl HB after use and the wash was collected and added to the sample. Ten percent 
of the homogenate (30μl) were snap frozen in liquid nitrogen and stored at − 80 °C for subsequent 
RNA TH analysis. Paired SN samples were isolated from the remaining 270μl of the homogenate. 
Homogenates were filtered through a 100-μm-pore filter (Millipore, MA) and subsequently through 
a 5-μm-pore filter (Millipore); filters were washed with HB before use for protection from RNAse. To 
maximize yield, the filters were washed with 50μl HB after use and the wash was collected and added 
to the homogenate. The homogenate was then centrifuged at 14,000g for 20 minutes at 4°C in order 
to pellet the cell fraction containing SN. The supernatant was removed and the pellet was snap frozen 
and stored at −80°C for SN RNA analysis. Microscopy was used to further characterize the SN 
preparation (Most, Ferguson et al. 2015). RNA was extracted from 20 paired SN and TH samples using 
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the Direct-Zol RNA extraction kit (Zymo, Japan) with small IC extraction columns according to the 
manufacturer’s instructions. The RNA was quantified using a Nano-Drop1000 (Thermo Fisher 
Scientific Inc., IL) and assayed for quality using an Agilent 2100 Tape Station (Agilent Technologies, 
CA; Supplementary Figure S2A). The criteria for RNA quantity and quality were as follows: total 
amount of RNA>500ng, 280/260>1.7, and RIN>6.5. We measured RIN of five of the control samples 
using the Bio-analyzer Nano kit (Agilent). To ensure that samples with high RINs also included high 
quality and quantity of microRNAs, the same five control samples were subjected to a small RNA 
analysis using the Bio-analyzer Small kit (Agilent). Micro-RNAs comprised >10% of the small RNA 
population in the samples (Supplementary Figure S2B). 
Microarray Hybridization, Data Quality Assessment, and Analysis 
Total RNA was extracted from the TH and SN samples. The homogenates were divided into 
two parts (90% was used for SN and 10% for TH). The 20 samples from the SN and 20 from the TH (40 
total) were hybridized to 40 microRNA microarrays. Previously, we used 40 mRNA microarrays from 
these same mice (Most, Ferguson et al. 2015). Four samples per mouse were hybridized (SN 
microRNA, SN mRNA, TH microRNA, and TH mRNA). The RNA samples were divided for mRNA (Most, 
Ferguson et al. 2015) and microRNA (this study) analyses. The RNA targeted for microRNA analysis 
was labeled with flash-tag biotin HSR (Affymetrix, CA) and hybridized to GeneChip microRNA 3.0 
Arrays (Affymetrix) at the University of Texas Southwestern Medical Center microarray facility in 
Dallas. Affymetrix microarrays show a high correlation with results obtained from other platforms 
such as qPCR (Kolbert, Feddersen et al. 2013, Mestdagh, Hartmann et al. 2014). This microarray 
platform uses annotations from miRBase version 17 and contains 19,724 probes for mature micro-
RNAs from 153 organisms. For this study, we focused on the 1,111 mature mouse microRNAs 
detected on the array. The mRNA and microRNA data discussed in this publication have been 
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deposited in NCBI’s Gene Expression Omnibus (Edgar, Domrachev et al. 2002) and are accessible 
through GEO Series accession number GSE51730. 
We analyzed the array data using R programming language and Bioconductor packages 
(http://www.bioconduc tor.org). Preprocessing (RMA, background correction, and quantile 
normalization) of the microRNA data was performed with the Bioconductor Oligo package. Quality 
measures were taken before and after preprocessing using the Array Quality Metrics package 
(Kauffmann, Gentleman et al. 2009, Kauffmann and Huber 2010) to generate the principal component 
analysis (PCA). For all further analyses, only the mouse mature microRNA data were used. The 
microarray expression data were then analyzed using the Bioconductor Limma package according to 
the author instructions (Smyth 2004). This analysis is the main approach currently used for studying 
thousands of genes from microarrays. We used differential expression analysis between paired SN 
and TH samples (paired/dependent t-test; N=20 per group). For comparison of SN and TH expression 
levels, fold changes were calculated as the ratio of SN to TH. Fold changes greater than 1 are referred 
to as ‘SN-enriched’ and fold changes less than 1 are referred to as ‘SN-depleted’. 
Independent t-tests were used to compare the alcohol (N=8) and control (N=12) groups to 
determine the effect of alcohol within SN and TH groups. These tests were performed in two separate 
analyses (one for each preparation). Equal sample sizes are not required for this analysis. For 
comparison of alcohol and control expression levels, fold changes were calculated as the ratio of 
alcohol to control expression levels. Fold changes greater than 1 are referred to as ‘upregulated’ and 
fold changes less than 1 are referred to as ‘downregulated’. P-values<0.05 were considered significant 
for all analyses in the study. 
For microRNA co-expression analyses, we used weighted gene correlation (co-expression) 
network analysis (WGCNA; Langfelder and Horvath, 2008). Individual mice can consume slightly 
different amounts of ethanol, and we were interested in the time period that represented a 
consistent amount of drinking and chose the average consumption per mouse from day 10 to day 30. 
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The alcohol consumption was correlated with the expression data using Pearson correlation (N=8). 
However, a WGCNA network was calculated using the 20 SN samples, including both alcohol and 
control samples. We then determined which of the microRNA modules correlated with alcohol 
consumption. The WGCNA parameters were as follows for the SN: power 12, signed network, 
cutHeight 0.995, minModsize 60. For cell type enrichment analysis, we used lists from CamkIIa+ 
glutamate neurons and Gad+, somatostatin+ and parvalbumin+ GABA neurons (He, Liu et al. 2012). 
We combined the microRNA data (see Table 3.1 for experimental design) with our previously 
published mRNA results (Most, Ferguson et al. 2015), which were obtained from the same samples. 
 
Alcohol consuming mice N=8 
SN 
N=8 X 2=16 
TH 
Control mice N=12 
SN 
N=12 X 2=24 
TH 
TABLE 3.1: EXPERIMENTAL DESIGN OF THE STUDY 
20 mice were allocated to either the alcohol or control group. Each mouse contributed an amygdala sample that was split into two 
parts, one for SN and one for TH. Total RNA was extracted from each of these preparations and was hybridized to microRNA 
microarrays. In our previous study (Most et al. 2015) we had hybridized the same samples to mRNA microarrays. Here, the total 
number of samples was 40: 8 SN and 8 TH, for a total of 16 alcohol samples; 12 SN and 12 TH, for a total of 24 control samples. 
Samples were individually hybridized to microarrays. 
To determine alcohol-sensitive SN and TH modules, we used the ‘alcohol-responsive mRNA’ 
lists from Most et al. 2015 (Most, Ferguson et al. 2015). All P-values from the bioinformatics analyses 
were adjusted using the Benjamini–Hochberg method. For cell types and immune response 
enrichment, we used the following lists of genes: neurons, astrocytes and oligodendrocytes (Cahoy, 
Emery et al. 2008), microglia (cured from Oldham et al. 2008 (Oldham, Konopka et al. 2008)), and 
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glutamate/GABA (Sugino, Hempel et al. 2006). For cross species comparison, we used lists from 
alcohol vapor-treated rats (Tapocik, Solomon et al. 2013) and human alcoholics (Lewohl, Nunez et al. 
2011) to identify conserved alcohol-responsive microRNAs. Drugs that potentially target the alcohol-
responsive mRNAs and the ‘mRNA targets of the alcohol-responsive microRNAs’ were found using 
Ingenuity Pathway Analysis (IPA, Ingenuity Systems, Qiagen, CA). 
Classification of microRNA–mRNA Interactions 
Mouse target predictions for microRNAs and mRNAs were extracted from microRNA.org 
(version 8-2010). The micro-RNA.org resource comprises predictions computed by the miRanda 
algorithm (John, Enright et al. 2004, Betel, Koppal et al. 2010). The algorithm predicts microRNAs 
according to the number of putative target sites and the sum of alignment scores determined by both 
seed match type and seed match context. The predictions that were considered were those 
annotated as ‘conserved microRNA’ and ‘good mirSVR score’. The individual binding locations can be 
found in http://www.microRNA.org. We then overlapped the list of mRNAs that were predicted to be 
targeted by alcohol-responsive micro-RNAs with the list of microRNAs that were predicted to target 
the alcohol-responsive mRNAs. Prediction analysis showed that a subset of alcohol-responsive 
microRNAs were predicted to target certain alcohol-responsive mRNAs and vice versa, providing a 
bidirectional analysis for identifying microRNA–mRNA interactions using a novel approach. 
Quantitative Real-Time PCR (qPCR) 
qPCR was used to validate the array data of microRNA expression levels in the same SN 
samples. First, RNA was DNase treated using the DNA-free Kit (Ambion, TX) and reverse transcribed 
into cDNA using the iScript Select cDNA Synthesis Kit (Bio-Rad, CA). Samples were then evaluated for 
the presence of genomic DNA by comparing GAPDH Cq values from RT+ and RT− reactions, using 
single threshold Cq determination. Then, RNA (4.5 ng) from four of the SN alcohol samples and five 
of the SN control samples was used to synthesize cDNA, using the TaqMan MicroRNA Reverse 
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Transcription Kit and the TaqMan PreAmp Master Mix, according to the manufacturer’s protocol for 
creating custom RT and preamplification pools (Applied Biosystems, NY). qPCR was performed in 
triplicates using TaqMan Universal PCR Master Mix (no AmpErase UNG). FAM-labeled TaqMan 
MicroRNA Assays (Applied Biosystems) were used to amplify mmu-miR-137 (Assay ID 001129) and 
hsa-miR-9* (Assay ID002231). Normalized relative expression was determined with respect to the 
most stably expressed small nucleolar RNAs, Sno-234 (Assay ID 001234) and Sno-202 (Assay ID 
001232), as determined by geNorm analysis (Vandesompele, De Preter et al. 2002). qPCR results were 
imported into qBase+ software, version 2.5 (Biogazelle, BE), where the ΔΔCt method was used 
(Hellemans, Mortier et al. 2007). Statistical analysis was completed in GraphPad Prism software, 
version 6. 
Results 
SN and TH microRNA Transcriptomes are Different in Control and Alcohol Samples 
We studied the microRNA transcriptomes in paired SN and TH preparations to compare 
synaptic vs total cell microRNA expression. PCA revealed a distinct clustering of microRNA expression 
in the two preparations, while showing a homogenous sample population (no outliers detected) 
within each preparation (Figure 3.1A). The clustering was evident along the first principal component, 
indicating the largest variation stems from the distinct expression profiles of the preparations. A 
comparison of the individual microRNA expression levels on the arrays showed similar values in the 
SN and TH preparations as well as microRNAs enriched in SN (‘SN-enriched’) and microRNAs depleted 
in SN (‘SN-depleted’; Figure 3.1B). We compared the mature mouse microRNA expression levels in SN 
and TH (non-treated control) and found 180 differentially expressed microRNAs. Eighty-one 
microRNAs were ‘SN-enriched’ showing up to an eightfold change in expression, and ninety-nine were 
‘SN-depleted’ (Supplementary Table S2). 
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We then compared SN and TH samples (referred to as SN-alcohol and TH-alcohol) from mice 
that chronically consumed 20% ethanol in a two-bottle choice paradigm and found 153 differentially 
expressed microRNAs, 96 of which were enriched in SN (Supplementary Table S2). It is possible that 
alcohol exposure changes the expression or trafficking of microRNAs to the synapse, resulting in 
different SN-enriched microRNAs in alcohol samples compared with control. We assessed the overlap 
between the differentially expressed microRNAs in SN and TH under alcohol and control conditions 





FIGURE 3.1: DIFFERENCES IN EXPRESSION PROFILES AS DETECTED IN SN AND TH PREPARATIONS 
A. Principal component analysis of paired SN (green) and TH samples (blue). All microRNAs on the array (including those from 
different species) were used for this analysis (25,119 probes). The primary purpose for this analysis is quality control to show the 
overall detection of transcripts on the array and to facilitate comparison of the preparations. Only the mouse mature microRNAs will 
be discussed and presented in subsequent tables and figures. B. Expression levels of microRNAs in SN and TH preparations (control 
group only). For comparison of SN and TH expression levels, fold changes were calculated as the ratio of SN to TH. MicroRNAs below 
the diagonal are enriched in SN relative to TH and have a fold change greater than 1 (referred to as ‘SN-enriched’; shown in green). 
MicroRNAs above the diagonal are depleted in the SN relative to the TH and have a fold-change less than 1 (referred to as ‘SN-
depleted’; shown in blue). C. Venn diagram showing the number of differentially expressed microRNAs from the SN-control/TH-




Alcohol Consumption Alters microRNA Expression in SN and TH 
We investigated alcohol’s effects on SN microRNA expression and identified 65 mature mouse 
microRNAs that were differentially expressed between the alcohol and control samples (Table 3.2; 
Supplementary Table S2). Seventy-seven alcohol-sensitive microRNAs were differentially expressed 
in TH samples (Supplementary Table S2). Twenty microRNAs with the greatest fold changes are shown 







responsive in SN 
Number of alcohol-




All species 25,119 1,377 1,623 77 
Mouse mature 1,111 65 77 1 
TABLE 3.2: ALCOHOL-RESPONSIVE MICRORNAS IN SN AND TH 
Number of microRNAs (mature and premature/precursor) from all species are shown next to the mouse-specific microRNAs 
examined for this study. The total number of microRNAs in each group is shown next to the number of alcohol-responsive (P-


























miR-1893 1.62 2.71E-02 0.91 6.36E-01 miR-1965 1.63 1.44E-02 1.06 7.66E-01 
miR-875-3p 1.61 4.45E-03 0.78 9.24E-02 miR-207 1.61 1.98E-04 0.99 9.48E-01 
miR-187* 1.56 2.87E-02 1.44 1.67E-01 miR-467d* 1.57 1.38E-02 0.68 1.04E-01 
miR-187 1.51 1.68E-02 1.33 1.76E-01 miR-193* 1.53 1.44E-02 1.27 2.42E-01 
miR-92a-2* 1.47 4.53E-02 1.18 4.59E-01 miR-3113* 1.45 1.98E-04 0.84 2.07E-01 
miR-466n-3p 1.43 3.83E-04 0.87 2.84E-01 miR-574-5p 1.39 1.61E-02 0.63 8.91E-02 
miR-669d-2* 1.38 1.67E-02 1.06 4.32E-01 miR-200c 1.35 2.95E-02 1.28 8.78E-02 
miR-216b 1.38 8.53E-03 0.98 8.67E-01 let-7b* 1.32 2.11E-02 0.78 9.23E-02 
miR-501-5p 1.37 4.41E-02 0.80 1.09E-01 miR-322 1.30 3.78E-02 0.99 9.32E-01 
miR-5115 1.34 3.51E-02 0.79 2.15E-01 miR-30c-2* 1.28 2.79E-02 1.03 8.43E-01 
miR-18a 0.65 1.41E-02 1.00 9.98E-01 miR-9 0.63 1.93E-02 1.18 3.64E-01 
miR-377* 0.65 1.73E-02 1.13 4.23E-01 miR-539-5p 0.62 1.40E-03 0.90 5.57E-01 
miR-466g 0.65 4.11E-02 1.33 1.97E-01 miR-411* 0.62 7.47E-03 0.83 1.73E-01 
miR-135a-2* 0.64 4.82E-03 0.74 2.09E-01 miR-3068 0.61 2.32E-02 0.95 8.25E-01 
miR-466f 0.64 3.33E-02 0.85 3.12E-01 miR-3473 0.60 1.67E-02 1.03 8.39E-01 
miR-5099 0.63 4.18E-02 0.90 3.74E-01 miR-5100 0.60 5.64E-04 1.28 9.73E-02 
miR-344c 0.59 8.78E-04 0.83 2.63E-01 miR-5097 0.58 1.07E-02 1.23 2.25E-01 
miR-34c* 0.58 3.78E-02 0.77 2.98E-01 miR-132* 0.54 9.32E-03 0.96 6.99E-01 
miR-1187 0.58 2.09E-03 1.48 1.75E-01 miR-720 0.52 3.52E-03 1.20 3.46E-01 
miR-466f-3p 0.43 3.83E-04 1.59 1.37E-01 miR-1298 0.37 1.78E-02 0.56 8.19E-02 
TABLE 3.3: ALCOHOL-RESPONSIVE MICRORNAS WITH THE LARGEST FOLD-CHANGE IN SN (LEFT) AND TH (RIGHT) 
The top 10 most upregulated microRNAs (top rows) and most downregulated microRNAs (bottom rows) in SN (left) and TH (right). 
Left side of the table contains the fold changes and P-values as detected in SN, whereas the right side of the table contains the fold 
changes and P-values detected in TH. For comparison of alcohol and control expression levels, fold changes were calculated as the 
ratio of alcohol to control expression levels. Fold changes greater than 1 are referred to as ‘upregulated’ and fold changes less than 1 
are referred to as ‘downregulated’. P-values<0.05 were considered significant. For example, miR-1893 is upregulated in SN, but is 






There were 23 and 39 upregulated microRNAs with average fold-change magnitudes of 33% 
and 26% in SN and TH, respectively (Figure 3.2A). There were 42 and 38 downregulated microRNAs 
with average fold-change magnitudes of 25% and 27% in SN and TH, respectively. The average fold 
changes between the preparations were not statistically significant (Supplementary Table S3). The 
fold changes in SN and TH were not influenced by inherent bias associated with either preparation, 






FIGURE 3.2: ALCOHOL-INDUCED MICRORNAS ARE DIFFERENT IN SN AND TH 
A. Number of alcohol-responsive microRNAs in SN and TH. Alcohol-induced microRNA expression fold-changes are shown on the y-
axis. For comparison of alcohol and control expression levels in each of the preparations, fold changes were calculated as the ratio of 
alcohol to control expression levels (SN-alcohol/SN-control and TH-alcohol/TH-control). Fold changes greater than 1 are referred to as 
‘upregulated’ and fold-changes less than 1 are referred to as ‘downregulated’. B. Volcano plot (scatter plot) of fold changes and P-
values of the effects of alcohol on microRNAs in SN and TH. 
Two microRNAs were chosen for qPCR validation: miR-137, which was found to be alcohol-
responsive in SN, and miR-9*, which was not alcohol responsive in SN. Pearson correlation for 
expression levels between the qPCR and arrays for miR-137 showed r=0.69. A one-tailed Students’ t-
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test was used to test the significance of the correlation between the array and qPCR data. The 
correlation for miR-137 was significant (P=0.021). Pearson correlation for expression levels between 
qPCR and microarrays for miR-9* showed r=0.70 and this was also significant (P=0.018). 
Synaptic microRNAs Coordinately Regulate Synaptic mRNAs Following Alcohol Consumption 
Co-expressed microRNAs may regulate their mRNA targets in response to alcohol treatment. 
We used WGCNA to create a co-expression network to group microRNAs with similar patterns of 
expression into modules. We then identified the modules that were significantly correlated with 
alcohol consumption and found 610 microRNAs that were co-expressed within six different modules 
(Supplementary Table S2). Sixty-five microRNAs were differentially expressed in SN (Table 3.2), and 
35 were co-expressed within these modules (Figure 3.3A). We identified microRNAs that correlated 
with alcohol consumption and found 74 in SN (Supplementary Table S2; average correlation: r>0.78), 




FIGURE 3.3: ALCOHOL INDUCES COORDINATED EXPRESSION OF MICRORNAS THAT ARE CORRELATED WITH ALCOHOL 
CONSUMPTION 
A. Hierarchical clustering of microRNAs from SN, including both alcohol and control data. The microRNAs are arranged by covariance 
similarity; thus, microRNAs under the same branch have greater expression similarity than those outside the branch. The dissimilarity 
among microRNAs is represented in the y-axis. The six different modules are shown in boxes. The width of the box represents the 
number of microRNAs co-expressed in that module. The correlation of each module with alcohol consumption is shown as a heat 
map (red represents positive correlation with consumption and green represents negative). The microRNA list contains co-expressed 
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microRNAs which are also alcohol-responsive. The microRNAs in the gap between the modules are ones that did not pass the co-
expression threshold as defined by the WGCNA and were not included in any module. B. Examples of three co-expressed microRNAs 
and the number of overlapping predicted alcohol-responsive mRNAs. C. Examples of microRNA predicted interactions. The greater 
the color intensity, the greater the fold-change magnitude (red is upregulated and green is downregulated). The unmarked circles 
represent mRNAs. The dotted circle emphasizes mRNAs that are co-targeted by the illustrated microRNAs. 
We next utilized mRNA expression data (alcohol-responsive modules of co-expressed mRNAs) 
from our previous study (Most, Ferguson et al. 2015) to identify the alcohol-responsive microRNAs 
co-expressed with the mRNA modules. The modules were defined as astrocytic, microglial, or 
neuronal if they contained a significant number of the cell type associated mRNAs based on a 
hypergeometric distribution. The astrocyte modules overlapped with the microglia ones and were 
therefore combined. Cell type-specific analysis revealed 16 microRNAs that were significantly 
correlated with the alcohol-responsive mRNA modules (Figure 3.4). 
 
 
FIGURE 3.4: MICRORNA–MRNA INTERACTIONS ARE COORDINATELY EXPRESSED IN RESPONSE TO ALCOHOL AND ARE 
ASSOCIATED WITH SPECIFIC CELL TYPES 
Shown are the alcohol-responsive mRNA modules and their correlation to individual microRNAs found in SN. The 10 alcohol-
responsive mRNA modules are shown. The modules’ correlation with consumption for the six alcohol-responsive modules is shown as 
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r-values (Pearson’s correlation coefficient). Alcohol-responsive mRNA module correlation to individual microRNAs is represented as a 
heat map, with red representing a positive correlation and green representing a negative. Cell type mRNA enrichment is also shown. 
Modules 1–6 were enriched with astrocytic/microglial mRNAs, whereas modules 7–10 were enriched with neuronal mRNAs. The 16 
microRNAs that were significantly correlated with at least one mRNA module are shown (mRNA data are from Most et al. 2015). 
Synaptic microRNA–mRNA Interactions are Regulated by Alcohol 
MicroRNA–mRNA interactions were constructed using target predictions from the 2010 
miRanda database for ‘good mirSVR scores’ and ‘conserved microRNAs’ (http://www.microrna.org). 
From these predicted interactions, the alcohol-responsive microRNAs were predicted to target 1,039 
target mRNAs of the 1,531 that were identified as alcohol-sensitive in Most et al. 2015 (Most, 
Ferguson et al. 2015). The alcohol-responsive mRNAs were predicted to be targeted by 15 of the 65 
alcohol-responsive microRNAs (Table 3.4). The 15 micro-RNAs showed 15–51% change. We found 
that 250 of the mRNAs were predicted to be targeted by more than five of the alcohol-responsive 





Number of predicted 
targets 
Overlap between alcohol-responsive 
and predicted tragets 
1,531 mRNA 13,857 mRNAs 1,039 mRNAs 
65 microRNAs 238 microRNAs 15 microRNAs 
TABLE 3.4: NUMBER OF ALCOHOL-RESPONSIVE MRNAS, MICRORNAS AND THEIR PREDICTED INTERACTIONS IN SN 
The number of alcohol-responsive microRNAs and mRNAs is shown together with their predicted targets, as defined by the miRanda 
mouse database for interactions. The overlapping participants between the alcohol-responsive microRNAs/mRNAs and the predicted 
targets of each are shown, and were termed ‘bidirectional’ interactions. The data for the alcohol-responsive mRNAs were taken from 
Most et al. 2015. P-values<0.05 were considered significant. 
We identified mRNAs cooperatively targeted by co-expressed microRNAs by combining the 


















Overlapping targets for the co-expressed 
microRNAs 
miR-203 0.66  1.63E-02 393 -157.76 
Module 1 
6330408A02Rik, Aebp2, Ank2, Ankfy1, Apc 
Asph, Camta1, Cdh8, Cobll1, Crbn, Dclk2, Dph3, 
Dpp3, Eif4a2, Etl4, Fam135a, Foxj3, Gria2, 
Hace1, Hnrnpa2b1, Hsd17b11, Huwe1, 
Ivns1abp, Maf, Mbd3l2, Mbd5, Mef2c, Mll3, 
Mtdh, Myt1l, Napepld, Narg2, Ndrg3, Necap1, 
Neto2, Oat, Ocrl, Osbp2, Pbrm1, Pbx1, Pja2, 
R3hdm1, Rgs7bp, Runx1t1, Scn1a, Sgk3 Ski, 
Slc30a1, Slc39a10, Srpk2, Syap1, Syncrip, 
Tmem209, Tmem87b, Trim37, Tshz3, Ube3a, 
Unc80, Zc3h6, Zfp644, Zxda. 
miR-374 0.85  2.90E-02 366 -181.00 
miR-106b 0.83 
 
3.43E-02 282 -129.25 
miR-488 0.83  1.20E-02 290 -123.16 
Module 2 
1600014C10Rik, 4833424O15Rik, AI314180, 
Acot11, Ahcyl1, Ankfy1, Ap2b1, Atl2, Camta1, 
Capn6, Car10, Cdc37, Cdc37l1, Cinp, Crbn, Cyld, 
Dgcr6, Etl4, Fam126b, Fbxo3, Gabrb2, Glce, 
Grm7, Gtf3c2, Hps5, Kif1b, Med18, Mllt3, Msi2, 
Mtdh, Myt1l, Ndst1, Pcdh10, Pja2, Pkp4, Prkd1, 
R3hdm1, Rab21, Rapgef4, Rarb, Rbbp9, Rftn2, 
Rnf4, Sec16a, Sesn1, Slc22a17, Slc35e3, Smc6, 
Snx12, Spnb2, Stx8, Tbxas1, Tcf25, Tle1, 
Tmem209, Tprkb, Tshz1, Tshz3, Tspan7, Unc80, 





1.48E-02 246 -84.36 
miR-137 0.65  2.03E-02 243 -133.62 
Module 3 
2700060E02Rik, 4732418C07Rik, Aebp2, 
Ahcyl1, Ank2, Ank3, Asph, Atl2, Cdk13, Crtc3, 
Ctdspl, Dgcr6, Dut, E2f6, Fry, Gatad1 , Gigyf1, 
Hnrpdl, Kdm5b, Khdrbs3, Lingo2, Lrrc16a, Maf, 
Mbnl2, Mfsd6, Mll1, Msi2, Nme7, Nrg1, Osbp2, 
Ppp2r5c, Rab8a, Rin2, Sae1, Scamp2, Scn1a, 
Seh1l, Slc13a3, Smc6, Sntg2, Snurf, Spag9, Stx8, 
Syncrip, Tmem87b, Ybx1, Zfp804a. 
miR-18a 0.65 
 
1.35E-02 198 -75.92 
miR-708 0.84  1.51E-02 192 -70.24 
Module 4 
Asph, Azi2, E2f6, Foxj3, Gpt2, Gucy1a3, Hspa9, 
Lipa, Mia3, Mtpap, Ocrl, Palld, Phf17, Pja2, 
Prkar1a, Pros1, Rapgef6, Rfx1, Robo2, Seh1l, 
Sgms1, Socs5, Txnip, Unc5c, Ybx1, Zfp804a. 
miR-92b 1.19 
 
4.40E-02 190 -90.99 
miR-365 1.18  4.45E-02 156 -58.25 Module 5   
miR-411 0.84  3.89E-02 153 -66.06 Module 6   
miR-141 0.87  4.10E-02 338 -144.24 
NA 
  
miR-216b 1.35  1.49E-02 230 -101.41   
miR-92a 1.19  3.62E-02 201 -94.12   
miR-187 1.50  1.85E-02 64 -22.28   
TABLE 3.5: CO-EXPRESSED ALCOHOL-RESPONSIVE MICRORNAS AND THEIR OVERLAPPING MRNA TARGETS 
Fifteen alcohol-responsive microRNAs and the number of predicted alcohol-responsive mRNAs (as identified in Most et al. 2015) is 
shown. The predictions were calculated using the miRanda database. The sum of each of the mirSVR scores per microRNA is shown 
for all predicted interactions per microRNA, with the scores representing the relative probability of occurrence of the microRNA–
mRNA interactions. The WGCNA co-expression module for each of the microRNAs and the number of overlapping predicted mRNA 
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targets for the microRNAs in the same module are shown. “NA” represents alcohol-responsive microRNAs which were not co-
expressed with other microRNAs, and therefore do not have overlapping mRNA targets with other microRNAs. For comparison of 
alcohol and control expression levels, fold changes were calculated as the ratio of alcohol to control expression levels. Fold changes 
greater than 1 are referred to as ‘upregulated’ and fold changes less than 1 are referred to as ‘downregulated’. P<0.05 were 
considered significant. 
 
MiR-106b, miR-203, and miR-374 are examples of co-expressed microRNAs that were 
predicted to target 61 overlapping targets (Figure 3.3B). MicroRNAs can be negatively or positively 
correlated with their mRNA targets; e.g., miR-106b, miR-203, and miR-374 were all downregulated 
and were predicted to target both up- and downregulated mRNAs (Figure 3.3C). 
The relationship among the alcohol-responsive micro-RNAs and the cell type specific 
glutamate and GABA microRNAs was examined using microRNA records (He, Liu et al. 2012). We 
identified 10 differentially expressed microRNAs that were unique to CamkIIa+ glutamate neurons, 5 
unique to Gad+ GABA neurons, 9 unique to somatostatin+ GABA neurons but none unique to 
parvalbumin+GABA neurons. In addition, 9 of the 15 alcohol sensitive microRNAs were previously 
shown to be specific to glutamate neurons, and 8 of the 9 were highly predicted to target the alcohol-




microRNA Grm7 Gria2 Grina Grip1 
miR-106b -0.58 -1.03 NA NA 
miR-137 -0.69 NA NA NA 
miR-18a NA -0.23 -0.34 -0.25 
miR-203 NA -0.52 NA -0.39 
miR-374 -0.77 -0.27 NA NA 
miR-411 NA -0.68 NA NA 
miR-708 NA NA NA NA 
miR-92a -0.70 NA NA NA 
miR-92b -0.70 NA NA NA 
TABLE 3.6: ALCOHOL-RESPONSIVE MICRORNAS AND THEIR MRNA TARGETS THAT ARE SPECIFIC TO GLUTAMATE NEURONS 
Nine glutamate-specific microRNAs of the 15 predicted alcohol-responsive microRNAs are shown. The numbers in the table represent 
the mirSVR scores for the predicted interactions between a microRNA and its glutamate-specific predicted mRNA targets (as defined 
by the miRanda mouse database for interactions). “NA” means no interactions were predicted for that specific microRNA with a 
glutamate mRNA. Alcohol-responsive mRNA data were taken from Most et al. 2015. Grm7 (glutamate receptor, metabotropic 7), 
Gria2 (glutamate receptor, ionotropic, AMPA2, also known as GluA2), Grina (glutamate receptor, ionotropic, N-methyl D-aspartate-
associated protein 1, glutamate binding), and Grip1 (glutamate receptor-interacting protein 1). 
 
Discussion 
The compartmentalization of RNA in cells allows for rapid responses to stimuli and may be 
important for the neuroadaptations in response to chronic alcohol consumption. The aim of this study 
was to identify the synaptic microRNAs that are altered by alcohol consumption and to propose 
microRNA–mRNA synaptic interactions that maybe changed by chronic alcohol. We compared the 
effect of alcohol in paired SN vs TH samples and identified those changes that were specific to the SN. 
Our data indicate that the microRNAs in the SN and TH respond differently to alcohol exposure: there 
was only one common alcohol responsive microRNA, miR-411, between the preparations 
(Supplementary Table S3). Such a small overlap was unexpected and underscores the advantage of 
the SN in examining discrete, localized responses to alcohol. We identified microRNAs that were SN 
enriched in alcohol but not control samples and vice versa. If only the magnitude of treatment fold 
changes for the same microRNA was larger in SN compared with TH, this might suggest that synaptic 
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enrichment was responsible for the differences. However, changes in magnitude do not explain all of 
the differences that we observed which appear to be both qualitative (different microRNAs) and 
quantitative (different amounts of the same microRNA). The differences between SN and TH are likely 
due to localized effects of alcohol and it is possible that alcohol changes the trafficking of microRNAs 
to the synapse, resulting in unique SN-enriched microRNAs. 
This regimen of alcohol consumption causes extensive and coordinated changes in gene 
expression in the brain, suggesting a network regulator such as a microRNA may be involved (Lewohl, 
Nunez et al. 2011). The question remains regarding how, or if, alcohol affects synaptic pathways 
through synaptic microRNA regulation. 
This is the first study to use SN profiling of microRNA and mRNA obtained from the same 
samples, enabling detection of alcohol-responsive synaptic microRNAs and mRNAs and the predicted 
interactions between them. We used a combination of unbiased methods to reveal key microRNAs 
and their targets. Chronic alcohol consumption caused robust changes in synaptic microRNA 
expression levels consistent with those seen in human alcoholics (Lewohl, Nunez et al. 2011) and in 
other animal models of dependence (Gorini, Nunez et al. 2013, Nunez, Truitt et al. 2013, Tapocik, 
Solomon et al. 2013). We further identified microRNAs with overlapping patterns of expression that 
correlated with alcohol consumption. 
Previous studies used different experimental conditions, such as alcohol paradigms, species, 
gender, and brain regions, and we were interested in identifying potential conserved microRNAs that 
extend across all these different conditions. We suggest that a conserved microRNA could potentially 
be important in human disease. We employed many different bioinformatic approaches, such as co-
expression and co-targeting, to identify the overlapping microRNAs and found some evidence that 
these are conserved among different species and genders. Further studies will be needed to validate 
the individual interactions. Nevertheless, the combined approaches provide a list of potential alcohol-
sensitive interactions in the synapse that are candidates for further study. 
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We found the following conserved microRNAs in our study and that of an alcohol vapor 
exposure study in rats: miR-137, miR-187, miR-18a, miR-34c*, miR-369*, miR-374, miR-382*, miR-
423, miR-488, and miR-92b (Tapocik, Solomon et al. 2013). Differentially expressed SN microRNAs in 
the current study also overlapped with differentially expressed microRNAs from human alcoholics 
(Lewohl, Nunez et al. 2011). These were miR-18a, miR-203, miR-369, miR-374, miR-92a, and miR-423. 
We analyzed the differentially expressed mRNAs as potential targets for known drugs using 
IPA software and found three of the few drugs currently used to treat alcohol dependence (baclofen, 
disulfiram, and acamprosate) in the list. Using the differentially expressed microRNAs for the IPA 
analysis, we identified 26 drugs, 10 of which were also in the list of drugs identified using differentially 
expressed mRNAs. Seven of the ten drugs are FDA approved (Table 3.7), with several of these having 
links with alcohol actions For example, aminophylline blocks the behavioral effects of alcohol in mice 
(Soares, Patrocínio et al. 2009) and has antidepressant effects after alcohol exposure (Escudeiro, 
Soares et al. 2013).Theophylline blocks alcohol withdrawal-induced hyperalgesia (Gatch and Selvig 
2002). Other drugs discovered from IPA were rasagiline (treatment for Parkinson’s disease) and 
vorinostat, regorafenib, gemcitabine (paclitaxel), and romidepsin (treatments for cancer). The 
mechanisms of these drugs include histone deacetylase inhibition, adenosine receptor antagonism, 






Drugs for alcohol targets Molecular mechanisms Potential uses 
Belinostat 





Gemcitabine/Paclitaxel DNA polymerase inhibitor 
Tributyrin Adenosine receptor antagonist 
Regorafenib Tyrosine kinase receptor inhibitor  
Rasagiline Monoamine oxidase inhibitor  Parkinson's disease 
Aminophylline 




TABLE 3.7: DRUGS IDENTIFIED BY IPA THAT POTENTIALLY TARGET ALCOHOL-RESPONSIVE MRNAS 
The alcohol-responsive mRNAs and the ‘mRNA targets of the alcohol-responsive microRNAs’ were overlapped to identify drugs 
known to affect these targets. Drug names, molecular mechanisms, and their current potential uses are shown. The data for the 
alcohol-responsive mRNAs were taken from Most et al. 2015. The seven drugs in bold are FDA approved. 
 
We used a bidirectional approach to predict synaptic microRNA–mRNA interactions that were 
sensitive to alcohol (1,039 mRNAs and 15 microRNAs). Of these RNAs, 99 mRNAs and 9 microRNAs 
were unique to glutamate neurons. Notably, eight of these nine microRNAs were predicted to target 
alcohol-responsive mRNAs, such as CamkII, Gria2, Grina, Grm7, and Grip 1. Moreover, miR-203, miR-
18a, and miR-374 were among the glutamate microRNAs that overlapped with the human data set 
(Lewohl, Nunez et al. 2011). These results suggest that alcohol regulates synaptic microRNAs, which 
in turn affect the expression of mRNAs in glutamate synapses and may partially explain the glutamate 
system dysregulation seen in alcoholics (Tsai and Coyle, 1998). We used the miRanda database to 
examine the most probable interactions that are regulated by alcohol consumption. This provides 
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further support for the predicted interactions, but it is important to note that these require direct 
validation to define their role in alcohol consumption. 
A single microRNA has the potential to target many alcohol-responsive mRNAs (Nunez and 
Mayfield 2012, Tapocik, Solomon et al. 2013). This mechanism may be of particular importance in the 
synaptic proteome where slight adaptions can greatly impact synaptic plasticity. Alcohol-responsive 
microRNAs were significantly correlated with astrocytic, microglial, and neuronal modules. The co-
expression of a microRNA with a network of alcohol-responsive mRNAs supports the role of 
microRNAs as master regulators in the synapse. The biological pathways associated with the mRNA 
modules include long-term potentiation and depression, glutamate and neuroimmune signaling, RNA 
processing, etc., suggesting the regulation of microRNAs in multiple processes. As for many other 
diseases (Maciotta, Meregalli et al. 2013), the neuroadaptations associated with alcohol dependence 
likely rely on many mRNAs. A subset of the mRNA changes may be driven by only a small number of 
microRNAs, each with the ability to target multiple mRNAs, thereby impacting alcohol-mediated 
responses and therapeutic strategies. 
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CHAPTER 4: SYNAPTIC MICRORNA-411 REDUCES ALCOHOL CONSUMPTION THROUGH HOMEOSTATIC 
INTERACTIONS WITH GLUA2  
Introduction 
Chronic drug and alcohol use causes widespread neuroadaptations in the brain, producing re-
organization of synaptic structure and function (Nestler 2001, Kalivas and Volkow 2005, Kauer and 
Malenka 2007, Robison and Nestler 2011), which are likely the result of the abnormal expression of a 
plethora of genes in the brain (Mayfield, Lewohl et al. 2002, Eipper-Mains, Kiraly et al. 2011, 
Ponomarev, Wang et al. 2012, Gorini, Harris et al. 2014). An effective treatment for alcoholism 
therefore would likely require simultaneous regulation through the targeting of many of those genes. 
Given the complexity of the disease, it is not surprising that few pharmacotherapies have been 
identified for treating alcohol addiction and preventing relapse (Nutt, King et al. 2010, Organization 
2014, Baingana, al'Absi et al. 2015). 
MicroRNAs are small non-coding RNAs (Ambros 2001, Lee and Ambros 2001), that can control 
the translation of many genes, making them ‘master regulators’ of cellular gene expression (Miranda, 
Pietrzykowski et al. 2010). They are highly abundant in the brain and are also altered in response to 
chronic alcohol consumption in both humans and animal models. Alcohol-induced changes in 
microRNAs have been associated with development of cellular tolerance to alcohol (Pietrzykowski, 
Friesen et al. 2008), cellular reward mechanisms (Li, Li et al. 2013) regulation of alcohol consumption 
and preference (Bahi and Dreyer 2013, Li, Li et al. 2013, Tapocik, Barbier et al. 2014), episodes of 
binge drinking (Darcq, Warnault et al. 2014), withdrawal (Tapocik, Barbier et al. 2014) and alcohol-
induced conditioned-place preference (Chandrasekar and Dreyer 2011, Bahi and Dreyer 2013). The 
extensive and coordinated alcohol-induced changes in gene expression may be driven by microRNA 
changes (Lewohl, Nunez et al. 2011, Mayfield and Nunez 2012, Mulligan, DuBose et al. 2013, Nunez, 
Truitt et al. 2013, Tapocik, Solomon et al. 2013, Mamdani, Williamson et al. 2015, Most, Leiter et al. 
2016, Smith, Lopez et al. 2016), or alternatively, it could be that the mRNA changes drive the 
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microRNA changes (Nunez, Truitt et al. 2013). Nonetheless, the co-expression of microRNAs with a 
network of alcohol-responsive mRNAs supports the role of microRNAs as key regulators (Most, Leiter 
et al. 2016) (Gorini, Nunez et al. 2013). 
Given that alcohol induces changes in synaptic structure and function, it is likely that these 
changes are caused by synaptic mRNAs. Chronic alcohol consumption in mice alters the synaptic 
expression of mRNA networks (Most, Ferguson et al. 2015) and of microRNAs (Most, Leiter et al. 
2016), as we have recently reported. Interestingly, the majority of these changes were isolated to 
synaptic fractions and were not found in total tissue homogenates. However, the underlying dynamics 
of this complex synaptic relationship between alcohol, microRNAs and mRNAs remains unclear and 
the functional importance for alcohol behaviors is yet to be determined. 
The primary focus of these experiments was to examine the functional significance of five 
different synaptic microRNAs – miR-411, miR-203, miR-187, miR-92a and miR-137 – on alcohol 
consumption in mice. An inhibitor of miR-411 - antagomiR-411, in the prefrontal cortex (PFC), 
decreased alcohol consumption and preference in alcohol-consuming mice without altering total 
fluid, saccharin consumption or anxiety related behaviors. Interestingly, antagomiR-411 did not 
change acquisition of alcohol consumption in mice without a history of alcohol consumption. 
Furthermore, antagomiR-411 increased the expression of a protein target specifically in neurons, 
providing a mechanism by which the interaction between synaptic microRNAs and alcohol can affect 
protein in the synaptic structure, and ultimately, behavior. This study provides a proof of concept that 
specific synaptic gene networks can predict viable microRNA candidates for in-vivo manipulation of 
excessive alcohol consumption. 
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Materials and Methods 
Animals 
Adult C57BL/6J female mice were obtained from Jackson Laboratory, and maintained at the 
University of Texas at Austin Animal Resources Center. Female mice were used in these experiments 
since in this mouse strain they achieve higher levels of alcohol consumption compared to males. Mice 
were group-housed and given a minimum of two weeks for acclimation in combined housing. Food 
and water were provided ad libitum and monitored daily, as were the temperature and light/dark 
cycles. Mice were weighed every four to eight days. All procedures were approved by the Institutional 
Animal Care and Use Committee at the University of Texas at Austin and adhere to NIH Guidelines for 
the ethical care and use of animals in research. Mice between the ages of two to six months were 
used. 
Brain Region-Specific microRNA Inhibition 
Mice were anesthetized with isoflurane and then placed in a stereotaxic apparatus (model 
1900, David Kopf) with a continuous flow of oxygen and isoflurane. The skull was exposed and a burr 
hole was drilled above the PFC using a drill carbide bit (#73, David Kopf), at the following coordinates 
relative to bregma: anteroposterior +2.0 mm, mediolateral ±0.5 mm, dorsoventral -2.0 mm. Mice 
intended for use in molecular studies were at this point injected with treatments, whereas mice 
intended for alcohol/behavioral experiments were only cannulated but not yet injected. 
Injections were performed using a microsyringe (10-μL syringe model #1701, Hamilton) and a 
30-gauge needle. Injections constituted either a microRNA LNA inhibitor – AntagomiRs: antagomiR-
411, antagomiR-203, antagomiR-187, antagomiR-92a or antagomiR-137 (Exiqon), or a microRNA 
mimic: mimic-411 or mimic-203 (Dharmacon). The sequences and specific modifications for each 
treatment are given in Supplementary Table S4.1. The microRNA mimics and antgaomiRs were diluted 
to 0.5 nmol/µl in artificial cerebrospinal fluid (ACSF; Harvard apparatus). The dose was chosen based 
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on previous studies using similar methods, such as Jimenez-Mateos et al. 2012 (Jimenez-Mateos, 
Engel et al. 2012), Mckiernan et al. 2012 (McKiernan, Jimenez-Mateos et al. 2012) and Li et al. 2013 
(Li, Li et al. 2013). This dose was 25 times less than that used in Darcq et al. 2014 (Darcq, Warnault et 
al. 2014), 8 times less than in Teppen et al. 2015 (Teppen, Krishnan et al. 2015), and 2 times less than 
in Zhu et al. 2007 (Zhu, Liu et al. 2014). 
One µl of either a treatment or ACSF (control treatment) was injected over a duration of two 
minutes. We chose a volume of 1 µl based on the similar volume used by Darcq et al. 2014 (Darcq, 
Warnault et al. 2014), Li et al. 2013 (Li, Li et al. 2013) and Hollander et al. 2010 (Hollander, Im et al. 
2010). After each injection, the injection needle was left in place for one minute before being 
retracted over a period of two minutes. Incisions were closed with Vetbond, a tissue adhesive 
(#13479726 Animal Health International). 
For cannulation experiments, mice were anesthetized, the skull was exposed and a burr hole 
was drilled above the PFC as described above. Then 37.5% Phosphoric Acid Gel Etchant (#31297, Kerr) 
was applied to the skull for 20 seconds and cleaned. Cannulas were glued in place using a cannula 
holder (#1966) and vetbond. The cannula guide (26 gauge; Plastics One) was inserted 1.5 mm into the 
prefrontal cortex (see supplementary methods for more detail on the cannulation procedure). 
OptiBond Solo Plus (#29669, Kerr) was applied and cured using Dental LED curing light (L5-F-ARTB-
A1-00-0, Bonart) for one minute. The cannula was then secured using dental cement from the Ortho-
Jet Package (#1334PT, Langdental), which was applied according to manufacturer’s instructions. The 
cannula was then capped using a dummy cannula cap, which was 2 mm long (33 gauge; Plastics One). 
At the end of either surgery, a preoperative analgesic was administered (5 mg/kg Metacam) 
(#11247402 Animal Health International) and the mice were placed in a recovery cage until recovery 
from anesthesia. Cannulated mice were individually housed after surgery and given a one-week 




Cannulated mice underwent a two-bottle choice paradigm with a continuous (24-h) access to 
one bottle of 15% ethanol (referred to as alcohol) and one bottle of water (Lim, Zou et al. 2012), 
generating levels of consumption similar to previously recorded consumption levels (Osterndorff-
Kahanek, Ponomarev et al. 2013, Most, Ferguson et al. 2015). Bottle weights were recorded daily and 
the amount of alcohol consumed was calculated as g/kg/24hr. 
Mice (N=47) were pre-trained to consume 15% alcohol for four weeks, reaching an average 
alcohol consumption of 12.7 g/kg/day (±2.1) and an average of alcohol preference over water of 0.65 
(±0.13). For the first four weeks of consumption, alcohol bottle positions were alternated daily as is 
the norm in most two-bottle choice paradigms (Blednov, Mayfield et al. 2012). However, in order to 
measure precise levels of consumption on a daily basis, we determined the preferred position for 
each mouse and thereafter kept the alcohol bottle in that position for the baseline and treatment 
periods.  
Also, in the experiments where the treatment was given to alcohol-naïve mice, the position 
switching continued throughout the entire experiment. This is because with no prior alcohol 
consumption, the alcohol preferred position could not yet be determined. 
MicroRNA Treatment Paradigm and Cannula Injections for Alcohol Consuming Mice 
After measuring the baseline consumption levels, treatments were infused through the 
cannulas into the prefrontal cortex of mice. Mice were carefully scruffed and dummy cannulas 
(cannula cap) were removed. Injectors (2 mm depth) connected to tubing were inserted into the 
cannulas. The tubing was connected on the other side to a 10 µl syringe and 1 µl of treatment was 
infused through the cannula for 30-45 seconds. Once finished, the dummy cannula was reinserted 
and the mice were returned to their home cage. Treatment induced-changes in alcohol consumption, 




Mice consumed 0.0165% saccharin in water for four weeks and were then infused with 
antagomiR-411 or ACSF.  The treatment-induced changes in consumption, preference and total fluid 
intake were recorded for ten days post infusion. 
MicroRNA Cannula Infusions for Alcohol Naïve Mice 
Mice were cannulated, had a subsequent recovery period of at least one week, and were then 
infused with antagomiR-411 or ACSF. Three days later, 15% alcohol was introduced in the same two-
bottle choice paradigm highlighted above, and the consumption levels, preference and total fluid 
intake were measured for two weeks. 
Open Field Test 
Three weeks after antagomiR-411 or ACSF infusions, alcohol-consuming mice were 
transported to the testing room during the light cycle, one hour prior to testing. Mice were 
individually placed in the open field and were allowed to freely explore the field while their activity 
was recorded every 5 minutes for 15 minutes using the Opto-microvarimex animal activity meter 
(Columbus Instruments) and monitored using 6 light beams placed along the width of the cage at 2.5 
cm intervals, 1.5 cm above the floor. The field was covered with a heavy plastic lid with holes for 
ventilation. After each mouse, the field was cleaned with 10% alcohol, and was left to air out before 
continuing with the next mouse. Recorded measurements include time, distance and number of 
entries into the different sections of the field. 
Elevated Plus Maze 
Three days after the open field test, mice were evaluated for alcohol- and antagomiR-411-
induced anxiolysis using the elevated plus maze. Mice were transported to the room one hour prior 
to testing during the light cycle. Each mouse was individually placed on the central platform of the 
maze facing an open arm, and allowed to freely explore the maze for 5 minutes during which the 
 
113 
following measurements were recorded: number of open arm entries, number of closed arm entries, 
total number of entries, time spent in open arms, and time spent in closed arms. A mouse was 
considered to be on the central platform or any arm when all four paws were within its perimeter. 
After each mouse, the field was cleaned with 10% alcohol, and was left to air out before continuing 
with the next mouse. 
RNA Isolation 
Alcohol-consuming microRNA-treated mice were sacrificed upon completion of behavioral 
experiments (10 days after cannula infusions of treatment). The alcohol-naïve mice were sacrificed 
10 days after injections. All mice were sacrificed by cervical dislocation and decapitated during the 
light phase of the light/dark cycle, while alcohol was still available to the mice (avoiding any 
withdrawal effects). Brains were removed, washed with ice-cold saline solution and placed in a 
coronal Zivic mouse brain slicer with a 0.5 mm resolution (Zivic Instruments). Slices were made at 
coronal levels Bregma 1-2.5 mm and the PFC was then microdissected, snap frozen in liquid nitrogen 
and stored in −80°C. Total RNA was extracted using the miRNeasy Mini Kit (#217004, Qiagen) 
according to the manufacturer’s instructions. RNA was then DNAse treated using an RNase-Free 
DNase Set (#79254, Qiagen). RNA yields and purity were assessed using a NanoDrop 8000 (Thermo 
Fisher Scientific) and Qubit Fluorometric Quantitation (Thermo Fisher Scientific). RNA quality was 
determined using the Agilent 2200 TapeStation (ScreenTape #5067-5576; ScreenTape Sample Buffer 
#5067-5577, Agilent Technologies) with RNA integrity numbers (RIN) above 7.5. 
Quantitative Real-Time PCR 
To calculate microRNA expression levels, single-stranded cDNA was synthesized from total 
RNA using reverse transcription PCR (RT-PCR). This was done using the TaqMan® MicroRNA Reverse 
Transcription Kit (#4366596, Life Technologies) and a primer pool, per manufacturer’s instructions, 
containing miR-411 primer (#001610) and sno-234 primer (#001234). Following the RT-PCR, real-time 
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quantitative PCR (qPCR) was done in triplicates of 10 µl reactions. Each data point, derived from qPCR 
assays, represents an average of the replicas. Relative microRNA expression was determined using 
the ΔΔCT method (Hellemans, Mortier et al. 2007), by calculating the mean difference between the 
cycle threshold (CT) of the microRNA of interest and the endogenous control (SnoRNA-234) for each 
sample (ΔCT), and normalizing it to control samples. Reactions were carried out in a CFX384™ Real-
Time PCR Detection System (Bio-Rad). For details about the PCR process, see supplementary 
methods. 
Immunohistochemistry and Image Analysis 
For immunohistochemistry purposes, tissue fixation was performed. Mice were deeply 
sedated with isofluorane and then sacrificed with 0.15 ml euthanasia solution (#54925-045, Med 
Pharmex). Transcardial perfusion was performed using Phosphate Buffer Saline (PBS) and freshly 
made 4% paraformaldehyde (PFA). Brains were removed and postfixed for 24 hours in 4% PFA at 4°C, 
and cyroprotected for 24 hours in 20% sucrose in PBS at 4°C. Brains were placed in molds containing 
OCT compound (VWR) and frozen in isopentane on dry ice. The brains were equilibrated in a -12 to -
14°C cryostat (Thermo Fischer Scientific) for at least 1 hour and coronal sections of 30 µm were taken 
of the PFC and stored in sterile PBS. 
See supplementary methods for detailed description of the immunostaining. In short, brain 
slices were treated with primary antibodies against the proteins of interest, treated with 
fluorescence-conjugated secondary antibodies, mounted on slides with mounting media and cover 
slipped. Two sets of control experiments were performed to test specificity: 1) omission of primary 
antibodies; and 2) omission of secondary antibodies. No immunostaining was detected under either 
of these conditions. Images were captured (without saturating the signal) using a Zeiss Axiovert 200M 
Fluorescent Microscope (Zeiss, Oberkocheen) in 20X and 63X magnification, imported into the ImageJ 
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software package (Schneider, Rasband et al. 2012), and composite images were split into individual 
channels and overlaid. 
To assess the location of the injection/cannula site, the distance of transfection, and the cell 
type specificity of transfection, fixed brain slices were stained with either a Neun or an Iba antibody 
or with DAPI. The injection was considered on-target if the needle placement was within 0.5 mm of 
the desired stereotaxic coordinates. The percent transfection per cell-type was calculated by counting 
100 Neun/Iba-positive cells and then looking in the Neun/Iba-antagomiR-411 merged picture to count 
the number of those cells which were antagomiR-411-positive. 
To calculate the effects of treatment on cell-specific GluA2, GABA-B-R1 and GRINA expression, 
the protein images were first traced using imageJ, then merged with the picture of the cell-type 
marker (Neun or Iba), and the traces which contained the cell-type of interest were measured for 
area, integrated density and mean gray value. Approximately 50 cells were counted per brain slice. 
Background values were collected for each image. The expression was calculated using the equation 
for corrected total cell fluorescence (CTCF) = Integrated Density – (Area of selected cell X Mean 
fluorescence of background readings) as done in McCloy et al. 2014 (McCloy, Rogers et al. 2014) and 
Burgess et al. 2010 (Burgess, Vigneron et al. 2010). This method corrects for background intensity and 
allows for a normalized comparison between images. 
Target Validation 
Ten treated brains were flash frozen without dissection in order to confirm the successful 
targeting of the PFC. These were transferred to a cryostat set at −6° C for 30 minutes before 
sectioning. Consecutive sections (300 µm) of the brains were sliced, mounted on slides and viewed 
with a Dual Fluorescent Protein Flashlight (Nightsea). Diffusion of treatment was calculated by the 
number of slices the treatment was imaged in. On average, four slices per brain contained evidence 




QPCR and immunohistochemistry data were analyzed by either a student’s t-test or when 
appropriate, by a two-way analysis of variance (ANOVA). The behavioral data was analyzed using a 
repeated measures ANOVA. Data from the ANOVA were corrected using Sidak’s Post Hoc multiple 
comparison’s correction. Calculated P-values of less than 0.05 were considered statistically 
significant. Simple calculations were done using Microsoft Office Excel 2013 (Microsoft). Histograms 
and all statistics and graphics were done using GraphPad Software (Prism). 
Results 
Development of an Alcohol Consumption Paradigm for Manipulation of microRNAs In-Vivo 
We first tested whether the infusion of ACSF itself (our control treatment) can affect the levels 
of alcohol consumption. Mice consumed alcohol for four weeks, thereafter ACSF was infused into the 
PFC (Figure 4.1A). Alcohol consumption (Figure 4.1B) and preference (Figure 4.1C) were significantly 
decreased by 23% and 19% respectively, on the first day post-infusion. Although consumption levels 
and preference were somewhat reduced for the next four days, they were not significantly different 
from baseline levels, and returned to baseline within that four day period. Total fluid consumption 
did not change (Figure 4.1D). These results suggest that the experimental model is suitable for testing 
microRNA treatment effects on alcohol consumption and preference, but that the effects of the 
injection itself may confound any treatment effects during the first day post infusion. 
We asked whether a second injection in the same mice is possible, and whether the alcohol 
consumption and preference response is similar to the first injection. Therefore, ACSF was infused a 
second time in the same mice. There were no significant differences in consumption levels or 
preference between the first and second infusions (see Figure 4.1). These results suggest that 
injecting the same mice with ACSF a second time is possible and will not alter the consumption levels 





FIGURE 4.1: INFUSION OF ACSF DOES NOT CHANGE ALCOHOL CONSUMPTION 
A. Timeline of the two-bottle choice alcohol consumption paradigm relative to treatment cannula infusion – a within subject analysis. 
Mice were cannulated and had a ten-day recovery period. Alcohol was then introduced in a two-bottle choice paradigm for four 
weeks. Side preference for the alcohol bottle was determined for ten days. Baseline (BS) levels of consumption, preference of alcohol 
over water and total fluid intake were measured for three to four days. We then infused treatments/ACSF into the PFC cannulas of 
the mice, and treatment effects were measured for five to ten days. For the reinfusion experiments, mice were re-infused with 
treatment/ACSF and the alcohol consumption was measured for another six to eight days. B. Alcohol consumption (g/kg/day) for the 






three days prior to injection. A repeated measures Analysis of Variance (ANOVA) by both factors revealed a significant treatment day 
effect (P=0.0002), stemming from differences in consumption levels between BS and day 1 for the first injection (P=0.0149) and 
between BS and day 1 and day 2 for the second injection (P=0.0047, P=0.0288, respectively). Although lower consumption levels 
were seen during the next four days, none of these days were significantly different from BS. No differences were seen between first 
and second injections for any of the days. For all panels, N=8, * denotes significance (P<0.05, determined by Sidak’s post hoc analysis) 
for the treatment day effects, in black for first injection, in gray for second injection and # denotes significance between treatments. 
Error bars are given as standard error of the means. C. Preference for alcohol over water (shown as a ratio) for the days before and 
after ACSF infusion. Repeated measures ANOVA by both factors revealed a significant treatment day effect (P=0.0044), stemming 
from differences in preference levels between BS and day 1 and day 2 for the first injection (P=0.0259, P=0.0377, respectively), and 
between BS and day 1 for the second injection (P=0.0111). D. Total fluid intake for the days before and after ACSF infusion. Repeated 
measures ANOVA by both factors revealed a significant day by treatment interaction (P=0.0014), stemming from differences between 
first and second injections on day 2 (P=0.0005) and a difference between BS and day 2 for the second injection (P=0.0493). 
Knockdown of miR-411 Decreases Alcohol Consumption in Alcohol Consuming Mice 
We recently showed that alcohol consumption changes the levels of miR-411, miR-203, miR-
92a, miR-187 and miR-137 in the synapse (Most, Leiter et al. 2016). We therefore selected these five 
microRNAs for manipulation. We hypothesized that manipulations of microRNA levels in the opposite 
direction produced by chronic alcohol consumption should oppose the neuroadaptations caused by 
alcohol and reduce alcohol consumption. We began by studying the effects of miR-411 manipulation 
in alcohol-consuming mice with either antagomiR-411 (N=13), mimic-411 (N=15) or ACSF (N=14). 
Alcohol consumption was markedly decreased following miR-411 knockdown (by antagomiR-411) 
compared to ACSF (Figure 4.2A; Supplementary Figure S4.1A), as well as preference for alcohol over 
water (Figure 4.2B). However, there was no change in consumption or preference with mimic-411 
compared with ACSF. There were no differences between the three treatments in total fluid 
consumption (Figure 4.2C, Supplementary Figure S1b). Observing the distribution of the changes in 
alcohol consumption on post infusion days, we determined that the population response to 














FIGURE 4.2: ANTAGOMIR-411 DECREASES ALCOHOL CONSUMPTION IN ALCOHOL CONSUMING MICE 
A. The effects of antagomiR-411 or mimic-411 on alcohol consumption. Data is presented as change in consumption levels from 
baseline (BS) per each day (BS - day X), in response to treatment with antagomiR-411 (N=13), mimic-411 (N=15) or ACSF (N=14). A 
repeated measures analysis of variance (ANOVA) showed a main effect of treatment (P=0.0132) and a main effect of time (P<0.0001). 
AntagomiR-411 reduces alcohol consumption compared to ACSF (day 1 P=0.0137; day 2 P=0.0033; day 3 P=0.0269; day 5 P=0.0208; 
day 8 P=0.0289). Mimic-411 does not change alcohol consumption compared to ACSF. For all panels, * denotes significance (P<0.05, 
determined by Sidak’s post hoc analysis) and error bars are given as standard error of the means. In day 4, mouse weights were 
measured, thus the data from that day was not included in the analysis or graphs. B. Change in preference from BS in response to 
treatment. A repeated measures ANOVA showed a main effect of treatment (P=0.0477) and a main effect of time (P<0.0001). 
AntagomiR-411 significantly reduced the preference for alcohol compared to ACSF (day 2 P=0.0299; day 8 P=0.0291). C. Change in 
total fluid consumption from BS in response to treatment. None of the treatments changed total fluid consumption compared to 
ACSF, though there was a main effect of time (P<0.0003). D. Histogram of the change in consumption levels in response to treatment 
with antagomiR-411 and ACSF, collapsed throughout the days post infusion. AnatgomiR-411 reduces alcohol consumption (mean = -
3.88 ± 1.02) and a t-test (unequal variance) shows this is significantly different (P=2.42E-10) from ACSF (mean =3.75 ± 2.57). 
 
We next tested whether the change in consumption levels was specific to manipulation of 
miR-411 or if it generalizes to manipulation with other alcohol-responsive microRNAs. In a different 
group of mice, we infused antagomiR-203 (N=5), mimic-203 (N=5) or ACSF (N=5) into the PFC of 
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chronically consuming mice and measured the changes in consumption levels, preference and total 
fluid intake. Neither treatment with antagomiR-203 nor treatment with mimic-203 changed alcohol 
consumption (Figure 4.3A), preference (Figure 4.3B) or total fluid intake (Figure 4.3C) compared to 
baseline or ACSF treatment. 
In a different group of mice, we tested the effects of knockdown of miR-92a, miR-187 or miR-
137 on alcohol consumption, by infusing either antagomiR-92a (N=13), antagomiR-187 (N=8), 
antagomiR-137 (N=18) or ACSF (N=31), into the PFC of alcohol-consuming mice. However, neither of 
these treatments were effective in changing the consumption levels (Figure 4.3D), preference (Figure 
4.3E), or total fluid intake (Figure 4.3F). We then studied the effects of a second treatment infusion 
in these mice. A cocktail of all three microRNAs (miR-92a, miR-187 and miR-137) (N=9), or antagomiR-
411 was infused into the PFC (N=12) and compared to ACSF infusion (N=8), to test the hypothesis that 
manipulation of a combination of microRNAs may be more effective than single microRNA 
manipulation. However, the microRNA cocktail was not effective in changing alcohol consumption or 
preference (data not shown) regardless of which treatment was given previously. In contrast, infusion 
of antagomiR-411 after treatment with ASCF or antagomiR-92a produced a reduction in alcohol 
consumption and preference, similar to the previous results with antagomiR-411 (data not shown). 
There were no significant differences between ACSF+antagomiR-411 infusion and antagomiR-
92a+antagomiR-411 infusion. Overall, this data suggests that the effects on alcohol consumption seen 

















FIGURE 4.3: MANIPULATION OF MIR-203, MIR-92A, MIR-187 OR MIR-137 DOES NOT CHANGE ALCOHOL 
CONSUMPTION 
A. The effects of miR-203, miR-92a, miR-187 or miR-137 on alcohol consumption. Data is presented as change in consumption levels 
from baseline (BS) per each day (BS - day X), in response to treatment with antagomiR-203, mimic-203 or ACSF (N=5 for all three 
groups). A two-way repeated measures Analysis of Variance (ANOVA) revealed that neither treatment changed alcohol consumption, 
preference or total fluid intake. There was a main effect of time (day post infusion, P<0.0001) for all three measures. For all panels, 
significance is denoted by P<0.05 and is determined by Sidak’s post hoc analysis, and error bars are given as standard error of the 
means. B. Preference for alcohol over water. C. Total fluid intake. D. Change in consumption levels from BS in response to treatment 
with antagomiR-92a (N=13), antagomiR-187 (N=8), antagomiR-137 (N=18) or ACSF (N=31). A two-way repeated measures ANOVA 
revealed that neither antagomiR-92a, antagomiR-187 nor antagomiR-137 changed alcohol consumption, E. preference or F. total fluid 
intake compared to control. There was a main effect of time (P<0.0001) for all three measures. 
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Knockdown of miR-411 Does Not Change Saccharin Consumption 
Because manipulation of miR-411 was successful in decreasing alcohol consumption, we 
determined whether miR-411 knockdown effects are specific to alcohol or generalize to another 
reward, by examining the effects of antagomiR-411 (N=12) on saccharin consumption and comparing 
them to ACSF (N=10). AntagomiR-411 did not change saccharin consumption (Figure 4.4A) nor 
preference (Figure 4.4B). There were no differences in total fluid consumption among the three 
groups (Figure 4.4C). Thus, the effects of miR-411 knockdown on alcohol consumption and preference 




FIGURE 4.4: ANTAGOMIR-411 DOES NOT CHANGE SACCHARIN CONSUMPTION 
A. The effects of antagomiR-411 on saccharin consumption levels, B. preference for saccharin over water and C. total fluid intake. 
Data is calculated as change from baseline (BS) per each day (BS - day X) in response to treatment with antagomiR-411 or ACSF 
infusion (N=10-12). A two-way repeated measures Analysis of Variance (ANOVA) revealed that neither treatment changed saccharin 





For all panels, significance is denoted by P<0.05 and is determined by Sidak’s post hoc analysis and error bars are given as standard 
error of the means. 
Knockdown of miR-411 Does Not Change Alcohol Consumption in Mice Without a History of 
Alcohol Consumption 
Because antagomiR-411 caused a decrease in alcohol consumption and preference when 
given after chronic alcohol consumption, we asked whether antagomiR-411 can affect the acquisition 
of alcohol consumption in alcohol-naïve mice. We infused antagomiR-411 (N=14) or ACSF (N=10) into 
the PFC of alcohol-naïve mice and then introduced 15% alcohol in a two-bottle choice paradigm. 
AntagomiR-411 did not change levels of alcohol consumption (Figure 4.5A) and preference (Figure 












FIGURE 4.5: PRETREATMENT WITH ANTAGOMIR-411 DOES NOT CHANGE ALCOHOL CONSUMPTION IN ALCOHOL-NAÏVE 
MICE 
A. The effects of antagomiR-411 on acquisition of alcohol consumption. Alcohol consumption levels (g/kg/day) for antagomiR-411 
treated mice (N=14) and ACSF treated mice (N=10). A repeated measures analysis of variance (ANOVA) revealed a main effect of time 
(P=0.0005), but no significant effect of treatment nor an interaction between the two. For all panels, significance is denoted by 
P<0.05 and is determined by Sidak’s post hoc analysis, and error bars are given as standard error of the means. B. Preference for 
alcohol over water. A repeated measures ANOVA revealed a main effect of time (P=0.0108), but no significant effect of treatment nor 
an interaction between the two. C. Total fluid intake. A repeated measures ANOVA revealed a main effect of time (P<0.0001), and a 
significant interaction effect (time X treatment, P=0.0032), but there was no significant effect of treatment. 
Knockdown of miR-411 Does Not Change Stress-Related Behaviors 
Stress is known to alter alcohol consumption (Lopez, Anderson et al. 2016). We therefore 
investigated whether miR-411 manipulation altered two different behaviors sensitive to stress, as a 
control for treatment’s effects on alcohol consumption. Elevated plus maze and open field test were 
performed on alcohol-consuming mice after infusion of antagomiR-411 (N=10) or ACSF (N=8). In the 
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open field test, distance traveled, resting time, horizontal and vertical counts, center and total events, 
and time in center were not different between antagomiR-411 and ACSF (Figure. 4.6A). The same was 
true in the elevated plus maze, where number, distance and duration of entries into each arm were 







FIGURE 4.6: ANTAGOMIR-411 DOES NOT CHANGE BEHAVIORAL RESPONSES IN THE ELEVATED PLUS MAZE OR OPEN FIELD 
TESTS 
A. Effects of antagomiR-411 on anxiety-related behaviors. Response to open field test after treatment with antagomiR-411 (N=10) or 
ACSF (N=8). A t-test revealed there were no differences between the groups. For all panels, significance is determined by P<0.05 and 
error bars are given as standard error of the means. B. Response to elevated plus maze after treatment with antagomiR-411 or ACSF. 
A t-test revealed there were no differences between the groups. 
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AntagomiR-411 is Functionally Active in the Cell, as seen by the Increase in a Target Protein After 
Treatment. 
We first confirmed that the cannulations were in the correct location (Figure 4.7A, B and C). 
AntagomiR-411 was found in neurons and microglia - 98% of Neun-positive (neurons, Figure 4.7D), 




FIGURE 4.7: ANTAGOMIR-411 TRANSFECTS BOTH NEURONS AND MICROGLIA 
A. Transfection of antagomiR-411 in the PFC. Representative image of a PFC slice from an antagomiR-411 treated alcohol-consuming 
mouse. AntagomiR-411 is shown in red and neurons (Neun-labeled cells) are shown in blue. The injection site was at the following 
coordinates relative to bregma: anteroposterior +2 mm, mediolateral ±0.5 mm, dorsoventral -2.0 mm. B. Magnified image of an area 
proximal to the injection site. C. Representative atlas mapping of the antagomiR-411 injection site within the PFC (denoted by an 
arrow), (image taken from Allen’s brain mouse reference atlas). D. Cell type-specific transfection with antagomiR-411 (red), in 
neurons (Neun-labeled cells, blue) and E. Microglia (Iba-labeled cells, blue), from an alcohol-consuming antagomiR-411-treated 
mouse (right) compared to an ACSF treated mouse (left). 
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We then measured the levels of miR-411 in response to antagomiR-411 or mimic-411, in 
chronically consuming mice compared to alcohol-naïve mice. Levels of miR-411 were reduced in 
response to treatment with antagomiR-411 (Figure 4.8A) and were increased after treatment with 
mimic-411 (Figure 4.8B), compared to the ACSF group, and this was true for both the alcohol-exposed 
and control mice. 
We measured the change in expression of a predicted target of miR-411 (Supplementary 
Figure S4.2.), the GluA2 subunit of the AMPA receptor, after treatment with antagomiR-411, and 
found that levels of GluA2 protein were increased in response to treatment with antagomiR-411, 
specifically in Neun-labeled cells (Figure 4.8C). This was not the case for GRINA (Figure 4.8D) and 
GABA-B-R1 (Figure 4.8E), two proteins which were not predicted to be targeted by miR-411 (Figure 
4.8F). These results suggest that a miR-411, a microRNA that decreases GluA2 levels in the PFC, plays 







FIGURE 4.8: ANTAGOMIR-411 DECREASES MIR-411 EXPRESSION AND INCREASES GLUA2 PROTEIN LEVELS 
A. MiR-411 expression levels in response to treatment with antagomiR-411. Levels of miR-411 as measured with qPCR of samples: 
ACSF (N=10), antagomiR-411 (N=8), alcohol-ACSF (ACSF-EtOH, N=8) and alcohol-antagomiR-411 (antagomiR-411-EtOH, N=6). QPCR 
was quantified using the ΔΔCt method (relative to ACSF naïve levels). Sno-RNA-234 was used as an endogenous control. A two-way 
Analysis of Variance (ANOVA) revealed antagomiR-411 significantly reduced miR-411 levels (P=<0.0001) and alcohol significantly 
reduced miR-411 levels (P=0.0196). This stemmed from differences between ACSF and antagomiR-411 (P=0.0015), ACSF-EtOH and 
antagomiR-411-EtOH (P=0.0147), and ACSF and antagomiR-411-EtOH (<0.0001). For all panels, significance (P<0.05) is denoted by *, 
and is determined by Sidak’s post hoc analysis. Error bars are given as standard error of the means. B. Levels of miR-411 as measured 
with qPCR of samples: ACSF (N=9), mimic-411 (N=6), alcohol-ACSF (ACSF-EtOH, N=8) and alcohol-mimic-411 (mimic-411-EtOH, N=6). 
A two-way ANOVA revealed mimic-411 significantly increased miR-411 levels (P=0.0011). None of the specific comparisons were 
significant, though there was a trend towards a significant difference between ACSF and mimic was (P=0.0504). C. Expression levels of 
GluA2 in Neun-labeled cells in the PFC. Representative X63 merged images of a GluA2 labeled slice (green) merged with an image of a 
Neun labeled slice (blue) from an alcohol-antagomiR-411 slice (right), compared to an alcohol-ACSF slice (left). D. Representative X20 
merged images of a GABA-B-R1 labeled slice (green) and E. GRINA labeled slice (green) merged with an image of a Neun labeled slice 
(blue). There were no differences in levels of GABA-B-R1 or GRINA, between alcohol-antagomiR-411 and alcohol-ACSF. F. Average cell 
fluorescence for GluA2, GABA-B-R1 and GRINA, as calculated with the Corrected Total Cell fluorescence (CTCF) method. A t-test 




Chronic alcohol consumption alters the expression of many microRNAs and mRNAs in the 
brain, providing a basis for long-lasting neuroadaptations. However, the specific microRNAs involved 
in the transition from chronic consumption to alcoholism, and the processes by which these 
microRNAs target mRNAs to affect cellular function and behavior are not well understood. Here we 
show that chronic alcohol consumption alters the expression of miR-411 and GluA2 protein in the PFC 
of chronically consuming mice. Silencing miR-411 activity decreases alcohol consumption and 
preference in chronically consuming mice, while simultaneously increasing miR-411 target-protein 
levels. This is in contrast to the effects of silencing of miR-203, miR-92a, miR-187 and miR-137, which 
did not have any apparent effects on alcohol consumption or preference. We also show that miR-411 
is selective for alcohol consumption and does not change saccharin consumption, locomotion or 
anxiety related behaviors. Importantly, we show that silencing miR-411 caused a reduction in alcohol 
consumption in already consuming mice, but did not affect the acquisition of consumption in mice 
without a history of alcohol consumption. These results suggest that miR-411 is specifically involved 
in the neuroadaptations after long-term alcohol use (see Table 4.1 for a summary of the molecular 




Behavioral paradigm Molecular effects Behavioral effects 
30 days of alcohol consumption 
compared to water consumption. 
Reduces miR-411 in the PFC. 
Alcohol consumption and preference are 
maintained. 
AntagomiR-411 infusion after 30 
days of alcohol consumption. 
Reduces miR-411 in the PFC. Increases 
expression of miR-411 target-protein 
GluA2. 
Decreases alcohol consumption and 
preference. Does not change total fluid intake. 
Mimic-411 infusion after 30 days of 
alcohol consumption. 
Increases miR-411 in the PFC. 
Alcohol consumption and preference are not 
changed. 
AntagomiR-411 infusion after 30 
days of saccharin consumption. 
NA 
Saccharin consumption and preference are not 
changed. 
AntagomiR-411 infusion before 
acquisition of alcohol consumption. 
Reduces miR-411 in the PFC. 
Alcohol consumption and preference are not 
different between treatment group and 
control. 
TABLE 4.1: SUMMARY OF THE MOLECULAR AND BEHAVIORAL EFFECTS OF MIR-411 MANIPULATION 
MiR-411 Knockdown by Alcohol may be a Homeostatic Adaptation to Oppose Alcohol 
Consumption 
The traditional view of the link between microRNA levels and behavior claims that if alcohol 
consumption (the behavior) decreases levels of a microRNA, then in order to reduce alcohol 
consumption (reversing the behavior), one needs to increase the microRNA (i.e. restore the microRNA 
to its original levels). However, our results show the opposite: Alcohol consumption decreased the 
levels of miR-411, but then our further reduction of levels of miR-411 led to a reduction in alcohol 
consumption. These results suggest that changes in microRNA levels produced by alcohol 
consumption may not promote consumption, but are rather a homeostatic adaptation, and actually 
oppose consumption. This has shown to be the case for miR-30a (Darcq, Warnault et al. 2014), miR-
206 (Tapocik, Barbier et al. 2014) and miR-124 (Bahi and Dreyer 2013). However, there are reports of 
the opposite, in which neuroadaptations resulting from drug use subsequently encourage further 
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consumption, and restoring the microRNA levels back to normal reduces the behavior. This  
relationship between effects of drugs on microRNA levels and the effects of microRNA manipulations 
on drug consumption has been seen with miR-382 (Li, Li et al. 2013), miR-212 (Hollander, Im et al. 
2010, Im, Hollander et al. 2010), miR-124, let-7d and miR-181 (Chandrasekar and Dreyer 2011). Drug-
induced neuroadaptations and transcriptional changes influence a complex regulatory network. One 
possibility is that alcohol only directly decreases mRNA expression (specifically mRNAs targeted by 
miR-411), and that the cellular response is to decrease the levels of miR-411 in order to cause an 
increase in the levels of its targets and bring the cell back to homeostasis (Nunez, Truitt et al. 2013). 
This ‘counter-adaptivity’ explanation makes sense in light of seeing no changes in consumption levels 
when using antagomiR-411 in alcohol-naïve mice. Future studies are warranted in order to reveal the 
exact order of the molecular cascade in response to alcohol, and how this is changed when 
manipulating a microRNA. 
AntagomiR-411 Decreases Alcohol Consumption in Chronically Consuming Mice 
We saw that treatment with antagomiR-411 in chronically consuming mice reduces 
subsequent alcohol consumption and that this effect was not seen in the saccharin consumption 
experiment. One potential explanation is that reduction of miR-411 expression levels is rewarding 
and that this reward can replace the alcohol-consumption induced-reward, thus reducing the need 
to consume alcohol. However, this reward is specific to alcohol and does not involve saccharin. Thus, 
it may be necessary to first induce dependence on a specific rewarding substance such as alcohol, 
before this reward can be replaced with a different type of reward such as antagomiR-411. Further 
experiments are necessary in order to determine if miR-411 expression levels directly control reward. 
For example: the use of conditioned place preference with antagomiR-411 in order to see if it is 
sufficiently rewarding to condition a mouse to a certain place in the cage; using an intracranial self-
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stimulation test (ICSS) to observe if antagomiR-411 can reduce the reward threshold of the 
stimulation. 
Knockdown of miR-411 Reduces Alcohol Consumption whereas Increased miR-411 Does Not 
Accomplish the Opposite 
Although antagomiR-411 decreased alcohol consumption and preference, administering 
mimic-411 did not change alcohol consumption or preference. There are a few possible explanations 
why this may have occurred. One reason may be that because female C57BL/6J mice display already 
high levels of drinking, a ‘ceiling effect’ may make it difficult to further increase the consumption 
levels with mimic-411. A second reason could be that the key mRNA targets of miR-411 are at low 
cellular levels (i.e. downregulated by alcohol or bound by other microRNAs/binding proteins), such 
that increasing the expression of miR-411 has no consequences on the molecular functional output 
of the RNA silencing machinery. This theory goes hand in hand with the ‘counter-adaptivity’ 
hypothesis, where alcohol directly reduces the expression of miR-411 targets, and in turn reduces the 
expression of miR-411 to prevent it from further decreasing the expression levels of its targets. 
Manipulation of Four Other microRNAs Did Not Change Consumption 
In order to determine if other microRNAs affect alcohol consumption, we manipulated five 
key alcohol-responsive microRNAs in the PFC of mice: miR-411, miR-203, miR-92a, miR-187 and miR-
137. These microRNAs were selected based on changes produced by alcohol treatments in other 
studies: in humans - miR-203 and miR-92a (Lewohl, Nunez et al. 2011); in rats - miR-187 and miR-137 
(Tapocik, Solomon et al. 2013); and in mice - miR-187 (unpublished data). These microRNAs were also 
altered in the amygdala of mice – miR-411 in the total homogenates (Most, Leiter et al. 2016); miR-
203, miR-187 and miR-137 in the synaptoenurosomes (Most, Leiter et al. 2016), and in non-PFC cell 
cultures - miR-203 (Van Steenwyk, Janeczek et al. 2013). Here we show that, the manipulation of 
these other four microRNAs did not change alcohol consumption levels or preference, whereas 
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manipulation of miR-411 did manage to change consumption levels and preference significantly. One 
possibility is that different microRNAs are involved in different periods of alcohol dependence, such 
that different time points are necessary for the manipulation of these microRNAs to take an effect. 
One example is from Im et al. who increased the levels of miR-212 and showed that cocaine intake is 
markedly lower in miR-212 rats with extended access to cocaine, but not in rats with restricted access 
to cocaine (Im, Hollander et al. 2010).  
Summary 
MicroRNAs are clearly involved in the neuroadaptive responses induced by exposure to 
substances of abuse, and their large number of targets encompass a dynamic regulatory network. 
Because a single microRNA targets many mRNAs, drugs of abuse can effectively hijack a complex 
network. If microRNAs live up to their role as master regulators suggested here and elsewhere, then 












SUPPLEMENTARY FIGURE S4.1: ANTAGOMIR-411 REDUCES ALCOHOL CONSUMPTION AND PREFERENCE WITHOUT 
CHANGING TOTAL FLUID INTAKE 
A. Effects of miR-411 manipulation on alcohol consumption levels and on B. total fluid intake, throughout the experimental days, 
including bottle position preference days (side preference) and baseline measurements. 
 
 
SUPPLEMENTARY FIGURE S4.2: LINING OF MIR-411 ON THE 3’UTR OF TARGET GENE GLUA2 (GRIA2) 
Target prediction data and image have been taken from www.miRNA.org (Enright, John et al. 2003, John, Enright et al. 2004, Betel, 






AntagomiR/Mimic Product number Vendor Sequence 
AntagomiR-411-5p 1999998 Exiqon GCTATACGGTCTACT 
AntagomiR-203-3p 1999998 Exiqon GGTCCTAAACATTTCA 
AntagomiR-92a-3p 1999998 Exiqon CGGGACAAGTGCAAT 
AntagomiR-187-3p 1999998 Exiqon TGCAACACAAGACACG 
AntagomiR-137 1999998 Exiqon GCGTATTCTTAAGCAA 
Mimic-411-5p C-121503-00-60 Dharmacon UAGUAGACCGUAUAGCGUACG 
Mimic-203-3p C-121502-00-60 Dharmacon GUGAAAUGUUUAGGACCACUAG 
SUPPLEMENTARY TABLE S4.1: SEQUENCES AND MODIFICATIONS FOR THE ANTAGOMIRS AND MIMICS USED IN THE STUDY 
All antagomiRs were HPLC purified and 5’ TYE-563 labeled. All mimics were HPLC purified and 5’DY547-psngr labeled. 
Supplementary Methods 
Cannulas properties: Guide cannulas (Plastics One) were 26 gauge with a 5 mm pedestal cut, 
and had cannula extending 1.5 mm below pedestal (#8IC315GS5SPC C315GS-5/SP). The injector 
properties were: 2mm depth (1.5 mm in the guide and 0.5 mm projecting out of the guide; 
#8IC315IS5SPC C315IS-5/SPC internal 33 gauge). The dummy properties: injector of 0.008/0.2 mm, 2 
mm below pedestal to fit the 1.5 mm guide and with 0.5 mm projection below the guide 
(#8IC315DCS5SP C315DCS-5/SPC (SM) C315GS-5 W). The cannulas, dummies and injectors were all 
from Plastics One. 
Dental cement procedure: Dental cement from the Ortho-Jet Package (#1334PT, langdental), 
was applied in either pink or transparent dental cement, following manufacturer instructions. In 
short, skull was covered with a thin layer of Liquid foil (#2203) for approximately one minute. Ortho-
Jet liquid, in either pink or clear colors (1304) was then mixed with the Ortho-Jet powder (#1330) on 
aluminum foil using the Disposable brushes (#1900). Once the mixture became homogenous, it was 
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gently applied to the skull, making sure to partially cover the cannula pedestal. The acrylic gel was 
then allowed to cure for approximately two minutes, and then polished with a layer of Jet Seal 
(#4102). 
PCR details: cDNA was synthesized from total RNA using reverse transcription PCR (RT-PCR), 
using the TaqMan® MicroRNA Reverse Transcription Kit (#4366596, Life Technologies) and a primer 
pool, per manufacturer’s instructions – 5 µl of each primer were combined (total of six primers) and 
470 µl of water was added in order to reach 500 µl of solution where each primer is 0.2X of the primer 
solution. RT-PCR was run in a 45 µl reaction containing: 18 µl RT Primer Pool, 0.9 µl dNTP with dTTP 
(100mM), 9 µl of Multiscribe Reverse Transcriptase (50 U/µl), 4.5 µl of 10x RT Buffer, 0.57 µl of RNAse 
Inhibitor (20 U/µl), 3.03 µl of water and 9 µl of 100ng/µl sample. 
Following the RT-PCR, qPCR was done in triplicates of 10 µl reactions as following: 10 µl of 
TaqMan Universal Master Mix II, No AmpErase UNG (2x), 7 µl of Nuclease-free water, 2 µl of RT cDNA 
product, for a total of 40 ng cDNA input per reaction, and 1 µl of Taqman MicroRNA assays were 
combined. Relative miRNA expression was determined using the ΔΔCT method (Hellemans, Mortier 
et al. 2007), by calculating the mean difference between the cycle threshold (CT) of the miRNA of 
interest and the endogenous control (SnoRNA-234) for each sample (ΔCT). ΔCT for the control 
treatment was averaged and subtracted from the ΔCT of the treated and control samples (ΔΔCT). The 
fold changes for each individual sample were calculated by raising 2 to the power of -ΔΔCt (2^-ΔΔCT), 
and expressed as the mean fold change over the mean fold change of the control group (by dividing 
the treatment 2^-ΔΔCT by the averaged control 2^-ΔΔCT). Reactions were carried out in a CFX384™ 
Real-Time PCR Detection System (Bio-Rad). 
Immunostaining details: Sections were penetrated with 0.1% Triton-X 100 (2 x 5 minutes at 
25°C), washed in PBS (3 x 5 minutes at 25°C), blocked with 10% filtered goat or donkey serum (30 
minutes at 25°C), and treated with 1:50 rabbit anti-GABAB-R1 (#Sc-14006-R-300, Santa Cruz 
Biotechnology), 1:50  rabbit anti-GluR2 (#ab52176, Abcam), 1:100 rabbit anti-GRINA (#GTX51232, 
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Gene Tex), 1:1000 guinea pig anti-NeuN (#ABN90, Emd Millipore), 1:500 mouse anti-NeuN (#MAB377, 
Neuromab), 1:300 goat anti-Iba1 (#ab5076, Abcam) antibodies (4°C overnight), washed in PBS (3 x 10 
min at 25°C), and then subjected to reaction of two hours at 25°C with 1:1000 fluorescence-
conjugated secondary antibodies of donkey anti-mouse Alexa 488, donkey anti rabbit Alexa 488, 
donkey anti-mouse Alexa 568, donkey anti-rabbit Alexa 568, donkey anti-guinea pig Alexa 660 
(Invitrogen); donkey anti-guinea pig CF 405M (#SAB4600468, Sigma Aldrich), and rinsed with PBS (3 x 
10 minutes at 25°C). The sections were mounted on slides using sterile 0.2% gelatin and then 
mounting media as applied with or without DAPI (Vector Laboratories) and cover slipped. 
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CHAPTER 5: DISCUSSION 
The goal of my dissertation project was to investigate the role of synaptic RNAs in alcoholism. 
To accomplish this, I aimed to identify the mRNAs and microRNAs involved in chronic alcohol 
consumption, and to manipulate microRNAs in alcohol-consuming mice in order to assess the 
resulting behavior and composition of synaptic mRNAs. This dissertation has two particularly 
noteworthy findings: 1) Alcohol changes the composition of synaptic RNAs in a biologically-
coordinated manner, and these changes are different than what is observed in the rest of the cell; 2) 
miR-411 is sufficient to alter alcohol consumption specifically, while not changing several other 
behaviors. 
The results from this project further our understanding of the molecular underpinning of 
alcoholism, facilitating further research into miR-411 and microRNAs in general as the master 
regulators of behavior. As what frequently happens in science, in addition to advancing the field, our 
results have led to many new questions, and have emphasized how important and difficult it will be 
to reveal the answers to these. In this chapter, I will discuss our results in a more global scheme of 
things and address some of these questions. 
“The scientific mind does not so much provide the right answers as ask the right questions.” 
 - Claude Levi Strauss 
Why Study Addiction? 
The main hypothesis for this project revolves around the theme that alcoholism causes 
neuroadaptations through changes in genetics. By this, I refer to alcoholism as a brain disease 
influenced by genetics. One of the first questions people ask me when I describe my project is: why 
study alcoholism? Is alcoholism a disease? 
The Oxford dictionary defines disease as “A disorder of structure or function in a human, 
animal, or plant, especially one that produces specific signs or symptoms or that affects a specific 
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location and is not simply a direct result of physical injury.” Chapter 4 shows a clear disorder of brain 
cell transcript/protein composition in response to chronic consumption of alcohol, suggesting 
structure has changed. And all three experimental chapters show an initial escalation in consumption 
of alcohol and in preference for alcohol over water throughout time, as one of the many symptoms 
caused by alcohol. So, by brain structure definition and by symptom definition, alcoholism is a disease. 
Another aspect of diseases is the rates of 1) fatality, 2) hospitalization, 3) population 
prevalence and 4) resources spent on the matter. A measure of alcoholism on these parameters gives 
further clarity of the importance of this science. (The following statistics are for the United States. It 
is safe to assume that these indications of importance would also stand out in other countries.)  1) 
The CDC shows that excessive drinking is responsible for 1 in 10 deaths among adults (Blincoe, Seay 
et al. 2000, Compton and Berning 2015, Jewett, Shults et al. 2015), and that approximately 45,000 
people die each year from drugs with 29,000 of them caused by alcohol (excluding accidents and 
homicides). (As a comparator, firearms, which are also a heavy burden on American society, caused 
33,636 deaths (Kochanek, Xu et al. 2011). Further, 31% of all US traffic-related deaths were due to 
alcohol (Jewett, Shults et al. 2015), with 19% of traffic deaths among children being caused by an 
alcohol-impaired driver (Control and Prevention 2012, Stahre 2014). There were nearly 4.6 million 
drug-related emergency room visits nationwide, with 23.5 million people needing treatment for an 
illicit drug or alcohol abuse problem (Substance Abuse and Mental Health Services Administration, 
Department of Health and Human Services, USA). 3) Alcoholism is widespread in the population, with 
approximately 16.3 million adults classified as alcoholics (Alcohol Facts and Statistics, National 
Institute on Alcohol Abuse and Alcoholism). 4) Excessive drinking costs the nation more than $249 
billion annually, from costs related to crime, lost work productivity and health care (Excessive Drinking 
Costs U.S., CDC; Alcohol Facts and Statistics, National Institute on Alcohol Abuse and 
Alcoholism)(Sacks, Gonzales et al. 2015). 
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So it is clear that alcoholism can be fatal and has a high social and financial price-tag. The last 
aspect of alcoholism I would like to touch on is the loss of control. People suffering from alcoholism 
do so despite the negative consequences associated with the consumption of it. For example, despite 
broad awareness of the deadly consequences of drinking and driving, there still are 121 million self-
reported episodes of alcohol-impaired driving among U.S. every year (Traffic safety facts, National 
Center for Statistics and Analysis), and quite likely this is an underestimate. 
The next question I get asked is, if alcoholism is a disease what are the cures or treatments for 
it? Today, there are only three FDA approved treatments for alcoholism, and all are significantly 
limited due to side effects and failure to relieve drug craving. One of the main reasons that more 
effective therapies are not prevalent is the complexity of the disease - alcohol is caused by 
environmental factors and the abnormal expression of many genes. Thus, in this thesis I used novel 
approaches to discover these key genes in order to develop a therapy for alcoholism. 
Why Study microRNAs? 
In this thesis I focused on mRNAs and microRNAs in the brain. Here I will discuss why I find 
these specific RNA subtypes important in the brains of alcoholics. It is now well accepted that the 
intake of drugs of abuse can lead to fundamental changes in neuronal processes that regulate synaptic 
structure and function (Jin, Zarnescu et al. 2004, Klein, Lioy et al. 2007). These changes can manifest 
in long-lasting neuroadaptations in several key regions of the brain that may, in turn, contribute to 
behavioral changes characterized by altered processing of contextual information. An outstanding 
question that remains is: what can be responsible for the persistent drug memory that is able to linger 
for years and causes relapse despite all the negative consequences of alcoholism? 
The DNA is stable and does not change throughout the life cycle of the cell. The molecular 
turnover of RNA and protein is relatively rapid, thus these molecules are not capable of encoding 
long-lasting effects. However, the chromatin structure of the DNA is influenced by RNAs and proteins 
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(epigenetics). In turn, the structure influences the downstream expression genes, and this continuous 
process can be perturbed by drugs of abuse. Therefore, these epigenetic mechanisms can potentially 
mediate the long-lasting effects of drug dependence. 
MRNAs code for proteins and thereby play a role in modification of cellular epigenetics. 
However, microRNAs are non-protein-coding RNAs (ncRNAs). So how are they involved in this 
process? It is well established today that microRNAs, and ncRNAs in general, can regulate the process 
of translation of mRNA into protein and therefore regulate the epigenetic structure of DNA. 
Furthermore, protein coding RNAs only comprise 2% of the genome, while at least 80% of transcripts 
floating in the cell are non-coding (Djebali, Davis et al. 2012). As the cell transcribes a lot of these 
ncRNAs, they must play an essential role in cellular function. This view is in stark contrast with what 
was commonly believed not very long ago: ncRNA were considered largely as “junk”. (Science 
sometimes struggles at dealing with the unknown. This “junk” classification was so far from the truth, 
it sounds today almost like the believing the world was flat.) 
Interestingly, while the proportion of the protein coding genes remains relatively static across 
organisms, analysis of ncRNA complexity through evolution reveals that the proportion of non-coding 
sequences in the genomes highly correlates with the complexity of the organism (Barrett, Fletcher et 
al. 2012), suggesting that regulation of the gene expression is increasingly important with higher level 
organisms. 
Complex organisms have a more complex brain and exhibit more complex behaviors 
suggesting the brain may be a particularly prominent organ within which microRNAs play an 
important role in controlling gene expression. Hence, it is likely that microRNAs play a critical role in 
basic aspects of brain function and behavior. Data from human alcoholics show changes in the 
expression of microRNAs in the brain, suggesting they play a role in alcohol related behaviors (Lewohl, 
Nunez et al. 2011). 
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However, the specific role of microRNAs in the brain is still widely unknown and the exact 
molecular mechanisms governing microRNA functionality are far from clear and are the subject of 
intense scientific inquiry. Consequently, the data presented in this dissertation aimed at revealing a 
neurobiological mechanism through which microRNAs are involved in regulation of mRNAs in regards 
to alcohol. 
To gain an understanding into the role of microRNAs in alcoholism, I started by investigating 
alcohol-induced mRNA expression in the brain (chapter 2), with the hypothesis that if microRNAs 
regulate mRNAs, then by drawing a map of mRNAs involved, I would be able to predict which 
microRNAs would be involved. Results revealed that many of the mRNAs which were responsive to 
alcohol were part of the same biological pathways, further emphasizing the overarching effects of 
alcohol on the brain. I then studied the brain microRNAs which were altered by alcohol (chapter 3) 
and discovered certain alcohol-responsive microRNAs which were predicted to target the alcohol-
responsive mRNAs from the same biological pathways, suggesting functional importance for the 
microRNAs. Lastly, I manipulated five of these microRNAs in the brain in order to affect alcohol 
consumption (chapter 4). Results from these experiments highlight some of the roles of microRNAs 
in alcohol-related behaviors Future research is needed in order to elucidate the molecular 
mechanisms through which this occurs. 
Why and How do the RNAs in the Synapse Respond Differently to Alcohol from those in the 
Soma? 
To add complexity to this story, it is well established that the specific mRNAs and microRNAs 
in particular cellular compartments play different molecular roles, but it is unclear what roles and 
why. In this project, I attempted to answer this question by profiling the mRNAs and microRNAs from 
specific cellular compartments and discovering their role in alcohol consumption. 
While most mRNAs are restricted to the neuronal soma, significant amounts of mRNA are 
found in synaptic compartments of the cell and translated into protein locally (Steward and Levy 1982, 
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Steward and Banker 1992). It stands to reason that molecules in the vicinity of the synapse may be 
the ones involved in the process synaptic plasticity. Studies examined the composition of microRNAs 
in the synapse and revealed many synaptically enriched and depleted microRNA families (Lugli, Torvik 
et al. 2008, Eipper-Mains, Kiraly et al. 2011, Pichardo-Casas, Goff et al. 2012). RNAs – specifically in 
the synaptic compartments of the cell – are found to play a key role in the different states of addiction, 
such as dependence, tolerance, withdrawal and craving (Russo, Dietz et al. 2010, Eipper-Mains, Kiraly 
et al. 2011, Mayfield and Nunez 2012). Therefore, I aimed to identify the molecules in the vicinity of 
the synapse which are involved in chronic alcohol consumption. To do this, I profiled mRNAs and 
microRNAs from SNs and paired TH preparations from the amygdala of mice chronically consuming 
alcohol. Using a within-subject comparison, I found a robust difference between the alcohol-
responsive mRNAs and microRNAs detected in the SN and TH. However, the question remains as to 
why there is a difference between the composition of RNAs in the SN and TH. How is this 
mechanistically possible? First, by using the SN preparation, I restricted the expression profiling to 
the synaptic compartments, thus preventing the dilution of the synaptic RNAs with the somatic 
transcriptome. The response of RNAs to alcohol in the synapse may be of larger magnitude than that 
seen in the soma, but this would become diluted as RNA is extracted from total, unfractionated tissue. 
Second, alcohol could selectively target synaptic RNAs, ultimately changing gene expression in the 
synapse, and this could be different or even opposite from the response in the TH. If the magnitude 
of treatment fold changes for the same RNAs were larger in SN compared with TH, it would suggest 
that synaptic enrichment/dilution was responsible for the differences seen between SN and TH 
response to alcohol. However, results presented in chapter 2 show that only some mRNAs had a 
similar response to alcohol, whereas some mRNAs responded in complete opposite directions. 
Furthermore, results reported in chapter 3 indicate that only one microRNA, (out of 1,111 microRNAs 
tested), miR-411, responded in a similar direction in both SN and TH, suggesting even more so that 
the differences between SN and TH are due to localized effects of alcohol. 
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How is Alcohol Affecting these Cellular Compartments Differently? 
One explanation to this would be that alcohol may be affecting the processing of microRNAs 
into their mature form, specifically in the synapse, allowing for the detection of these microRNAs (on 
our microRNA arrays) and rendering them active/inactive to regulate synaptic mRNA expression. In 
chapter 2, I showed that alcohol changed the expression of synaptic Dicer and eif2c (also known as 
Ago2). It stands to reason therefore that alcohol changes microRNA composition through microRNA 
processing enzymes, ultimately changing mRNA composition in the synapse. This is supported by data 
from Lugli et al., who have demonstrated that microRNA precursors are present in the synapse as 
well as the microRNA processing enzymes, and that their activity is modulated by neuronal activity 
(Lugli, Torvik et al. 2008). Furthermore, in chapter 3, I revealed that synaptic miR-92a, miR-92a-1∗, 
miR-92a-2∗, and miR-92b, microRNAs are derived from the same premature precursor or derived 
from the 5′ and 3′ ends of the same double strand and were all upregulated in response to alcohol. 
Moreover, the precursor for these microRNAs, Pre-miR-92a (unpublished data), was also upregulated 
in response to alcohol - highly suggesting that the premature form of the microRNA was processed 
into the mature form in response to alcohol. This was not seen in the TH, suggesting these processes 
occurred in the vicinity of the synapse. Interestingly, miR-92b is involved in synaptic signaling (Ceman 
and Saugstad 2011) and may be involved in the aberrant synaptic plasticity seen after alcohol 
exposure. 
A second hypothesis which can explain the different responses to alcohol between the SN and 
TH would be that alcohol affects the synaptic translation of mRNAs by binding to the translational 
machinery, and these in turn affect the levels of microRNAs. There are two ways changes in mRNA 
expression can affect microRNA levels – first, if the mRNA encodes for a protein that regulates the 
transcription of the microRNA (such as a transcription factor). This has shown to be the case with miR-
212 and MeCP2 where the levels of MeCP2 affect its association with the DNA encoding for miR-212, 
thus affecting levels of miR-212 (Im, Hollander et al. 2010). In chapter 3, I described how alcohol 
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affects the expression of the synaptic translational machinery and the expression of a variety of 
transcription factors suggesting this may be the case. Furthermore, I identified ten alcohol-responsive 
synaptic microRNAs that were all located in nearby areas of chromosome 12 and were all 
downregulated by alcohol, suggesting that the observed expression changes by alcohol resulted from 
modification on a transcriptional level. This further supports the notion that alcohol directly affects 
mRNAs and those in turn change the transcriptome in downstream expression of microRNAs. A 
second way by which the effects of alcohol on mRNAs affect microRNA expression downstream is 
when mRNA levels change, it changes the number of available targets for microRNAs to bind to, 
causing these microRNA to float solo in the cell leaving them exposed to degradation, or allowing 
them to bind to other mRNA targets which they would not have been binding otherwise. Data from 
studies examining RNA processing enzymes suggest that change in the composition of RNA in the cells 
can change the probability of these interactions. Moreover, when I manipulated miR-411 (chapter 4), 
alcohol consumption and preference was decreased in alcohol-consuming mice. However, when I 
gave the same treatment to alcohol-naïve mice, there was no difference in subsequent consumption 
levels between the miR-411 manipulated group and control. Thus, miR-411 does not influence 
behavior in a normal mouse, but does influence behavior after alcohol-induced neuroadaptations 
take place. This suggests that alcohol directly influences mRNA expression (specifically mRNAs 
targeted by miR-411), and that the cellular response to that is to change the levels of miR-411 in order 
to oppose the change in mRNA levels and bring the cell back to homeostasis (Nunez, Truitt et al. 
2013), further supporting the idea that alcohol targets mRNAs which in turn affect microRNAs. 
Lastly, the differences between the response to alcohol in SN and TH may be caused by the 
effects of alcohol on the trafficking of RNAs to the synapse, resulting in unique SN-enriched RNAs. 
Whether alcohol directly affects the activity of the synaptic microRNA processing machinery, the 
activity of the mRNA translational machinery, or the trafficking of RNAs to the synapse, may be tested 
using an enzyme activity assay with the application of alcohol. One, two, or all three of these cases 
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may be true (alcohol specifically affects synaptic microRNA processing, synaptic mRNAs directly or 
translation of mRNAs, or trafficking of RNAs to the synapse), and it is exciting to take part in the 
science that will lead to an answer to this question. The SN studies help pinpoint the role of synapse-
related microRNA-mRNA interactions and demonstrate the importance of the discrete cellular 
microenvironment in identifying the effects of alcohol. 
Studies of local translation can be aided by new tools to block translation of specific genes of 
interest in specific areas such as axons (Lin and Holt 2007), using microfluidic compartmentalized 
cultures (Coquinco and Cynader 2015, Jain and Gillette 2015) and axonal application of siRNA (Cox, 
Hengst et al. 2008). Application of these and other refined tools will advance our appreciation of 
localized control of gene regulation orchestrated by microRNA and mRNA populations. The activity of 
individual microRNAs in discrete cellular compartments underscores their essential role in cellular 
function and the widespread impact that drugs of abuse can exert by targeting microRNAs. 
How is it that Synaptic microRNA–mRNA Interactions Respond to Alcohol in a Coordinated 
Manner? 
Experiments in chapter 2 revealed that many of the synaptic mRNAs responsive to alcohol 
were from similar biological pathways and had a similar change in expression (co-expression) in 
response to alcohol. A question arises as to how these mRNAs know when to respond to alcohol. And 
how do they communicate to respond in a coordinated manner? 
It is reasonable to believe that a common regulator, such as a microRNA, can regulate the co-
expression of these mRNAs in a coordinated manner. Studies using computational sequence analysis 
predicts that a single microRNA can target 10–100s of mRNA transcripts (He and Hannon 2004), and 
these may be alcohol-responsive mRNAs (Lewohl, Nunez et al. 2011, Tapocik, Solomon et al. 2013). 
In addition, each mRNA transcript can be targeted by potentially hundreds of miRNAs. In chapter 3, I 
show that a subset of alcohol-responsive microRNAs were predicted to target many alcohol-
responsive mRNAs in the synapse, and that these may be participants of the same biological pathway. 
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For example, I found that synaptic miR-369∗, tumor necrosis factor α (TNF-α), fragile-X mental 
retardation-related protein 1 (FXR1) and argonaute 2 (Ago2) were altered in response to alcohol. 
Other studies have shown that miR-369* directly associates with mRNA to initiate its activation under 
conditions of arrested growth (Vasudevan, Tong et al. 2007), and this effect is dependent on the 
recruitment of the RNA-binding proteins (Vasudevan, Tong et al. 2007). These results are a 
demonstration that all of the vital components of this pathway were coordinately changed in SN, 
lending support to the utility of the SN preparation in studying alcohol regulation of the 
transcriptome. 
Also in chapter 3, I utilized a combination of unbiased network and bioinformatic methods to 
identify microRNAs and mRNAs with overlapping patterns of expression that correlated with alcohol 
consumption. I also identified the biological pathways associated with those mRNAs, pinpointing the 
alcohol-responsive microRNA which may regulate certain mRNAs and result in change in specific 
biological pathways. The co-expression of microRNAs with a network of alcohol-responsive mRNAs 
further supports the role of microRNAs as master regulators of translation in the synapse. 
The co-expression of microRNA also illustrates a mechanism by which alcohol changes the 
expression of a few microRNAs and how they can cooperate to target an mRNA that is known to be 
involved in alcoholism as well. This cooperation between the microRNAs may be of particular 
importance because it enables a reduced number of active microRNAs to regulate gene expression, 
greatly impacting synaptic RNA composition and the response to alcohol. Because alcoholism is a 
complex trait with global changes in gene expression, microRNAs serve as worthy targets for 
treatment, as they control global cellular changes in gene expression. Further studies will be needed 
to validate the individual interactions between microRNAs and mRNAs. Nevertheless, the combined 
approaches provide a list of potential alcohol-sensitive interactions in the synapse that are candidates 
for further investigation. 
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Can microRNAs be used as Targeted Therapies for Human Diseases? 
In the last chapter of this thesis, I hypothesized that manipulation of microRNA levels in the 
opposite direction produced by chronic alcohol consumption should oppose the neuroadaptations 
caused by alcohol, and reduce alcohol consumption. The rationale of using microRNAs as an anti-
addiction therapy was the result of the observation that microRNA expression is altered in addiction 
compared with healthy ‘normal’ samples and that microRNAs are capable of targeting many genes 
from the same cellular pathways and functions, enabling the use of a small number of microRNAs to 
achieve an orchestrated regulation of a cellular pathway. 
There are three approaches for manipulating an expression of a microRNA: 1) Directly 
targeting the microRNA with specific nucleotide constructs - such as the microRNA antagomiRs and 
mimics (such as the ones I have used in chapter 4). 2) Using viral vectors to deliver the DNA encoding 
the microRNA/microRNA inhibitor into the genome. 3) Using a manipulator that can affect a 
microRNA (either directly or indirectly) while also affecting other molecules.  I explain each of these 
approaches below: 
1) In chapter 4, I showed that antagomiR-411 was successful in decreasing alcohol 
consumption and preference in alcohol-consuming mice without affecting total fluid intake or 
saccharin consumption. Future studies will need to address whether this treatment can be 
administered safely to humans and whether it is successful in altering behavior. 
There is however evidence for antagomiRs being safe to use in humans and having clinical 
importance. AntagomiR-122 was safely tolerated in chimpanzees and healthy humans (van Rooij and 
Kauppinen 2014), and was successful in treating chronic hepatitic C virus (HCV) infection in mice 
(Baek, Kang et al. 2014). Another clinical trial used antagomiR-34, encapsulated in a liposomal 
nanoparticle formulation (MRX34) to inhibit the formation of cancer stem cells by inhibiting multiple 
oncogenic pathways as well as stimulate anti-tumor immune response to induce cancer cell death 
(Bouchie 2013). In Phase 1 trial, MRX34 has demonstrated partial responses to treatment in patients 
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with renal cell carcinoma, acral melanoma and hepatocellular carcinoma. The evidence for the clinical 
efficacy and tolerability in humans for microRNA therapeutics in treating cancer suggests that this 
may be a valid form of treatment for other diseases such as addiction. Future studies are warranted 
in order to identify and test treatments in humans suffering from addiction. 
2) The second way to manipulate microRNAs can be done with the use of viral vectors which 
incorporate these inhibitors and activators into the DNA under certain promoters, such that the cell 
itself will be synthesizing them. The vectors available today can be activated by simple consumption 
of a drug and can also be halted in a similar manner. The ability to both activate and stop a specific 
microRNA from being transcribed is of importance - It enables the long-lasting expression of the 
treatment while providing a possible cessation of a treatment in case it causes severe side effects. 
This also enables an elegant within subject analysis, where it is possible to test the changes in behavior 
with and without that microRNA in the same organism. 
3) The third method is to manipulate microRNA expression through the use of drugs to 
modulate microRNA expression by targeting their synthesis, transcription and their processing (Ling, 
Fabbri et al. 2013, Giza, Vasilescu et al. 2014) or by the use of vagal nerve stimulation (Jiang, Li et al. 
2015). In chapter 3, I analyzed the differentially expressed mRNAs and microRNA as potential targets 
for known drugs and identified ten drugs. Seven of these ten drugs are FDA-approved, with several 
of these having known links with alcohol actions. The FDA approved drugs provide a potential off-
label treatment for alcoholism in humans. Because these are approved for use in humans with known 
side effects, this may allow foregoing the animal studies and proceeding directly to human studies. 
Currently, there is an ongoing clinical study to assess the safety and efficacy of gemfibrozil in 
modulating microRNA-107 levels for the prevention of Alzheimer's disease in subjects with intact 
cognition and mild cognitive impairment (clinicaltrials.gov identifier # NCT02045056). Another clinical 
trial (which is opening soon) is set to determine the effects of transcutaneous vagal nerve stimulation 
on plasma microRNAs in healthy humans with the hope of using this to treat epilepsy in the future 
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(clinicaltrials.gov identifier #NCT02359188). Further evidence from rats demonstrates that miR-210 
mediates the vagus nerve stimulation-induced neuroprotection following cerebral 
ischemia/reperfusion injury (Jiang, Li et al. 2015). 
These are exciting times to be a researcher in the microRNA field, as the role of microRNAs in 
the brain and their relationship to behavior is being elucidated and their direct therapeutic efficacy 
in humans is being revealed. Call me optimistic, but I believe that soon enough we will be able to find 
safe and efficacious ways to treat brain diseases with microRNA manipulators. Though since 
microRNAs are master regulators of gene expression in the cell, and since there are roughly 25,000 
genes in a human cell, it may take time to reveal the exact molecular mechanism by which microRNA 
exert their effects. It is my hope that continued scientific activity in this field will overcome these odds 
and help find a pathway to alcohol related therapies. 
“Science never solves a problem without creating ten more.” 
 - George Bernard Shaw 
Future Directions 
MANIPULATION OF SYNAPTIC SPECIFIC MICRORNAS  
In order to attempt changing alcohol consumption levels, I chose to manipulate five key 
alcohol-responsive microRNAs in the PFC of mice: miR-411, miR-203, miR-92a, miR-187 and miR-137. 
In chapter 4, I showed that with the exception of miR-411, the manipulation of these other four 
microRNAs did not change alcohol consumption levels or preference, whereas manipulating miR-411 
did manage to change consumption levels and preference significantly. In chapter 2, chronic alcohol 
consumption was found to change the expression of these microRNAs (miR-411, miR-203, miR-92a, 
miR-187 and miR-137) in the synaptic areas of the cell, and that this effect can be different from that 
seen when measuring the whole-cell total homogenate alcohol-induced expression of these 
microRNAs. This is true for all of these microRNAs except for miR-411, which was decreased by alcohol 
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both in synaptic regions of the cell as well as the whole-cell total homogenates. These results imply 
that it may be necessary to manipulate a microRNA that is influenced by alcohol in the whole cell and 
not just in the synapse, and that a microRNA that is only affected by alcohol in the synapse may have 
different or opposite effects in the rest of the cell (referred to as total homogenates). However, this 
explanation is unlikely since alcohol consumption and dependence was found to change the 
expression of these microRNAs in the total homogenates of the PFC as identified by other studies in 
humans - miR-203 and miR-92a (Lewohl, Nunez et al. 2011); in rats - miR-187 and miR-137 (Tapocik, 
Solomon et al. 2013); in mice - miR-187 (unpublished data), and in non-PFC cell cultures - miR-203 
(Van Steenwyk, Janeczek et al. 2013) . One way to test this would be to manipulate the microRNAs 
that are changed by alcohol in the total homogenates but not in the synaptic areas. A more direct 
way to answer this could be to manipulate these microRNAs in a spatially specific location in the cell 
using viral vectors that express microRNAs specifically in the synapse or in the soma and compare the 
behavioral changes. 
Another explanation to as why only one of five of our microRNAs was successful in changing 
behavior is that different microRNAs are involved in various periods of alcohol dependence, such that 
different time points are necessary for the manipulation of these microRNAs to take an effect. One 
example is from Im et al. who increased the levels of miR-212 and demonstrated that cocaine intake 
is markedly lower in miR-212 rats with extended access to cocaine, but not in rats with restricted 
access to cocaine (Im, Hollander et al. 2010). 
MANIPULATION OF MICRORNAS WITH A RESCUE 
One of the consensus experiments in this scientific field is to show that a certain molecule is 
both necessary and sufficient to explain a change in behavior. In order to do that, some studies include 
a ‘rescue experiment’, where they use one type of manipulation to prove it is sufficient in changing a 
behavior, and then use the opposite manipulation to show that the induced-behavior is stopped when 
 
152 
taking away the original manipulator, thus determining the necessity of the molecular manipulation. 
In chapter 4, I conveyed that antagomiR-411 was sufficient to decrease alcohol consumption and 
preference while reducing the levels of miR-411. Unfortunately, when increasing the levels of miR-
411, I did not see the opposite behavior – when using mimic-411 there was no increase in alcohol 
consumption and preference. Because of this issue, I was not able to do a rescue experiment. Future 
studies will need to find a good opposite treatment to antagomiR-411 in order to set up a rescue 
experiment. One way to find a treatment that increases alcohol consumption would be to do a dose 
response curve with mimic-411 and measure the changes in alcohol consumption in each dose. 
Another possibility would be to use brain specific viral vectors to deliver miR-411 under an active 
promoter which would chronically drive up the levels of miR-411. 
There is a current effort of the W.M. Keck Center for non-coding RNAs (University of California, 
San Francisco) together with the Jackson laboratories (Bar Harbor, Maine), to create transgenic mice 
with genetic deletion of individual microRNAs. They also produced a strain that has the option to both 
induce the knockout and then later remove the knockout to restore a functional wild type allele. 
Performing this step is critical for a rescue experiment, allowing the measurements of the before and 
after for the knockout in the same mouse (Park, Jeker et al. 2012)(http://rna.keck.ucsf.edu/miRKO-
DB). 
Another way to show that a microRNA is both sufficient and necessary for the aberrant 
translation of proteins during addiction would be to halt the translation process during the 
manipulation of the addiction-behavior. Some antibiotics (such as anisomycin) have the ability to 
inhibit protein translation (Chan, Khan et al. 2004). If indeed microRNAs control mRNA translation in 
addiction without an intact process of protein translation, a microRNA manipulation will not be able 




The one pervasive theme throughout this dissertation is alcohol’s propensity for modifying 
the neural landscape which is reflected by its many responsive molecules and signaling pathways. 
Establishing causality between alcohol and the succeeding cellular and behavioral adaptation is a 
difficult task, and identifying the small effects on each system that culminate in alcoholism is a 
complex challenge. Evidence gathered through pharmacological manipulation, genetic modification, 
and direct measurement supports the importance of microRNAs in alcohol-induced 
neuroadaptations. The availability of a large variety of animal models (ranging from flies and worms 
to primates), as well as the advancement of neurobiological techniques (genomics, transcriptomics, 
proteomics, function-omics) provide hope for discovering the molecular mechanisms underpinning 
the neurobiology of alcoholism and revealing new therapeutic targets for this societal health burden. 
If microRNAs live up to their role as master regulators, then their impact on drug-mediated responses 
and therapeutic strategies will be of critical clinical importance. The results of this thesis project 
provide proof of concept that synaptic gene networks can yield viable candidates for manipulation of 
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